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Professor Kenneth M. Murphy, Chair 
 Classical dendritic cells (cDCs) are specialized antigen presenting cells that can be 
divided into distinct subsets based on the types of pathogens they respond to and the type of 
immune response they generate. The cDC1 subset is specialized in priming CD8 T cell responses 
through the process of cross-presentation. During cross-presentation, exogenous protein antigens 
are taken up by cDC1 and presented on MHCI molecules, allowing for the priming of CD8 T 
cells during conditions when DCs themselves are not directly infected. The ability to cross-
present in vivo is unique to cDC1, and is essential for anti-viral responses and rejection of 
immunogenic tumors. The molecular mechanisms of cross-presentation remain incompletely 
understood, due to limited biochemical analysis of rare cDC1 cells, difficulty in their genetic 
manipulation, and reliance on in vitro systems based on monocyte-derived dendritic cells.   
 Through gene expression analysis of cDC1 versus cDC2, we found the vesicular 
transport gene Rab43 to be highly and specifically expressed by cDC1. Using a mouse line 
deficient in Rab43, we found that cDC1 lacking Rab43 were not able to cross-present to the 
same efficiency as wild type cDC1. However, monocyte-derived dendritic cells from these mice 
were normal in their ability to cross-present, calling into question the published data using these 
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cells to study the cross-presentation pathway. Therefore, we developed a CRISPR-Cas9 
screening system to discover additional members of the in vivo cross-presentation pathway. 
Through this process, we discovered Wdfy4, a gene specific to both cDC subsets and B cells that 
is essential for in vivo cross-presentation. Wdfy4 knockout mice are the first known genetic 
model to specifically lack the cross-presentation pathway without any observable deficiencies in 
other antigen presentation pathways or cell development. Through the use of these mice, we 
were able to show that cross-presentation is essential for the generation of CD8 T cell responses 
to viruses, the clearance of immunogenic tumors, and rejection of minor-mismatched antigen 
grafts but not for susceptibility to Listeria monocytogenes or protection against Toxoplasma 
gondii (both of which involve other functions of cDC1 which remained intact without Wdfy4). 
Through mass spectrometry, we determined that WDFY4 likely interacts with vesicular transport 
machinery after clathrin-mediated endocytosis and may be involved in vesicle sorting or 
recycling. These advances give new insight into the proteins involved in performing cross-
presentation in vivo and improve our understanding of how the immune system responds to 
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Classical dendritic cells (cDCs) are antigen presenting cells that activate and polarize 
adaptive immune responses after exposure to pathogens or tumors. The cDC1 subset of classical 
dendritic cells is specialized in priming CD8 T cell responses through the process of cross-
presentation while acting as a cellular platform to integrate “help” signals from CD4 T cells. 
Cross-presentation is the process of presenting exogenous antigens through the MHCI 
presentation pathway, allowing for CD8 T cell priming in situations where DCs are not directly 
infected. The molecular mechanisms of cross-presentation remain incompletely understood 
because of limited biochemical analysis of rare cDC1 cells, difficulty in their genetic 
manipulation, and reliance on in vitro systems based on monocyte- and bone-marrow-derived 
dendritic cells (moDCs). Recent work has called into question the in vivo relevance of studies 
performed using moDCs and highlighted the importance of studying the cross-presentation 
pathway within cDC1s. 
1.2 Introduction to Dendritic Cells 
Dendritic cells (DCs) are a distinct lineage of innate immune cells that was originally 
defined based on its unique stellate morphology and ability to prime T cell responses1-3. DCs 
broadly segregate into four groups, plasmacytoid DCs (pDCs), classical DCs (cDCs), 
Langerhans cells, and monocyte-derived DCs (moDCs) based on function and surface markers. 
pDCs are potent producers of type I interferons in response to viral pathogens4-7. cDCs 
themselves are divided into two lineages, recently renamed8 as cDC1 (CD8α+ DCs) and cDC2 
(CD8α˗ DCs). The cDC2 lineage is heterogeneous and expresses the Irf4 transcription factor9-11. 
Notch 2-dependent cDC2s are required for IL-23 production in response to Citrobacter 
rodentium infection12,13, while a separate Klf4-dependent subset of cDC2s is required for type II 
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responses to house dust mite antigen and Schistosoma mansoni infection14. By contrast, cDC1 
cells require the Irf810,15,16 and Batf3 transcription factors10,16,17 and produce the IL-12 necessary 
for protection against Toxoplasma gondii18,19. They are also the subset involved in priming CD8 
T cell responses to tumors and virally infected cells through cross-presentation17,20. All cDCs in 
vivo arise from a common DC progenitor (CDP) in the bone marrow21. 
Cultures of monocytes in GM-CSF and IL-4 are able to produce DC-like cells, distinct 
from those that develop from the CDP22, termed monocyte-derived DCs (moDCs), in large 
numbers23. Similar cells that derive from cultures of whole bone marrow with GM-CSF with or 
without IL-4 in vitro have been referred to as “moDCs”, despite the uncertainty of the origin, or 
bone-marrow-derived DCs (BMDCs). BMDCs have been the basis for many studies aimed at 
understanding the properties of cDCs24,25. Recent studies have shown that these cultures are 
actually heterogeneous and that it may not be appropriate to refer to the cells that are generated 
as moDCs, since many display macrophage characteristics and the precursor to the DC-like cells 
from whole bone marrow is not known26. Some investigators object to the use of the term moDC 
for in-vitro-derived cells from whole bone marrow, since it is misleading with regard to their 
development; however, it has been argued that the DC-like cells that develop from GM-CSF 
cultures develop from monocytes27. The term BMDC can also lead to confusion, since DCs can 
also be derived from bone marrow cultures with fms-related tyrosine kinase 3 ligand (Flt3L) and 
produce cells that are distinct from those produced in GM-CSF cultures27. Therefore, this chapter 
will refer to cells generated from monocytes as moDCs and cells generated from whole bone 
marrow GM-CSF cultures as GMDCs. Conceivably, both may be derived from monocytes and 




1.3 Cellular Studies of Cross-Presentation 
Cross-presentation is the process by which exogenous antigens are taken up by antigen-
presenting cells and presented on major histocompatibility class I (MHCI)28. cDC1s are the 
unique DC subset specialized in cross-presentation in vivo20. The molecular mechanisms specific 
to DCs that govern cross-presentation have been the subject of a large body of work over the past 
decade29, while much of the early work on cross-presentation was done in macrophages30-32 the 
majority of our understanding of cross-presentation is based on experiments carried out using 
GMDCs. GMDCs are generated from bone marrow cultures with GM-CSF alone or GM-CSF 
with IL-4 originally developed in the early 1990s24-26. While these cells can cross-present in 
vitro, it is unlikely that these are the cells that operate in vivo, since Batf3-/- mice that lack cDC1s 
fail to mount CD8 T cell responses to challenges requiring cross-presentation17. However, Batf3-
/- mice can generate moDCs that are able to cross-present normally in vitro33, indicating that any 
moDCs that may develop in vivo do not compensate for the loss of cDC1s for in vivo cross-
presentation. 
Surprisingly little work has been done to analyze cross-presentation in DCs derived from 
bone marrow cultures with Flt3L. DCs that resemble splenic cDC1 and cDC2 by surface markers 
can be generated in large numbers in bone marrow cultures with Flt3L34,35. These cells are able 
to present antibody-targeted antigens and activate T cells to a similar extent as cDCs of the same 
lineage derived in vivo36. Also, Flt3L-derived DCs express Rab43, a molecule necessary for 
cross-presentation in in vivo cDC1s but not moDCs37. While more studies may be needed to 
compare the cross-presentation efficiency of Flt3L-derived DCs to in-vivo-generated cDCs, 
Flt3L-derived DCs are arguably more appropriate for in vitro studies of DC function than 
GMDCs. Nonetheless, the examination of macrophages and GMDCs has been useful for 
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identifying the components of two major cross-presentation pathways, the cytosolic and vacuolar 
pathways. 
1.4 Cytosolic Pathway of Cross-Presentation 
In the cytosolic pathway, exogenous antigens that are taken up into phagosomes are 
exported into the cytosol to enter the traditional proteasome- and TAP-dependent MHCI 
presentation pathway32,38,39. The cytosolic pathway is dependent on the reduced acidification of 
phagosomes produced by the activity of NADPH oxidase Nox2, leading to delayed antigen 
degradation40,41. Recruitment and localization of NOX2 components was determined to be 
regulated by the activities of Rac2 and Rab27a41,42. Phagosomal alkalization has also been 
demonstrated to involve Rab3c (a marker of recycling vesicles43), Rab34 (an LPS-regulated 
protein that can delay phago-lysosomal fusion44), and TFEB (a transcription factor that can 
negatively regulate cross-presentation45). The delay in antigen degradation caused by 
phagosomal alkalization acts to allow antigens to move into the cytosol, possibly through 
channels such as Sec61, promoting antigen processing and presentation through the normal 
MHCI pathway46. These pathways have mainly been shown to act in phagosomes containing 
latex beads, raising the question of whether this process is specific to uptake of beads or if 
antigens that bind different receptors are processed through similar mechanisms. Decreased 
antigen degradation by lysosomes has recently been shown to improve tumor rejection after 
knockout of the RNA binding protein YTHDF147. YTHDF1 was shown to increase antigen 
degradation by improving translation of lysosomal cathepsins; however, when knocked out, 
cross-presentation of neoantigens improved, suggesting that delayed antigen degradation may be 
important for cross-presentation in vivo47. 
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NOX2 has been shown to play a role in cross-presentation in vivo40,42, suggesting that 
phagosomal alkalization may also be important for cross-presentation by cDC1s. However, the 
magnitude of the contribution of this pathway is limited, as loss of NOX2 activity decreased 
cross-presentation of antibody-targeted antigen only by about 50%40. The remainder of the 
molecules in the cytosolic pathway, including Rac2, Rab27a, Rab3c, Sec61, TFEB, and Rab34, 
have not been examined in in vivo cDCs41-45. Genetic studies with mouse models will be 
necessary to determine the importance of these molecules and the cytosolic pathway in general to 
cross-presentation in vivo. 
1.5 Vacuolar Pathway of Cross-Presentation 
The vacuolar pathway involves the loading of MHCI molecules by antigens processed 
directly within endosomes without transport to the cytosol and is independent of TAP and the 
proteasome48,49. One molecule linked to the vacuolar pathway is the insulin-regulated 
aminopeptidase (IRAP)50. IRAP can trim peptides in DC phagosomes to lengths appropriate for 
loading into MHCI molecules50, similar to the action of endoplasmic reticulum aminopeptidase 
associated with antigen processing (ERAAP) in the endoplasmic reticulum51. The role of IRAP 
in vivo remains unclear. Although an early study detailing the mechanism of IRAP was 
conducted using in vitro GMDCs, IRAP-deficient mice were also shown to have reduced cross-
presentation50. However, a subsequent study concluded that IRAP was not required for cross-
presentation of soluble OVA or OVA-coated splenocytes by splenic cDC1s in vitro, suggesting 
that IRAP may not play a role in cDC1-mediated cross-presentation52. But another study, using 
OVA-expressing yeast in vitro, showed that IRAP is recruited to endosomes in cDC1 cells and 
that cross-presentation is reduced in IRAP-deficient cDC1s53. Conceivably, the use of differing 
forms of antigen underlies some of these variances. While the ability of cDC1 cells to cross-
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present is not solely due to their ability to capture antigens54,55, it is plausible that distinct antigen 
internalization and processing pathways are used for different forms of antigen. For example, 
cell-associated and soluble antigens are not cross-presented equally and cDC2s, which do not 
cross-present in vivo20, have the capacity to present soluble antigens in vitro53,55. Therefore, work 
is still needed to compare cross-presentation of different antigens by cDC1s and cDC2s in vitro 
to find a system that mimics in vivo models where only cDC1s are able to cross-present. 
Developing standardized assays for the field through careful comparison of DC subsets may help 
to eliminate confusion between whether or not molecules are necessary for cross-presentation in 
vivo as in the case of IRAP. 
Presentation through the vacuolar pathway requires the loading of MHCI molecules 
within endosomes. The molecule Sec22b was described in GMDCs to regulate the movement of 
the peptide-loading complex to endosomes56. However, the role of sec22b in vivo is 
controversial; while one study showed it to be necessary for checkpoint blockade mediated 
tumor rejection through cross-presentation57, another study showed no defect in cross-
presentation in Sec22b-deficient mice58. It has also been shown that GMDCs contain pools of 
MHCI in endosomal recycling compartments marked by Rab11a59. A model has been proposed 
where TLR signals induce MHCI movement from these intracellular pools to phagosomes, 
where they meet antigen and the peptide-loading complex machinery brought by Sec22b59. A 
second proposed model involves CD74, the MHCII invariant chain, which was also shown to 
control the movement of MHCI to endosomes and to regulate cross-presentation in vivo60. CD74 
acts in both splenic cDC1s and GMDCs, meaning CD74 and IRAP are the two molecules shown 
to be involved in the vacuolar pathway of cross presentation in cDC1s53,60. However, as with the 
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cytosolic pathway, many gaps still remain in our understanding of what proteins and signals are 
involved in regulating the cross-presentation ability of cDC1s. 
1.6 Role of moDCs in vivo  
The discovery that moDCs cannot compensate for the loss of cross-presentation by 
cDC1s in vivo has called into question their relevance in vivo33. Bone marrow cultured with GM-
CSF produces a heterogeneous population of CD11c+ MHCII+ cells which contain functionally 
distinct macrophages and DCs26. While moDCs have a stellate morphology, express the cDC-
specific ZBTB46 transcription factor61, and can cross-present cell-associated antigens, they do so 
in a manner distinct from ex vivo cDC1 cells33,52. 
Further, recent work has called into question if moDCs exist in vivo. Studies of moDCs 
started with the observation that transferred monocytes are able to generate CD11c+ DC-like 
cells in vivo22. These moDCs have been observed in numerous models including viral 
infections62, alum-OVA immunization63, arthritis64, and house dust mite exposure65. They can be 
distinguished from cDCs in vivo by expression of CD64 and MAR-163,65 and are dependent on 
CCR2 and CD115 (MCSF-R)63,66. However, it is unclear whether the moDCs identified in these 
studies in vivo are equivalent to those generated with GM-CSF and IL-4 in vitro. Recent lineage 
tracing has suggested that the inflammatory cells that develop during house dust mite challenge 
lack expression of the cDC marker ZBTB4661 and instead express the macrophage-specific 
transcription factor MafB67,68, suggesting that these cells are not moDCs but rather monocyte-
derived macrophages. Furthermore, others have shown little functional difference among 
moDCs, monocyte-derived macrophages, myeloid-derived suppressor cells, and immature 
monocytes8,69,70, also suggesting that in vivo moDCs may actually be monocyte-derived 
macrophages. In addition, no in vivo model has yet to be described where moDCs are required 
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for cross-presentation. Lineage tracing of in vivo moDCs and comparisons to in vitro-derived 
GMDCs will be necessary to determine whether GM-CSF cultures are an appropriate model to 
study DC function. Owing to the observed differences between GMDCs and cDC1s, studies of 
cross-presentation in vitro should rely on either ex vivo cDCs or Flt3L-derived DCs to more 
appropriately model how cross-presentation occurs in vivo. 
1.7 Cross-presentation during Viral Infections 
Though cDC1s are the major cell that appears to carry out cross-presentation for 
expanding CD8 T cells in vivo20, many cells are able to present antigens on MHCI to CD8 T 
cells71. Therefore, it is unclear whether cross-presentation is the only pathway used in priming 
CD8 T cells to pathogens, or alternately whether direct presentation by infected cells might 
contribute in some settings. Indeed, the cell type responsible for T cell priming and the pathway 
of antigen processing may vary with the pathogen and could depend on factors such as viral 
tropism and the time after infection72-74. For example, using DC-tropic vaccinia virus expressing 
an extended OVA peptide that could not be cross-presented, Xu et al. demonstrated that direct 
presentation is sufficient for generating a CD8 T cell response72. However, during infection with 
mouse cytomegalovirus, another DC-tropic virus, the predominant T cell clones react to epitopes 
that were presented through cross-presentation73,74. It is likely that both direct and cross-
presentation can contribute in priming CD8 T cell responses and that the predominant form of 
presentation may depend on the stage of infection. Early during infection, antigen presentation 
requires viral replication, suggesting direct presentation is playing a role; however, late during 
infection most presentation occurs by uninfected DCs through cross-presentation75 (Figure 1.1). 
Imaging of T cells and cDC1s during vaccinia virus infection showed a similar phenomenon and 
observed that multiple DC subsets could prime CD8 T cell responses early during infection; 
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however, later in infection CD8 T cells interacted with only XCR1-expressing cDC1s76. cDC1s 
are also essential for priming CD8 T cell responses during secondary infections and generating T 
resident memory cells, a process recently shown to depend on cross-presentation77,78. 
In lymph nodes, cDC1s can be separated into two categories of migratory and resident 
DCs that are developmentally related79, either of which could be involved in the presentation of 
antigen to CD8 T cells during an infection. Tracking of migratory DCs from the skin during 
herpes simplex virus (HSV) infection has shown that CD8 T cell priming occurs in lymph nodes 
and movement of migratory DCs from the skin is required for priming to occur80. Then in the 
lymph node, antigens acquired by migratory DCs can be transferred to lymph-node-resident DCs 
for presentation to CD8 T cells80 (Figure 1.1C). These results imply that there may be two 
distinct priming events: an initial priming from migratory cDC1s that directly captured antigen 
and then a secondary priming that occurs after antigen has been transferred to resident cDC1s. 
Imaging of the anti-viral response to HSV suggested that CD4 T cells are primed before CD8 T 
cells and that they interact with migratory DCs, while CD8 T cells interact with resident cDC1s 
in the lymph node81. However, others have demonstrated that antigen-specific CD8 T cells 
preferentially interact with migratory cDC1s82,83. These results raise the question of whether all 
CD8 T cell priming occurs through migratory cDC1s, which are directly exposed to antigens, or 
through resident cDC1s, which can present their antigens through either cross-presentation76,80 or 
cross-dressing, a process by which loaded MHCI is transferred between different cells84. 
Conceivably, early CD8 and potentially CD4 T cell priming is mediated by direct presentation 
from migratory cDC1s, since they encounter antigen first, and then later CD8 T cell priming 
occurs after antigen transfer to and cross-presentation by lymph-node-resident cDC1s (Figure 
1.1A and 1.1D). 
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1.8 CD4 T cells and cDC1s  
For many pathogens, DCs alone are not enough to prime a CD8 T cell response. CD4 T 
cells and type I interferons have been shown to be involved in the “help” reaction, which 
stimulates DCs and enables them to prime CD8 T cells85,86. Early work on cross-presentation 
showed that CD4 T cell help to DCs is necessary for the generation of a CD8 T cell response 
against cell-associated antigens85. This help is mediated through interactions between CD40 on 
DCs and CD40L on CD4 T cells87-89. These results describe a “bridge” model, where CD4 T 
cells and CD8 T cells interact with the same dendritic cell, albeit likely at different times, in 
order to properly prime a cytotoxic T cell response81,88. This suggests that CD4 T cells must be 
activated prior to CD8 T cells, likely by migratory cDCs, in order for them to act on cDC1s 
through CD40L to help induce CD8 T cell priming (Figure 1.1B and 1.1D). 
Questions remain as to whether the interaction between cDC1s and CD4 T cells is 
antigen specific. Initial studies that showed that CD4 T cell help for CD8 T cell priming required 
cognate CD4 T cell interactions85. However, later it was suggested that CD40 signaling was 
sufficient to provide help, even when DCs lack MHCII88. In vitro analysis of presentation by DC 
subsets using antibody-targeted antigen implied that cDC1s were relatively poor in antigen 
presentation to CD4 T cells relative to cDC2s, while cDC2s were adept at activating CD4 T cells 
in vitro36,90. This leads to the question of whether cDC1s use MHCII presentation solely to obtain 
help from previously activated CD4 T cells for CD8 T cell priming or, alternatively, whether 
cDC1s can also prime naïve CD4 T cells. A recent study has shown that CD8 T cells cluster with 
cDC1s, while CD4 T cells cluster with cDC2s during OVA immunization91, suggesting that T 
cell priming may be DC-subset specific. However, late during viral infection both cDC1 and 
cDC2 subsets have the capacity to activate CD4 T cells82. In addition, both CD4 and CD8 T cell 
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priming against insulin in non-obese diabetic mice is decreased in the absence of cDC1s92. In the 
tumor context, cDC1s are necessary for priming of both CD4 and CD8T cells to cell-associated 
antigens (Ferris et al, Unpublished) Since CD4 T cells were shown to be primed first by 
migratory DCs81, it is possible that migratory cDC1s prime the CD4 T cells that later help 
lymph-node-resident cDC1s induce CD8 T cell priming (Figure 1.1B and 1.1D). Further studies 
will be necessary to determine to what extent each DC subset contributes to T cell priming in 
different infection contexts. 
1.9 Conclusions 
cDC1s are the predominant cross-presenting cells functioning in CD8 T cell priming in 
vivo20. Recent imaging studies suggest that cDC1s also function as a platform for CD4 T cell 
help during viral infections77,81, likely through CD40–CD40L interactions87,88. However, it 
remains unclear whether cDC1s can also prime naive CD4 T cells or whether they receive only 
help from them36,82,85,92. More sophisticated in vivo models will need to be generated in order to 
determine the role of cDC1s in priming CD4 T cell responses in vivo in order to further 
distinguish the unique roles of DC subsets. 
Transcriptional profiling has suggested that moDCs may not be a functional cross-
presenting DC subset in vivo33 and at least in one setting may represent monocyte-derived 
macrophages68. Many molecules described previously to be involved in cross-presentation were 
evaluated in the context of GMDCs and need to be examined in the context of cDC1s41-45. 
Recent advances in DC biology have allowed for the conditional deletion of genes in cDC1s 
through the use of XCR1-cre93 and analysis of transcriptional differences between DC subsets94. 
Examining molecules described in moDCs also in cDC1s and studying other cDC1-specific 
genes will aid in our understanding of how cross-presentation against viral and cancer antigens 
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occurs and may provide more insight into whether moDCs are a true DC subset in vivo. 
Elucidating the mechanisms by which cDC1s activate CD8 T cells and the mechanisms 
underlying the various interactions between DC subsets and T cells should be of value in 






















Figure 1.1 Model for CD8 T cell priming by resident classical CD8α+ dendritic cells 
(cDC1s)  (A) Antigen is captured by migratory cDC1s or CD11b+ cDCs (cDC2s) at the site of 
infection by either direct infection or phagocytosis. (B) After antigen capture, migratory cDC1s 
or cDC2s with antigen then migrate to the draining lymph node, where they prime naïve antigen-
specific CD4 and possibly CD8 T cells through major histocompatibility (MHC):T cell receptor 
(TCR) interactions. (C) Migratory cDCs transfer antigens to resident cDC1s through either 
“cross-dressing”, the process by which loaded MHCI is transferred between cell membranes, or 
by transferring the antigen itself, which is then taken up by the resident cDC1s for cross-
presentation. (D) Resident cDC1s receive “help” through CD40:CD40L interactions with CD4 T 
cells, which allow them to prime antigen-specific naïve CD8 T cells through MHCI:TCR 
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To study cross-presentation by classical dendritic cells (cDCs), we evaluated the role of 
RAB43, a protein found to be selectively expressed by Batf3-dependent CD8α+ and CD103+ 
CD8α+ compared with other DCs subsets and immune lineages. Using a specific monoclonal 
antibody, we localized RAB43 expression to the Golgi apparatus and LAMP1– cytoplasmic 
vesicles. Mice with germline or conditional deletion of Rab43 are viable and fertile, have normal 
development of cDCs, but show a defect for in vivo and in vitro cross-presentation of cell-
associated antigen. This defect is specific to cDCs, since Rab43-deficient monocyte-derived DCs 
showed no defect in cross-presentation of cell-associated antigen. These results suggest that 
RAB43 provides a specialized activity used in cross-presentation selectively by CD8α+ DCs but 
not other antigen presenting cells. 
1.2 Introduction 
 Rab proteins are a family of small GTPases that have been shown to regulate vesicular 
localization and are important markers for identifying intracellular vesicles1-3.  Rab proteins 
switch between an active GTP-bound form and an inactive GDP bound form, allowing their 
function to be regulated by guanine nucleotide exchange factors (GEFs) and GTPase activating 
proteins (GAPs)4. One of the best characterized Rab proteins is Rab5, a marker of early 
endosomes. Rab5 interacts with the membrane tether Early endosomal antigen 1 (EEA1) causing 
it to change conformation allowing Rab5+ vesicles to come in contact and fuse with other 
vesicles expressing EEA15-8. Rab proteins have also been shown to act in cascades, where an 
initial Rab protein will recruit a GEF for another Rab protein or a phosphoinositol phosphate 
which can recruit another Rab protein leading to sequential Rab activation along a vesicle 
membrane as the vesicle matures4,9.  Since cross-presentation involves the uptake of antigens 
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into endosomes and likely the regulated movement of these antigens to allow for MHCI 
presentation, it is likely that specific Rab proteins are involved in regulating this process. 
 Some Rab proteins have already been shown to be involved in regulating cross-
presentation in GM-CSF derived DCs.  Rab11a, a marker of recycling endosomes, was shown to 
mark pools of MHCI in cytosolic vesicles within these cells. It was proposed that toll-like 
receptor (TLR) signals could induce the movement of MHCI from these pools to other vesicles 
containing antigens to allow for cross-presentation10.  Rab27a, Rab34, and Rab3c were all also 
shown to play a role in the cytosolic pathway of cross-presentation11-13.  Through different 
mechanisms, all three proteins were suggested to regulate phagosomal alkalinization, therefore 
maintaining antigen in an incompletely degraded state to allow for it to be exported to the cytosol 
for cross-presentation11-13.  Despite these mechanisms being described, the role of these Rab 
proteins in cross-presentation by cDC1s in vivo has never been analyzed.  In addition, none of 
these studies analyzed the expression Rab27a, Rab34, or Rab3c in cDC1 cells, analysis which 
would indicate that they are very lowly expressed and not within the most differentially 
expressed Rab proteins between DC subsets.   
 The two most differentially expressed Rab proteins between cDC1 and cDC2 cells are 
Rab7b and Rab43.  Rab43 has been shown in cell lines to potentially play a role in either 
development of or transport through the Golgi Apparatus, suggesting it may play a role in 
localization of newly synthesized or edited proteins14-16.  Its selective expression makes it an 
interesting candidate for analysis in cross-presentation.  The second most differentially expressed 
Rab protein is Rab7b.  Rab7b has been shown in macrophages to regulate movement of TLRs, 
altering signaling dynamics17,18.  Rab7b is also used as a marker for late endosomes3,19,20.  Since 
Rab proteins often function in cascades, it is possible that both Rab43 and Rab7b are involved in 
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a similar process to regulate antigen or peptide-loading complex movement during cross-
presentation4,9.  Like Rab43, the role of Rab7b has never been described in cDC1s. 
1.3 Results 
Rab43 is highly expressed in CD8α+ dendritic cells. 
We evaluated expression of all RAB family members present in Mouse Genome 430 2.0 
microarrays21,22 for expression in CD8α+ DCs, CD8α– DCs, and common dendritic cell 
progenitors (CDPs)23 (Figure 2.1A). Rab43 was among the most highly expressed RAB proteins 
in CD8α+ DCs compared with CDPs and CD8α– DCs. Mouse and human RAB43 are 95% 
identical (Figure 2.2), suggesting evolutionary conservation. Using RT-PCR, we directly 
confirmed that Rab43 was most highly expressed in CD8α+ DCs compared with CD8α– DCs, 
plasmacytoid DCs (pDCs), monocytes, T cells, and B cells (Figure 2.1B). In the skin-draining 
lymph node (sLN), CD8α+ resident and CD103+ migratory DCs express the highest levels of 
Rab4324(Figure 2.1C). 
To analyze RAB43 at the protein level, we generated a monoclonal antibody, 2E6, directed to 
amino acids 179 to 203, a region of RAB43 that is highly divergent from other RAB family 
members. Using 2E6 for Western analysis, we confirmed that RAB43 protein was specifically 
expressed in CD8α+ cDCs at levels that were substantially higher than in CD8α– DCs, pDCs, 
monocytes, T cells, and B cells (Figure 2.1D). Intracellular staining with biotinylated 2E6 also 
showed that RAB43 is most abundant in CD8α+ resident and CD103+ migratory DCs in the sLN 
compared to other DC subsets, similar to what is observed in the spleen (Figure 2.1E).  
Rab43-deficient mice are viable and have normal cDC development 
 RAB43 has only been examined by overexpression or shRNA-mediated knock-down in 
transformed cells line in vitro14-16.  A potential dominant negative RAB43 (T32N) mutation 
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reportedly induced Golgi fragmentation in Hela cells15, suggesting that RAB43 may function in 
golgi development or maintenance. However, these conclusions were based on in vitro 
morphological analysis of HeLa and hTERT-RPE1 cells, in which endogenous levels of RAB43 
protein were not determined. No studies have yet analyzed the in vivo role of RAB43 or its 
function in CD8α+ DCs where it is most highly expressed.   
 To test the in vivo role of RAB43, we generated Rab43f/f mice that allow conditional 
deletion of the Rab43 exon 2, which encodes critical residues of the Rab domain (Figure 2.3). 
Conditional deletion in cDCs was achieved by crossing to CD11c (Itgax)-Cre25 to produce 
Rab43cKO mice, and constitutive germline Rab43 deletion (Rab43Δ/Δ) was achieved on 129SvEv 
and C57BL/6 backgrounds by crossing to germline-expressing Cre-deletor strains.   
 Rab43Δ/Δ and Rab43cKO mice were viable and produced fertile offspring at normal 
Mendelian frequencies. To confirm that RAB43 protein was absent from DCs in Rab43Δ/Δ and 
Rab43cKO mice, we performed Western analysis for RAB43 using 2E6 on CD11c– or CD11c+ 
splenocytes (Figure 2.1F). In wild type (WT) mice, RAB43 protein was detected in CD11c+ 
splenocytes, but not in CD11c– splenocytes (Figure 2.1F), as expected. In Rab43Δ/Δ mice, RAB43 
was not detectable in either CD11c+ splenocytes or CD11c– splenocytes, indicating that germline 
deletion of Rab43 exon 2 is sufficient to eliminate RAB43 protein (Figure 2.1F). In Rab43f/f 
mice, RAB43 was detectable in CD11c+ splenocytes as expected, but RAB43 was nearly 
undetectable in Rab43cKO mice (Figure 2.1G). This result indicates that exon 2 deletion by 
CD11c-Cre can efficiently eliminate RAB43 protein in cDCs.  
Loss of RAB43 in Rab43Δ/Δ mice caused no changes in the development of mature B 
cells, CD4+ T cells, CD8+ T cells, BM monocytes, or plasmacytoid DCs (pDCs) (data not 
shown). Further, there was no impact on DC development in Rab43Δ/Δ mice, which showed 
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normal populations of splenic cDCs (Figure 2.1H) and normal migratory and resident DCs in 
sLNs (Figure 2.1I). Populations of DCs were normal in nonlymphoid tissues such as the liver 
and small intestine lamina propria (SILP) (Figure 2.1J). RAB43 deficient DCs also produced 
normal levels of cytokines upon stimulation by LPS, CpG, PolyI:C, and STAg (Figure 2.1K). 
Thus, RAB43 is selectively expressed in CD8α+ cDCs, but is not required for their development 
or response to stimuli.  
RAB43 is localized to the Golgi and LAMP1– vesicles in CD8α+ DCs 
 To determine the localization of RAB43 within DCs, we carried out immunofluorescence 
microscopy on FLT3L cultured bone marrow (BM) cells using 2E6 antibody along with markers 
of various organelles (Figure 2.4). RAB43 was expressed in brightly staining perinuclear 
organelles that co-localized with giantin, a cis-Golgi marker (Figure 2.4A and 2.4E). 2E6 
staining was specific for RAB43, since no 2E6 signal was seen in Rab43Δ/Δ DCs (Figure 2.4A, 
lower panels). RAB43 did not co-localize with the endoplasmic reticulum marker calnexin, 
(Figure 2.4B and 2.4E) and showed only limited co-localization with the trans-Golgi marker 
TGN38 (Figure 2.4C and 2.4E).  
 Specific RAB43 staining was also evident in small cytoplasmic vesicles throughout the 
DCs' long dendritic branches (Figure 2.4F). No vesicular staining was seen in Rab43Δ/Δ DCs 
(Figure 2.4A). 2E6 staining did not co-localize with LAMP1, suggesting that the RAB43 
expressing vesicles are not lysosomes (Figure 2.4D and 2.4E). In summary, RAB43 appears to 
be expressed on cis-Golgi and in a non-lysosomal vesicular compartment.  
RAB43 deficient CD8α+ DCs have an intact Golgi Apparatus 
 Because RAB43 was suggested to control Golgi integrity in Hela cells15, we asked if the 
Golgi was intact in DCs isolated from WT and Rab43Δ/Δ mice (Figure 2.5A and 2.5B). RAB43 
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co-localized with giantin in CD8α+ cDCs freshly isolated from WT mice (Figure 2.5A), in 
agreement with analysis of in vitro generated cDCs (Figure 2.4). Freshly isolated CD8α– cDCs 
were negative for 2E6 staining (Figure 2.5A), consistent with RAB43 expression assessed by 
Western analysis (Figure 2.1D) and ICS (Figure 2.1E). The area of giantin staining is similar in 
both WT and Rab43Δ/Δ DCs, suggesting that the absence of RAB43 protein had no apparent 
impact on its distribution (Figure 2.5C).  
 Further, we used electron microscopy to examine CD8α+ DCs purified from Rab43f/f and 
Rab43cKO mice . There were no notable differences in morphology or density of Golgi 
membranes (Figure 2.5D and 2.5E). Glycoprotein analysis of LAMP1 shows that Golgi-
mediated glycosylation is normal in Rab43Δ/Δ DCs (Figure 2.5F). It has also been shown that 
overexpression of RN-tre, a possible GTPase-activating protein for RAB4316, does not alter ER 
to Golgi transport of VSVg in HeLa cells15. Therefore, RAB43 appears to be dispensable for 
development and function of the Golgi apparatus in cDCs.   
 To analyze the localization of RAB43 after antigen uptake, we incubated in vitro Flt3L-
derived DCs with heat-killed Listeria monocytogenes expressing ovalbumin (HKLM-OVA). We 
found that RAB43 still localizes to the Golgi after uptake of antigen and also that HKLM-OVA 
localized to a peri-nuclear region near the Golgi apparatus in both WT and Rab43Δ/Δ DCs (Figure 
2.5G).  Therefore, RAB43 localization is not dependent on the uptake of antigen. 
 Previous reports have suggested that RAB43 is involved in the recruitment of Cathepsin 
D to phagosomes26. Since Cathepsin D has been implicated in cross-presentation in human 
moDCs27,we examined whether the mechanism of RAB43 action could involve regulation of 
Cathepsin D. We found that Cathepsin D was not expressed in either cDC population at either 
the transcript or protein level, and that this did not change upon activation by LPS (Figure 2.5I 
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and 2.5J).  This suggests that the mechanism of action of RAB43 in CD8α+ DCs does not involve 
the regulation of Cathepsin D. 
RAB43-deficient CD8α+ cDCs have reduced cross-presentation both in vitro and in vivo 
 Because trafficking of intracellular vesicular compartments is necessary for antigen 
cross-presentation, and CD8α+ DCs are efficient for this activity28-31, we asked whether RAB43 
might have a role in antigen presentation by DCs. CD8α+ DCs and CD8α– DCs purified from 
WT and Rab43Δ/Δ mice were tested for their ability to cross-present HKLM-OVA to OT-1 T cells 
in vitro (Figure 2.6A and 2.6B). WT CD8α+ DCs cross-presented HKLM-OVA in a dose 
dependent manner, however; CD8α+ DCs from Rab43Δ/Δ mice induced significantly less OT-1 
proliferation at both low and high doses of bacteria (Figure 2.6A). Cross-presentation of HKLM-
OVA by CD8α– DCs from WT or Rab43Δ/Δ mice was not observed at any dose tested (Figure 
2.6B).  
 OT-1 T cells also proliferated in response to soluble antigen presented by WT CD8α+ 
DCs in a dose dependent manner (Figure 2.6C). Using CD8α+ DCs from Rab43Δ/Δ mice, OT-1 
proliferation was significantly reduced at intermediate doses of soluble OVA, but not at the 
maximal dose (Figure 2.6C). CD8α– DCs were able to cross-present soluble OVA, but this 
required a higher concentration than that needed for OT-1 stimulation by CD8α+ DCs, and there 
was no difference between WT and Rab43Δ/Δ DCs  (Figure 2.6D). These results suggest that 
CD8α+ DCs have a unique cross presentation program that is Rab43-dependent. This pathway is 
involved in the presentation of cell-associated, but less so soluble antigens and may not be 
necessary for presentation of high soluble antigen loads. As a control, presentation of SIINFEKL 
peptide was equal between CD8α+ DCs and CD8α–cDCs from either WT or Rab43Δ/Δ mice, 
suggesting MHCI levels are normal on Rab43Δ/Δ DCs (Figure 2.6E).   
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 We next tested the ability of Rab43cKO mice to prime T cells in vivo using cell-associated 
antigen32. The number of active (CD44+CD62L–) Kb SIINFEKL tetramer positive T cells in the 
spleen were analyzed 8 days after injection of irradiated MHCI TKO (Kb–/–Db–/–β2m–/–) 
splenocytes loaded with OVA or PBS. We found that Rab43cKO mice had a reduced ability to 
prime CD8 T cells against cell-associated antigen in vivo (Figure 2.6F).  
The defect in T cell priming was specific to cross-presentation because direct 
presentation of intracellular OVA and MHCII presentation were not affected in Rab43Δ/Δ mice 
(Figure 2.6G and 2.6H). In summary, RAB43 functions in a cross-presentation specific pathway 
that is involved in the presentation of cell-associated and low dose soluble antigen by CD8α+ 
DCs.  
Monocyte-derived DCs from RAB43-deficient mice show no defect in cross-presentation 
 Monocyte-derived DCs (moDCs) generated with GM-CSF and IL-4 can cross-present 
cell-associated antigen to a similar efficiency as CD8α+ DCs but use a distinct transcriptional 
program to acquire this capacity33. We asked whether cross-presentation by moDCs is Rab43-
dependent (Figure 2.7). Western analysis using 2E6 showed that RAB43 is expressed at a low 
level in moDCs generated with GM-CSF only (moDC GM) or with GM-CSF and IL-4 (moDC 
GM/4) (Figure 2.7A). OT-1 priming by Rab43Δ/Δ  moDC-GM/4 was equal to that of WT moDC-
GM/4 at all antigen doses for both presentation of OVA-loaded irradiated splenocytes and 
HKLM-OVA (Figure 2.7B and 2.7C). Thus, cross-presentation by moDCs uses a Rab43-
independent pathway distinct from the Rab43-dependent pathway in CD8α+ DCs. Similarly, 





2.4 Discussion  
Several in vitro studies have relied on monocyte-derived DCs (moDCs) cells to analyze 
cross-presentation10,35-37, even though in vivo cross-presentation appears specific to CD8α+ 
DCs31,38,39. Based on our data, moDCs may not be appropriate in vitro models for cross-
presentation, and molecules analyzed using moDCs should be confirmed using primary CD8α+ 
DCs obtained from animal models. 
 In conclusion, RAB43 functions in a CD8α+ DC specific pathway necessary for efficient 
cross-presentation of cell-associated antigen. Our data suggests that there are two separate 
pathways for soluble antigen presentation, and low-dose presentation was seen only in CD8α+ 
DCs and is dependent on RAB43. These results suggest that the form and amount of internalized 
antigen may impact how it is eventually processed and presented in CD8α+ DCs.  This could be 
due to differential endocytosis (i.e. receptor-mediated versus micropinocytosis) or alternative 
methods of processing soluble proteins versus intact cells.  The Golgi and vesicular localization 
of RAB43 suggests it may function in intracellular transport of antigen or the peptide loading 
complex. Our data shows that moDCs cross-present through mechanisms distinct from those 
used by CD8α+ DCs in vivo, suggesting that previous mechanisms proposed for cross-
presentation that relied on moDCs may need to be re-evaluated in the correct cell type. These 









Figure 2.1. Rab43 is highly and selectively expressed in CD8α+ cDCs and does not impact 
cDC development. (A) Sorted WT CD8α+ DCs, CD8α– DCs, and BM CDPs analyzed by gene 
expression microarray. Expression levels determined for list of Rab proteins in Mouse 430 2.0 
and plotted based on CD8α + DC/CDP (X-axis) versus CD8α + DC/CD8α– DC (Y-axis) 
expression ratios. Each dot indicates an individual probe set. Representative of at least two 
independent experiments with three pooled mice. (B) Expression value (AU) of Rab43 mRNA 
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normalized to Hprt by qRT-PCR for indicated cell populations. Data from three independently 
sorted replicates of three wild type mice. (C) Immgen data showing expression of Rab43 in 
indication populations from skin-draining lymph node (D) Western analysis of RAB43 and β-
Actin for indicated spleen or BM populations from wild type mice. Data representative of at least 
three independent experiments. (E) Intracellular staining for RAB43 in indicated cells from 
spleen and sLN from WT and Rab43Δ/Δ B6 mice. Numbers represent MFI of RAB43 staining for 
indicated cells. Data representative of two independent experiments. (F) Western analysis for 
RAB43 and Lamin B from WT or Rab43Δ/Δ 129 (Δ/Δ) splenocytes. CD11c-negative (-) or 
CD11c-positive (+) splenocytes were isolated using CD11c microbeads. Representative of at 
least two experiments. (G) Western analysis for RAB43 and Lamin B from CD11c-negative (-) 
or CD11c-positive (+) B6 splenocytes isolated as in (A) derived from Rab43f/f mice that were 
either CD11cCre– (Cre-) or CD11cCre+ (Cre+) as indicated. Representative of at least two 
experiments. (H) Percentage (left) and absolute number (right) of DC subpopulations from 
spleen of WT and Rab43Δ/Δ B6 mice. (I) Percentage (left) and absolute number (right) of DC 
subpopulations from sLN of WT and Rab43Δ/Δ mice. Cells gated based on resident (B220–
MHCIIintCD11chi) and migratory (B220–MHCIIhiCD11cint/lo) populations. Data for (H and I) 
from three independent experiments, each dot represents a single mouse. (J) Contour plots of 
tissue DCs from the small intestine lamina propria (SILP) or liver of WT or Rab43Δ/Δ  129 (Δ/Δ) 
mice pregated on B220–CD45.2+MHCII+CD11c+. Data representative of at least two 
experiments. (K) Percentage of IL-12 and TNF-alpha positive cells after incubation of FLT3L 
cultured BM cells from WT and Rab43Δ/Δ 129 mice with LPS, CpG,PolyI:C, or STAg. Data 
















Figure 2.2. Sequence alignment of RAB43. 
(A) Sequence alignment for mouse RAB43 (mRAB43) and human RAB43 (hRAB43). 
Conserved sequence (*), conservative mutation (:), semi-conservative mutation (.), and non-


















Figure 2.3. Targeting strategy for Rab43cKO.  
Shown is the Rab43 genomic locus, targeting vector, and mutated allele prior to removal of the 
neomycin cassette (pGK-Neo). Exons are displayed as boxes with coding regions shaded. An 
orphan LoxP sequence was inserted at the AccI site (A). Correctly targeted alleles show a 5.3 kB 
band detected by the 5’ probe and a 10 kB band detected by the 3’ probe. TK, thymidine kinase 
















Figure 2.4. RAB43 is abundant in Golgi and vesicles of Batf3-dependent dendritic cells. (A) 
Day 10 FLT3L cultured BM from WT (top panels) or Rab43Δ/Δ (bottom panels) 129 mice were 
treated with LPS for four hours (to improve attachment), allowed to attach to coverslips, fixed, 
and stained with 2E6 (anti-RAB43, green) and anti-giantin (red) and attached to slides using 
Prolong Gold antifade with DAPI (blue). (B-D) WT cells as described in (A) untreated with LPS 
were stained with 2E6 (green) and anti-Calnexin (red) (B), anti-TGN38 (red) (C), or anti-
LAMP1 (red) (D). Coverslips were attached to slides using Prolong Gold antifade with DAPI 
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(blue). Scale bars indicate 5μm. (E) Percentage of organelle stain that is co-localized with 
RAB43 stain for indicated organelles. Each dot represents a single cell. Data obtained using 
Imaris Coloc2. (F) WT cells prepared as described in (A) shown at increased zoom to highlight 
vesicular staining. All microscopy data representative of at least two independent experiments. 

























Figure 2.5. Rab43Δ/Δ CD8α+ DCs have normal Golgi development. 
(A and B) Sorted Ly6G–Ly6C–Thy1.2–B220–DX5–F4/80–CD11c+ splenocytes from WT (A) or 
Rab43Δ/Δ (Δ/Δ) (B) 129 mice were allowed to attach to coverslips, fixed, and stained for CD8α 
(white), giantin (red), and RAB43 (green). Coverslips were attached to slides using ProLong 
Gold antifade with DAPI (blue). Data is representative of at least three independent experiments. 
Scale bars represent 5μm. (C) Area of golgi staining from WT and Rab43Δ/Δ DCs, each dot 
represents a single cell from staining in (A and B). Area obtained using ImageJ, statistics 
analyzed by two-tailed Mann-Whitney U test with p>.5 (D and E) Electron microscopy of sorted 
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B220–CD11c+MHCII+CD24+CD172a– splenocytes from Rab43f/f-CD11cCre- (D) or Rab43f/f-
CD11cCre+ (E) B6 mice showing normal Golgi development. Data is from analysis of cells from 
five pooled mice. Scale bars represent 500nm. (F) Western analysis for LAMP1 in splenocyte 
protein lysate given no treatment, endoH, or PNGaseF. Representative of three independent 
experiments (G) Sorted SiglecH–CD11b–Sirpa–Bst2– cells from FLT3 cultures of WT (G) or 
Rab43Δ/Δ (H) B6 BM were incubated with Alexa-Fluor 647 labeled HKLM-OVA (white) and 
then prepared as in (B) without CD8α stain. Images representative of three experiments (I) 
Immgen expression data for Cathepsin D in red pulp macrophages, CD8α+ DCs, and CD8α–  
DCs. (J) Western analysis for Cathepsin D in bone marrow macrophages, CD8α+ DCs, and 






















Figure 2.6. CD8α+ DCs from Rab43Δ/Δ mice are defective in cross-presentation of cell-
associated and soluble antigens. 
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(A and B) Sorted CD8α+ (A) or CD8α– (B) DCs from WT (black) or Rab43Δ/Δ (red) B6 mice 
were cultured for 3 days with CFSE labeled OT-I T cells and different doses of heat-killed 
Listeria monocytogenes expressing OVA (HKLM-OVA) and assayed for OT-I proliferation and 
activation (CFSE–CD44+) (C and D) Sorted CD8α+ (C) or CD8α
– (D) DCs from WT (black) or 
Rab43Δ/Δ (red) mice were cultured and analyzed as in (A) with various doses of soluble OVA as 
antigen. (E) Sorted CD8α+ (solid lines) or CD8α– (dashed lines) DCs from WT (black) or 
Rab43Δ/Δ (red) mice were cultured and analyzed as in (A) with indicated amounts of SIINFEKL 
peptide as antigen. (F) Rab43f/f-CD11cCre- (black) or Rab43f/f-CD11cCre+ (red) mice were injected 
with the indicated numbers of PBS (OVA–) or OVA (OVA+)-loaded irradiated MHCI TKO 
splenocytes and analyzed 8 days later for the number of Kb SIINFEKL Tetramer+ T cells that 
were CD44+CD62L–. Each dot represents cells obtained from one mouse. (G) Sorted CD8α+ 
(solid) or CD8α– DCs (dashed) from WT (black) or Rab43Δ/Δ (red) mice were osmotically loaded 
with OVA and cultured and analyzed as in (A). (H) Sorted CD8α+ (solid) or CD8α– DCs 
(dashed) from WT (black) or Rab43Δ/Δ (red) mice were cultured for 3 days with CFSE labeled 
OT-II T cells and irradiated splenocytes osmotically loaded with OVA. T cells were assayed for 
proliferation and activation (CFSE–CD44+). All data displayed as mean ± SEM from at least two 

































Figure 2.7. Monocyte-derived DCs from Rab43 Δ/Δ mice show no defect in cross-
presentation. 
(A) Western analysis of RAB43 and β-actin in CD8α+ and CD8α– cDCs compared to moDCs 
cultured for four days with either GM-CSF alone (GM) or GM-CSF + IL-4 (GM/4). Data 
representative of at least two experiments. (B) GM-CSF + IL-4 cultured moDCs from WT 
(black) or Rab43Δ/Δ (red) 129 monocytes were cultured with indicated numbers of PBS (OVA–) 
or OVA (OVA+) -loaded irradiated MHCI TKO splenocytes and OT-I T cells. After 3 days, 
cultures were assayed for OT-I proliferation and activation (CFSE–CD44+). (C) Sorted CD8α+ 
and CD8α–DCs and in vitro generated moDC GM/4 from WT (black) or Rab43Δ/Δ (red) B6 mice 
were cultured for 3 days with CFSE labeled OT-I T cells and different doses of heat-killed 
Listeria monocytogenes expressing OVA (HKLM-OVA) and assayed for OT-I proliferation and 
















2.5 Materials and Methods 
Mice.  
 Wild-type (WT) 129SvEv mice were purchased from Taconic. WT C57BL/6, B6.SJL-
PtprcaPepcb/BoyJ (B6.SJL) and C57BL/6-Tg(TcraTcrb)1100Mjb/J (OT-1) mice were purchased 
from Jackson.  Mice designated as WT are from in house breeding of C57BL/6 or 129SvEv 
strains, experiments done with Rab43f/f mice used littermate controls. MHCI KO mice (Kb–/–Db–/–
β2m–/–; TKO) were a gift from Herbert W. Virgin and Ted Hansen, Washington University, St. 
Louis40. Experiments were performed with age- and sex-matched mice between 6-12 weeks of 
age. All mice were bred and maintained in specific pathogen-free facilities according to 
institutional guidelines protocols approved by the Animal Studies Committee of Washington 
University in St. Louis. 
Generation of the Rab43cKO mouse. 
The Rab43f/f
 
targeting construct was generated using Gateway recombination 
(Invitrogen) as follows. The Entry vector, pENTR-lox-FRT-rNeo, was created by replacing the 
puromycyin resistence gene in pENTR-lox-Puro41 with the neomycin resistance gene from 
vector pLNTK, and frt sites flanking each lopP site were added. The Rab43 5' homology arm 
was amplified by PCR from 129SvEv- EDJ22 ES cell genomic DNA using oligonucleotides 
containing attB4 and attB1 sites, 
GGGGACAACTTTGTATAGAAAAGTTGGCAGACCTCCTACTCCAAAG and 
GGGGACTGCTTTTTTGTACAAACTTGCAAGGCTGCACTGAGGCTA. The attB4-attB1 
PCR fragment was inserted into the pDONR (P4-P1R) plasmid (Invitrogen) by the BP 
recombination reaction generating pENTR-RAB43-5HA. The Rab43 3' homology arm was 
amplified by PCR from genomic DNA using the following oligonucleotides containing attB2 and 
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attB3sites, GGGGACAGCTTTCTTGTACAAAGTGGGAGCCAATTCCTTACCTCCA and 
GGGGACAACTTTGTATAATAAAGTTGTAGAAGGGACGGATGCAGC. The attB2-attB3 
PCR fragment was inserted into pDONR(P2R-P3) plasmid (Invitrogen) by the BP recombination 
reaction generating pENTR-RAB43-3HA. pENTR-RAB43-3HA was digested with Acc1 to 
produce an overhang where an overlapping oligonucleotide containing an orphan loxP site could 
anneal. The annealed oligonucleotides for insertion of the orphan loxP site were as follows: 
CTATAACTTCGTATAGCATACATTATACGAAGTTATGGATCC and 
AGGGATCCATAACTTCGTATAATGTATGCTATACGAAGTTAT. After ligation, 
sequencing confirmed the insertion of the orphan loxP and the resulting plasmid was called 
pENTRE-RAB43-3HA-Acc1. LR recombination reaction was performed using pENTR-RAB43-
5HA, pENTR-RAB43-3HA-Acc1, pENTR-lox-FRT-rNeo and pDEST-DTA-MLS to generate 
the final targeting construct.  
The linearized vector was electroporated into EDJ22 embryonic stem cells (129SvEv 
background), and targeted clones were identified by Southern analysis with the 5’ probe and 
confirmed with the 3’ probe. Probes were amplified from genomic DNA using the following 
primers: RAB43_5P_F GCCGATGTCCTCAGATCAAT, RAB43_5P_R 
GTAGAGCCCTCGCTCCTTCT, RAB43_3P_F GAAACAGGTTGGAGCCCATA, and 
RAB43_3P_R TGACTTGGAAAAGCCCATTC.  
Blastocyst injections were performed to generate male chimeras. Germline Rab43+/fl mice 
were crossed to 129S6-Tg(Prnp-GFP/Cre)1Blwd mice for constitutive germline deletion 
(RAB43Δ/Δ 129). Germline Rab43+/f were also crossed to B6.129S4-
Gt(ROSA)26Sortm1(FLP1)Dym/JRainJ (FLPeR) to delete the neomycin cassette, generating the 
Rab43fl allele. Rab43+/fl mice were backcrossed 10 generations to the C57BL/6J background 
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(Stock no. 029844). Rab43+/fl were either bred to B6.C-Tg(CMV-cre)1Cgn/J to generate 
Rab43Δ/Δ B6 mice or bred to B6.Cg-Tg(Itgax-cre)1-1Reiz/J (CD11c-cre) mice from Jackson to 
generate conditional deletion of Rab43 (Stock no. 029845).  
Genotyping PCR was conducted to confirm germline transmission and to confirm neo 
deletion from the FLPeR mouse. The primers used were the following: 
CACTGCCCAGTCTAGCTTCC, GAGTGGCTCTCCCCTTAACC, 
GGGTGGGGTGGGATTAGATA. To screen for the presence of the orphan loxP or constitutive 
deletion, we used the following primers: AGGCAGAAGCAAGCAGGTTT, 
GTGATCTGGGCCAAAACGTA, and CAAAGCTATCCGACCAGGAC.  
Antibodies and flow cytometry.  
Flow cytometry and cell sorting experiments were completed on a FACS CantoII, 
FACSAriaII or FACSAria Fusion (BD Biosciences) instrument and analyzed using FlowJo 
analysis software (Tree Star, Inc.). Staining was performed at 4°C in the presence of Fc Block 
(clone 2.4G2; BD) in MACS buffer (DPBS + 0.5% BSA + 2 mm EDTA).The following 
antibodies were purchased from BD Biosciences: anti-CD3 (145-2C11), anti-CD8 (53-6.7), anti-
CD11c (HL3), anti-CD19 (1D3), anti-B220 (RA3-6B2), anti-CD172a (P84), anti-Ly6C (AL-21), 
anti-Ly6G (1A8), and anti-H-2Kb (AF6-88.5). The following antibodies were purchased from 
Biolegend: anti-CD4 (RM4-5), anti-CD11c (N418), anti-CD24 (M1/69), anti-CD115 (AFS98), 
anti-CD135 (A2F10), anti-MHCII (I-A/I-E) (M5/114.15.2), and anti-TCR-V2 (B20.1). The 
following antibodies were purchased from eBiosciences: anti-CD44 (IM7), anti-CD45.2 (104), 
anti-CD90.2 (53-2.1), anti-CD103 (2E7), anti-CD117 (2B8), anti-CD317 (eBio927), anti-F4/80 
(BM8), anti-TER119 (TER-119), anti-CD62L (MEL-14), and anti-SiglecH (eBio440c). The 
following antibodies were purchased from Tonbo Biosciences: anti-CD11b (M1/70) and anti-
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CD45.1 (A20).  
 For immunofluorescence and confocal microscopy, the following antibodies were 
purchased from Abcam: rabbit polyclonal anti-giantin (ab24586) and rabbit polyclonal anti-
calnexin (ab22595). The following antibody was purchased from Santa Cruz: rabbit polyclonal 
anti-TGN38 (sc-33784). The following antibodies were purchased from Invitrogen: Alexa 
Fluor® 488 Goat Anti-Mouse IgG (H+L), Alexa Fluor® 488 Goat Anti-Rabbit IgG (H+L), 
Alexa Fluor® 647 Goat Anti-Rabbit IgG (H+L), and Streptavidin, Alexa Fluor® 555 conjugate.  
 For Western analysis, the following antibodies were purchased from Santa Cruz: anti--
actin (C4) and anti-laminB (M-20), Abcam: anti-Lamp1 (ab24170), or R & D Systems: anti-
Cathepsin D (AF1029). H2-Kb SIINFEKL Tetramer was purchased from MBL International. 
DC preparation. 
 To harvest DCs from lymphoid tissue, organs were minced and digested with 250 g/mL 
collagenase B (Roche) and 30 U/mL DNAse I (Sigma-Aldrich) for 30-60 minutes at 37°C with 
stirring in 5 mL complete Iscove’s modified Dulbecco’s media + 10% FCS (cIMDM). 
Erythrocytes (RBCs) were removed using ACK lysis buffer (150 mM Ammonium chloride, 10 
mM Potassium bicarbonate, 0.1 mM EDTA). Cells were passed through a 70 m nylon mesh 
and counted with a Vi-CELL analyzer (Beckman Coulter). For FACS analysis, 5-10 X 106 cells 
were stained in MACS buffer. Prior to sorting, DCs were first enriched using CD11c-microbeads 
(Miltenyi).  
 For peripheral tissue DCs, organs were digested in collagenase D (Roche) and DNAseI 
(Sigma-Aldrich) for 1 hour at 37°C with stirring in 5 mL cIMDM. Liver cells were separated 




Bone marrow culture with FLT3L. 
 BM was flushed from mouse tibias and femurs, and red blood cells were removed using 
ACK lysis buffer. BM cells were cultured at 2 X 106 cells/mL in cIMDM containing 100 ng/mL 
FLT3L for 8-10 days. Loosely adherent cells were harvested for analysis. 
MoDC preparation. 
 To obtain BM monocytes, femurs, tibias and hip bones were crushed using a mortar and 
pestle in MACS buffer. After passage through a 70 m strainer, BM cells were isolated by 
gradient centrifugation using Histopaque 1119 (Sigma). Prior to sorting, B cells were depleted 
using B220 microbeads (Militenyi). Up to one million sorted monocytes were cultured in 3 mL 
cIMDM with 20 ng/mL GM-CSF with or without 20 ng/mL of IL-4 (Peprotech) for 4 days. 
Loosely adherent cells were obtained for analysis. 
Cell sorting. 
 Spleen DCs were sorted as B220–MHCII+CD11c+CD24+CD172– (CD8 +) and  B220–
MHCII+CD11c+ CD24–CD172+ (CD8α–) DCs. Populations from BM were sorted as Lin– 
CD117intCD135+CD115+CD11c–MHCII– (CDP), B220+CD317+SiglecH+ (pDC), MHCII–
CD11c–SiglecH–B220–c-kit–Ly6G–MCSFR+CD11b+Ly6chi (BM monocytes). Other populations 
were sorted from spleens as auto+ F4/80+ (macrophages), CD90.2+CD8+ (CD8 T cells), 
CD90.2+CD4+ (CD4 T cells), B220+ (B cells). OT-1 cells were sorted as B220–CD4–CD11c–
CD45.1+CD8+Vα2+. OT-II cells were sorted as B220–CD4+CD11c–CD45.1+CD8–Vα2+. 
In-vitro TLR stimulation 
 2 X 105 FLT3-L cultured bone marrow cells were plated into 96-well plates and 
stimulated with the following TLR agonists: 1 g/mL Lipopolysaccharide from E. coli 055:B5 
(LPS, Sigma), 50 g/mL polyI:C (Sigma), 63 nM ODN1826, Class B CpG oligonugleotide 
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(CpG, Invivogen), and 2.5 g/mL soluble Tachyzoite antigen (STAg, prepared as described43). 
Cells were allowed to incubate at 37C and 8% CO2 for one hour, then 1 g/mL Brefeldin A was 
added for an additional four hours. Cells were then washed and prepared for surface and 
intracellular cytokine staining. 
Antigen presentation assays. 
 The in vivo cross-presentation assay has been previously described29. Briefly, for both in 
vivo and in vitro cross-presentation assays, MHCI TKO splenocytes were osmotically loaded 
with 10 mg/ml ovalbumin (Worthington), irradiated at 1350 rad, and injected i.v. at indicated 
doses. After 8 days, the spleens from the mice were harvested and  analyzed for tetramer+ T 
cells. 
 For in-vitro cell-associated antigen cross-presentation assays by moDCs, 25,000 CFSE-
labeled OT-1 T cells were plated with 25,000 moDCs from WT or Rab43Δ/Δ 129 mice and 
various doses of MHCI TKO PBS- or OVA-loaded and irradiated splenocytes in cIMDM in a 
96-well plate. After incubating for three days in a 37C and 8% CO2 incubator, CD45.1 OT-1 T 
cells were analyzed by FACS analysis for CFSE dilution and upregulation of CD44. 
 HKLM-OVA (a gift from H. Shen, University of Pennsylvania, Philadelphia, PA) was 
grown in Brain-Heart-Infusion Broth at 37°C for 6 hours and then frozen overnight after dilution 
plating for titer enumeration. Bacteria was then thawed and washed 3 times with DPBS before 
heat-killing at 80°C for 1hr and frozen at -80°C. 10,000 DCs from WT or Rab43Δ/Δ B6 mice 
were incubated with various doses of HKLM-OVA and 25,000 CFSE-labeled OT-1 T cells for 3 
days in a 37°C 5% CO2 incubator and assayed for CFSE dilution and CD44 expression of OT-1 
cells. Soluble OVA and peptide presentation assays used 10,000 DCs and 25,000 CFSE-labeled 
OT-1 T cells for 3 days. In peptide presentation assays, DCs were incubated with SIINFEKL for 
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45min, then washed with cIMDM before incubation with 25,000 OT-1 T cells. Class II 
presentation assays were performed with 10,000 DCs incubated with OVA-loaded irradiated 
splenocytes and sorted OT-II T cells for 3 days and then analyzed for OT-II proliferation. Direct 
presentation assays were performed by sorting DCs and performing hypertonic loading with 
soluble OVA protein (Worthington). After loading, 10,000 DCs were plated with 25,000 OT-1 
cells for 3 days and then analyzed for OT-1 proliferation. 
Generation of RAB43 monoclonal antibody. 
 For immunization, we used Rab43-/- mice that were generated from Rab43tm1(KOMP)Wtsi ES 
cells (Knockout Mouse Project). Genotyping primers for Rab43-/- mice were: 
5'GCCATCACGAGATTTCGATT, 5'TCCCTTCCTACACAGCATCC, and 
5'CCTGGCTGAGCACTATGACA. Rab43-/- mice were immunized with keyhole limpet 
hemocyanin (KLH) conjugated RAB43 peptide, KLH-CIMRHGGPMFSEKNTDHIQLDSKDIA 
(Genscript). Sera and hybridoma supernatants were screened by ELISA using recombinant His-
tagged-RAB43 produced as follows: Rab43 was amplified from cDNA using the primers RAB43 
Nde1 F (5'ATTAAGATCTATGGCGGGCCCTGGCC) and RAB43 Xho1 R 
(5'ATTACTCGAGTCAGCACCCACAGCCCCA) and cloned into the pET-28a(+) vector 
(Novagen). Recombinant protein was purified on Ni-NTA agarose (Qiagen). Anti-mouse RAB43 
antibody clone 2E6, an IgG1, was purified from hybridoma culture supernatant (BioXCell).  
Intracellular staining. 
 After staining for surface molecules, splenocytes were fixed in 4% paraformaldehyde in 
DPBS for 15 minutes at room temperature, washed and suspended in permeabilization buffer 
(DPBS + 0.5% saponin + 2% FCS). Cells were incubated with anti-mouse RAB43 antibody 
biotinylated using NHS-dPEG4-Biotin (G-Biosciences) for 30-60 min at 4C, washed with DPBS 
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buffer containing + 0.05% saponin + 2% FCS, and incubated with streptavidin-FITC (BD 
biosciences).  
Confocal microscopy. 
 DCs from FLT3-L-cultured BM were added to 24-well plates containing Alcian Blue 
(Electron Microscopy Sciences)-coated coverslips at 500,000 cells/well in cIMDM either alone 
or with 1 g/mL LPS (Sigma) and allowed to adhere for 3-4 hours at 37C and 8% CO2. Cells 
were fixed in 4% paraformaldehyde (Electron Microscopy Sciences) in DPBS for 15 minutes at 
RT, quenched with 0.4M glycine in DPBS, washed, and incubated with BlockAid (Invitrogen) in 
0.2% saponin. Cells were stained with primary antibody in 2% FCS, 0.2% saponin in DPBS 
overnight at 4C. After washing 3 X 5 min in DPBS with 0.2% saponin, cells were stained with 
secondary antibody in 2% FCS, 0.2% saponin in DPBS for 1-2 hours at 4C. Cells were washed 
and mounted in ProLong® Gold Antifade with DAPI (Invitrogen) and allowed to cure overnight 
at RT before imaging. FLT3-L-cultured DCs were imaged using a Zeiss LSM-510 confocal 
microscope with a 63x oil immersion objective and analyzed using ImageJ. 
 Sorted Ly6G–CD90.2–B220–DX5–Ly6c–F4/80–CD11c+ splenocytes were plated at 
100,000-300,000 cells/well in cIMDM onto anti-MHCII-coated coverslips in 24-well plates. 
After centrifuging at 1000 rpm for 3 min, cells were allowed to adhere for 30-60 minutes at 37C 
and 8% CO2, surface stained, and then fixed and stained similar to the FLT3-L DCs. 
 Labeled HKLM-OVA was prepared by labeling 3x109 bacteria with 100ul Alexa Fluor 
647 NGS Ester (Life Technologies) for 1hr while vortexing. Bacteria were then washed three 
times in PBS with reducing concentrations of BSA. HKLM-OVA was added to cells during 
attachment as described above and then stained as described. 
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 Images of splenocytes and images after HKLM-OVA internalization were acquired on a 
Nikon-A1Rsi confocal microscope with a 60X oil immersion objective and analyzed using 
ImageJ. Colocalization analysis was performed using ImarisColoc. Briefly, fluorescence was 
masked on a cell by cell basis for organelle stain and percentage of Rab43 staining within that 
area was recorded. Golgi area was determined using ImageJ ROI area calculations. 
Western analysis. 
 Isolated cells were washed in DPBS and resuspended in RIPA lysis buffer with protease 
inhibitors at 1 X 107 cells/mL. Whole-cell extracts were obtained and denatured in Laemmli 
sample buffer at 95C for 5 minute. 1 X 105-2.5 X 105 cell equivalents of whole-cell extract was 
run on a poly-acrylamide gel and transferred onto a nitrocellulose membrane. Immunoblots were 
blocked in DPBS containing 3% BSA and 0.1% Tween-20 at RT for 1 hour and then incubated 
with primary antibody overnight at 4C. After extensive washing, membranes were incubated 
with goat anti-rabbit IgG (H+L) or goat anti-mouse IgG (H+L) conjugated to horseradish 
peroxidase (Jackson Immunoresearch Laboratories) for 1 hour at RT in 5% non-fat milk and 
0.1% Tween-20 DPBS. Membranes were then washed and developed with ECL Plus Western 
Blotting Substrate (Pierce). Membranes were stripped using 37.5 mM Tris-HCl pH 6.8, 1% SDS 
and 0.1M -mercaptoethanol at 60C for 30 min.  
 For glycosylation analysis 2-3x106 cell equivalents of protein lysate were incubated with 
either EndoH Hf (NEB) or PNGaseF (NEB) for 1hr at 37C as per manufacturer's protocol before 
Western analysis as described above. 
Quantitative RT-PCR. 
 Cells were processed using RNeasy Mini Kit (Qiagen) and Superscript III reverse 
transcriptase (Invitrogen) following the manufacturer’s protocol to obtain RNA and subsequent 
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cDNA. StepOnePlus Real-Time PCR System (Applied Biosystems) was used according to 
manufacturer’s instructions with the Quantitation-Standard Curve method and HotStart-IT 
SYBR Green qPCR master mix (Affymetrix). PCR conditions were 95C for 10 min, followed 
by 40 two-step cycles of 95C for 15 s and 60C for 1 min. Primers used for measurement of 
RAB43 were as follows: RAB43 qPCR F: ACTGGATCGAGGATGTGAGG and RAB43 qPCR 
R: ACATTGCTGGAGTCCTTTGC. HPRT primers were as follows: HPRT qPCR F: 
TCAGTCAACGGGGGACATAAA and HPRT qPCR R: GGGGCTGTACTGCTTAACCAG. 
Microarray analysis. 
 Microarray data previously generated in our lab21,22 (GSE53312 and GSE37030) or by 
the Immgen Consortium24 (GSE15907) were analyzed. Gene array data was processed using 
RMA quantile normalization and data was modeled using ArrayStar software (DNASTAR). 
Statistics. 
Statistical analyses were performed with Prism (GraphPad Software). Two-way ANOVA 
with multiple comparisons was performed for statistical significance.  
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Cross-presentation is essential for the initiation of productive immune responses to 
viruses and tumors. The genes involved in regulating cross-presentation in vivo have remained 
poorly understood, in part due to the reliance on in vitro-derived model cells to study candidates 
of interest. Since cross-presentation is mediated by the Batf3-dependent cDC1 subset of dendritic 
cells in vivo, we sought out to develop a candidate based CRISPR-Cas9 screen that could be 
performed in cDC1 cells to find novel regulators of cross-presentation. We developed a screen 
where dendritic cell progenitors in the bone marrow were infected with single guide RNAs  to 
candidate genes of interest and cultured to produce cDCs before assaying for defects in cross-
presentation via T cell proliferation to model antigens. Using this screen we were able to find 
genes that are likely involved in anti-viral and anti-tumor responses in vivo. 
3.2 Introduction 
The majority of work on cross-presentation to this point has been performed using a 
heterogeneous mixture of GM-CSF derived cells with includes both macrophage- and DC-like 
cells1,2. We have recently shown both transcriptionally, through Batf3, and molecularly, through 
Rab43, that GM-CSF derived DCs from monocytes cross-present through a mechanism that is 
distinct from that employed by cDC1s in vivo3,4. The advent of CRISPR-Cas9 technology has 
facilitated our ability to knock down genes of interest in a wider range of cell types, making it 
possible to do high throughput screens for a variety of cellular functions5. In order to find genes 
involved in the cross-presentation pathway we will generate a system where we can analyze the 






Generating list of cDC1-specific genes 
To find targets for our CRISPR screen we used microarray data generated both in our lab 
and by Immgen in order to find genes that were differentially expressed between cDC1 and 
cDC2s6,7. Since cDC2s are not capable of cross-presenting either in vivo or in vitro we expect 
genes involved in cross-presentation to be differentially expressed between those two subsets8.  
After finding a list of differentially expressed genes we compared their expression profile on 
BioGPS to find the expression profile of each gene over a wide range of cell types9-11.  We then 
filtered out genes with known functions in cDC1s and genes that were regulated by Batf3, since 
Batf3 deficient DCs are still capable of cross-presenting12. We also curated the list by looking for 
genes that changed in expression after DC activation using publically available microarrays, 
since the cross-presentation pathway has been shown to be shut down after DCs become 
activated13.  This left us with a list of over 90 genes that we ordered for testing based on their 
expression level and differential expression between cDC1 and cDC2s (Table 3.1). 
While we believe the criteria we used will likely include some genes involved in the 
cross-presentation pathway, it is likely that we have excluded some genes that could have 
interesting functions in cDC1s. It is possible that genes that are not differentially expressed 
between cDC1s and other cells perform specific functions in cDC1s due to the presence of other 
unique proteins. This could lead to us undersampling genes; however, in order to produce a 
manageable list that is capable of being tested in our screening procedure we believe that the 
criteria that we have used is valid.  If few hits were to be found we could loosen our criteria for 
either differential expression between cDC1 and cDC2 or changes in expression upon DC 
activation to generate a larger list of candidates. 
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Determining appropriate antigen for study of cross-presentation 
The efficiency and cell-type specificity of cross-presentation can vary, depending on 
whether the antigen is soluble or associated with cells or pathogens3. Bacterial-associated antigen 
in the form of heat-killed Listeria monocytogenes expressing ovalbumin (HKLM-OVA) is 
efficiently cross-presented by cDC1 to OT-I T cells, but not presented by cDC2 (Figure 3.1A).  
In contrast, soluble OVA is cross-presented by both cDC1 and cDC2 lineages, with 3-10 fold 
lower efficiency in cDC2 (Figure 3.1B). Presentation of SIINFEKL peptide to OT-I cells is 
equally efficient in cDC1 and cDC2, as expected (Figure 3.1C).  Previous studies have suggested 
that the majority of antigens undergo translocation to the cytosol during cross-presentation in 
vivo14-16.  We found that cell-associated antigens, which are presented only by cDC1 and not 
cDC2, are Tap1-dependent, suggesting presentation through the cytosolic pathway (Figure 
3.1D). In contrast, soluble antigens were presented by both Tap1-/- cDC1 and cDC2, with only 
slight differences in efficiency compared to WT cDCs (Figure 3.1E). For these reasons, we 
concluded that use of cell-associated antigens in a screen would best emphasize cDC1-specific 
processing functions. 
Develop assay for analyzing cross-presentation with low cell numbers 
 For typical cross-presentation assays in our lab we have been able to reduce the number 
of cDC1s that are incubated with the OT-1 T cells to 10,000 cells per condition.  However, in 
order to screen large numbers of genes in a system where the cDC1s need to be infected with 
guide RNA expressing viruses the assay would need to function with much fewer cDC1 cells. 
First, we tested the efficiency of guide RNA transduction by using a guide RNA specific for 
beta2-microglobulin and analyzed the resulting cDCs by FACS for MHCI. To generate DCs we 
sorted cKIT-hi cells from the bone marrow of CAS9 expressing mice and then infected them the 
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next day with a retrovirus carrying the guide RNA of interest.  The cells were then grown in 
culture with Flt3L for 7 more days to generate DCs. We found that the β2m guide RNA was 
capable of reducing the amount of MHCI on the cell surface in this system, suggesting that we 
could generate knockout cDCs through this method to screen for cross-presentation ability 
(Figure 3.2).   
 We then tested a FACS based assay for cross-presentation where we gave guide RNA 
transduced DCs antigen (either OVA-loaded splenocytes, HKLM-OVA, or soluble OVA) after 7 
days of culture and then stained the cells 48 hours later with an antibody specific for H2-Kb-
SIINFEKL, the MHCI haplotype of B6 mice with the OVA peptide bound to it.  While we were 
able to see visible shifts with soluble OVA (Figure 3.3A), an antigen that is presented on MHCI 
by both DC subsets, but we were not able to see a shift by FACS when using the more cDC1-
specific antigen of OVA-loaded irradiated splenocytes (Figure 3.3B).  These results prompted us 
to change our methods and test how few cells from a Flt3L culture could be used to stimulate 
OT-1 T cells to a set dose of HKLM-OVA antigen.  We found that proliferation could be 
observed with as few as 3,000 bulk Flt3L cultured cells (which likely included as few as 300 
cDC1s), suggesting that we could use our original antigen presentation assay with bulk 
transduced cultured cells to test for cross-presentation capacity after gene knockdown (Figure 
3.3C). 
Screening of  target genes for cross-presentation efficiency 
 Since as few as 3,000 cells from Flt3L cultures are able to induce OT-1 T cell 
proliferation to HKLM-OVA we decided to use that as our assay in order to screen genes using 
CRISPR-Cas9. We designed 2 pairs of guides targeting early exons for genes in table 3.1 using 
the MIT CRISPR design tool17. We limited our guides to sequences that produced scores >90% 
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whenever possible and preferentially targeted exon 1 when possible (Table 3.2). We then cloned 
the guide RNAs into an MSCV expression vector that uses Thy1.1 as a marker for infection 
(Figure 3.4A).  To test genes we first sorted cKIThi cells from the bone marrow of Cas9-
expressing mice and the next day infected them with a retrovirus containing the guide RNA.  
After 7 days of culture in Flt3L, infected cells were sorted based on Thy1.1 expression and then 
co-cultured with CFSE-labeled OT-1 T cells and 10^7 CFU of HKLM-OVA for three days 
before being analyzed by flow cytometry (FACS) for dilution of CFSE and upregulation of 
CD44 (Figure 3.4B and 3.4C). Candidate genes were compared against a scramble guide RNA in 
each experiment to determine if their knockdown reduced cross-presentation efficiency in the 
infected cells. We have so far screened 35 genes from the list generated in table 3.1 and have 
found one hit, WDFY4, which will be discussed in chapter 5 (Figure 3.5). 
Due to the nature of the assay very few cells are produced after the Flt3L culture which 
means we are unable to confirm that the genes are being knocked out efficiently by the guide 
RNAs that we are using.  This could be causing us to miss interesting target genes which would 
have had a reduction in cross-presentation capacity compared to scramble if our guide RNAs had 
functioned.  In order to address this we have generated two separate guides to each gene that are 
tested separately in order to increase that chances that one guide will function correctly. It is also 
difficult for us to analyze genes that are involved in cell survival or growth since knocking them 
out leads to less cells developing in the final culture and therefore it is not possible to get enough 
cells to perform the cross-presentation assay. Upon sorting transduced cells we use antibodies for 
DC subset markers in order to ensure that no cDC1 developmental genes are being influenced in 





 We developed a functional CRISPR-Cas9 screening protocol to test for the function of 
unknown genes in the cross-presentation pathway. The screen is candidate based, using a list of 
genes generated by analyzing gene expression differences between cDC1 and cDC2 that were 
not dependent on Batf3 and that were down-regulated upon DC activation. In order to improve 
the in vivo relevance of our screen results we modeled our assay based on how cross-presentation 
occurs in vivo, using bona-fide cDC1 as the antigen presenting cell type8 and using an antigen 
(HKLM-OVA) that is only presented by cDC13.  Using this assay we were able to discover that 
the gene Wdfy4 (which will be discussed in chapter 4) may be involved in in vivo cross-
presentation. This screening procedure will be a valuable tool for future studies looking at the 
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Table 3.1. Expression profiles of candidate genes for CRISPR screen 
Expression values taken from previously published resources 6,7,13.
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  Gene Primer 1 Primer 2 
A WDFY4 CACCGATCTGCTTCGCCAACGATGG AAACCCATCGTTGGCGAAGCAGATC 
B WDFY4 CACCGAAAGACTGAGGACAGACCCG AAACCGGGTCTGTCCTCAGTCTTTC 
C Fam149a CACCGGAAGGTCGCTGTGTTGGACC AAACGGTCCAACACAGCGACCTTCC 
D Lrrk2 CACCGCATGGCCAGTGGCGCCTGTC AAACGACAGGCGCCACTGGCCATGC 
E Fam190a CACCGTCTCCCGGTTGCCAATATTC AAACGAATATTGGCAACCGGGAGAC 
F Pdia5 CACCGTGGGGGCTGCTACTGGCGAT AAACATCGCCAGTAGCAGCCCCCAC 
G Txndc15 CACCGGGGCCTTCCGGCCCACGGCC 
AAACGGCCGTGGGCCGGAAGGCCC
C 
H Ttc39a CACCGGGGCTGTCATGCACTGGTCC AAACGGACCAGTGCATGACAGCCCC 
I Mtmr4 CACCGGGGCATCGGTTGCCCGGCCC AAACGGGCCGGGCAACCGATGCCCC 
J Ece1 CACCGGCGGACCGTGTGGTCGCCGC AAACGCGGCGACCACACGGTCCGCC 
K Ece1 CACCGGGTGCAGCATGCGGACCGTG AAACCACGGTCCGCATGCTGCACCC 
L Tex2 CACCGCCGGCAATGACAAGTCTGAA AAACTTCAGACTTGTCATTGCCGGC 
M Tex2 CACCGTGATGGTTTTGGCATGTCAA AAACTTGACATGCCAAAACCATCAC 
N Cacnb3 CACCGTGTAGGAGTCGGCTGAACCC AAACGGGTTCAGCCGACTCCTACAC 
O Rogdi CACCGCGCGGCGCTCGCAGCCATCG AAACCGATGGCTGCGAGCGCCGCGC 
P Srsf11 CACCGGCAGTGGTCCCCAGCGCGCC AAACGGCGCGCTGGGGACCACTGCC 
Q Srsf11 CACCGAGCTGCTACATGATTCAATC AAACGATTGAATCATGTAGCAGCTC 
R Strip2 CACCGTGCCGCGGGGTCGTCCATGC AAACGCATGGACGACCCCGCGGCAC 
S Strip2 CACCGAAACGGCTCTTCATTATGTG AAACCACATAATGAAGAGCCGTTTC 
T Etv3 CACCGGAAAGCAGGCTGTAGCATCG AAACCGATGCTACAGCCTGCTTTCC 
U Etv3 CACCGCTACAAAGCCGAGTCGTCGC AAACGCGACGACTCGGCTTTGTAGC 
V Foxp4 CACCGCCGTCTGGTCAGAACGGCGT AAACACGCCGTTCTGACCAGACGGC 
W Foxp4 CACCGACAATCAGGTCGGCTCCGTC AAACGACGGAGCCGACCTGATTGTC 
X Insm1 CACCGCCCGTGTCCTACCGGGTCCG 
AAACCGGACCCGGTAGGACACGGG
C 
Y Insm1 CACCGGGTCACTGTCCTCGCCGCCG 
AAACCGGCGGCGAGGACAGTGACC
C 
Z Naaa CACCGCCACCAGGGCCGCGTGCCAT AAACATGGCACGCGGCCCTGGTGGC 
AA Naaa CACCGTACTGTCGCTGTCCGGTCCC AAACGGGACCGGACAGCGACAGTAC 
AB Sdad1 CACCGGCGGGACCCGCCGGCCTACG AAACCGTAGGCCGGCGGGTCCCGCC 
AC Sdad1 CACCGCCGGCGGGTCCCGCTTGATC AAACGATCAAGCGGGACCCGCCGGC 
AD Gpr126 CACCGTGTTTGACACTCTCGGGAAG AAACCTTCCCGAGAGTGTCAAACAC 
AE Gpr126 CACCGGGAGACGTAAAGGTACCGGA AAACTCCGGTACCTTTACGTCTCCC 
AF Rala CACCGTCTGCAGTTCATGTACGACG AAACCGTCGTACATGAACTGCAGAC 
AG Rala CACCGTCGCAGCTACCGCGGACTTC AAACGAAGTCCGCGGTAGCTGCGAC 
AH Rnf115 CACCGCGGGGCTCTTACCGGTAGTT AAACAACTACCGGTAAGAGCCCCGC 
AI Rnf115 CACCGCATGGCGGAGGCCTCGGCGG AAACCCGCCGAGGCCTCCGCCATGC 
AJ Slamf8 CACCGCAACGGCCATGTGGTCCCTC AAACGAGGGACCACATGGCCGTTGC 





a CACCGGCCGCCGACCAACGTCTGTA AAACTACAGACGTTGGTCGGCGGCC 
AM 
Tmem39


























































































































































































































































































Table 3.2. sgRNA sequences used in this study 





Figure 3.1.  Modeling in vivo cross-presentation.  (A-C) Increasing concentrations of HKLM-
OVA (A), soluble ovalbumin (B) or SIINFEKL peptide were cultured with sort-purified 
cDC1and cDC2 for three days with CFSE-labeled OT-I T cells and assayed for proliferation 
(CFSE-CD44+).   (D, E) WT or Tap1-/- sort-purified cDC1 and cDC2 were cultured for three days 
with varying concentrations of HKLM-OVA (D) or soluble OVA (E) and CFSE-labeled OT-I T 


























Figure 3.2. Test of guide RNA control. c-Kithi bone marrow progenitors from Cas9 transgenic 
mice were infected with retroviruses expressing sgRNAs for beta-2 microglobulin or scramble, 
































Figure 3.3 Test of small scale cross-presentation assay in Flt3L DCs. (A-B) Sorted cDC1 
were cultured with 100 µg/mL soluble ovalbumin (A) or 106 splenocytes osmotically loaded with 
OVA (B), cultured for 48 hours and stained with 25-D1.16 and analyzed by flow cytometry.  (C) 
CFSE-labeled OT-I cells were cultured with the indicated number of whole Flt3L-generated DCs 
and 107 HKLM-OVA or 25 fg/mL SIINFEKL peptide (SIIN) and assayed for proliferation 


































Figure 3.4. Functional cross-presentation screen using CRISPR/Cas9.  
(A) A vector was constructed to express a single sgRNA (red/blue) under control of an internal 
human U6 promoter (green). This cassette is encoded on the sense strand downstream of the 
Thy1.1 marker18.  (B) Sorting strategy and gating of infected cDCs after Flt3L culture. DCs were 
sorted as Thy1.1+ and analyzed by flow cytometry for expression of B220, CD11c, MHC-II, 
CD24, and Sirpα to verify normal development after target knockout. Sorted Thy1.1+ cells were 
then tested for cross-presentation of cell-associated antigen. (C) Example flow cytometry of OT-
I T cells 3 days after co-culture with sgRNA infected DCs and HKLM-OVA. OT-I cells were 





Figure 3.5. Example cross-presentation screen using CRISPR-Cas9. c-Kithi bone marrow 
progenitors from Cas9 transgenic mice were infected with retroviruses expressing various 
sgRNAs (Table 3.2), cultured with Flt3L for seven days, and infected cDCs tested for cross-



























3.5 Materials and Methods 
Mice. 
All mice were bred and maintained in specific pathogen-free facilities according to 
institutional guideline protocols approved by the Animal Studies Committee of Washington 
University in St. Louis. WT C57BL/6 (WT), C57BL/6-Tg(TcraTcrb)1100Mb/J (OT-I), 
C57BL/6-Tg(TcraTcrb)425Cbn/J (OT-II) were purchased from The Jackson Laboratory. MHCI 
TKO mice (Kb−/−Db−/−β2m−/−) were originally provided by H.W. Virgin and T. Hansen 
(Washington University, St. Louis, MO 19). 4-14 week old mice that were age and sex matched 
were used for all experiments. Cas9-eGFP mice were a gift from Feng Zhang (MIT). 
Antibodies and Flow Cytometry 
  Flow cytometry and cell sorting were completed on a FACS CantoII or FACS Aria 
Fusion instrument (BD) and analyzed using FlowJo analysis software (Tree Star). Staining was 
performed at 4ºC in the presence of Fc block (2.4G2; BD) in magnetic-activated cell-sorting 
(MACS) buffer (PBS + .5% BSA + 2mM EDTA). The Following antibodies were used. From 
BD Biosciences: MHCI (AF6-88.5), CD4 (RM4-5), CD8α (53-6.7), B220 (RA3-6B2), CD19 
(1D3), CD3 (145-2C11), CD45 (30-F11); from Tonbo Biosciences: CD44 (IM7), CD45.1 (A20), 
CD45.2 (104), CD11c (N418); from Biolegend: TCRβ (H57-597), CD3 (145-2C11), CD8 (53-
6.7), CD4 (RMA4-5), CD44 (IM7), CD16/32 (93) ; from eBiosciences: TCRVα2 (B20.1), 
CD90.1 (HIS51), CD90.2 (53-2.1), SIINFEKL/H-2Kb (25-D1.16); from Invitrogen: CD172α 
(P84), CD45 (30F11). 
Cell sorting 
  Splenic and Flt3L DCs were sorted as B220–MHCII+CD11c+CD24+CD172α– (cDC1) and 
B220–MHCII+CD11c+CD24–CD172α+ (cDC2). OT-1 cells were sorted from the spleen as B220–
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CD11c–CD4–CD8+CD45.1+Vα2+. OT-II cells were sorted from the spleen as B220–CD11c–CD8–
CD4+CD45.1+Vα2+. Infected DCs for CRISPR screen were sorted as CD90.1+.  
BM culture with Flt3L 
  Tibias, femurs, and hips from mice were crushed into MACS buffer and RBCs were 
removed with ACK lysis buffer. BM cells were cultured at 2x10^6 cells/ml in cIMDM 
containing 5% FLT3L for 8-10 days. Loosely adherent cells were harvested for analysis. 
sgRNA vector design 
The ires-GFP fragment from the MSCV-ires-GFP retrovirus vector was replaced with 
Thy1.1 cDNA from MSCV-ires-Thy1.1 retrovirus vector18 using Xho1 and EcoR1 digests to 
produce Thy1.1- RV. Two PCR DNA fragments containing the hU6 promoter and gRNA 
scaffold from pSpCas9(BB)-2A-GFP (PX458) (a gift from Feng Zhang (Addgene plasmid 
#48138)20) and a Bbs1 stuffer fragment from pLentiCrisprV1, provided by Feng Zhang 
(Addgene plasmid #49535) were sequentially cloned into the T easy vector (Promega). An 
EcoR1 fragment from the resulting plasmid was cloned into the EcoR1 site of Thy1.1-RV to 
produce Thy1.1-hU6-gRNA-Bbs1 stuffer-RV. To produce retroviral guide plasmids, annealed 
oligonucleotides with Bbs1 compatible overhangs and containing guide target sequences as 
described21 were ligated into Bbs1 digested Thy1.1-hU6-gRNA-Bbs1 stuffer-RV. 
Antigen Preparation 
MHCI TKO splenocytes were osmotically loaded with 10mg/ml soluble ovalbumin 
(Worthington Biochemical Corporation), irradiated at 1350rad.  HKLM-OVA (a gift from H. 
Shen, University of Pennsylvania, Philadelphia, PA) and soluble OVA were prepared as 
described previously3.  
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For FACS of Kb-SIINFEKL, Day 8 Flt3L cultured DCs were cultured for 48 additional 
hours with either 0.1mg/ml soluble OVA or 1x106 OVA-loaded irradiated splenocytes prepared 
as described above.  
Cross-presentation screen 
Retroviral vectors were transfected into Platinum-E cells as described22 and supernatant 
containing virus was collected after 2 days. Sorted Lin-cKIThi cells from the bone marrow of 
Cas9-expressing mice (a gift from Feng Zhang23) were infected with viral supernatants with 
2µg/ml polybrene at 2,250r.p.m. for at least 1hr. Cells were then grown in Flt3L culture for 7 
days before sorting for Thy1.1+ cells. Sorted cells were then diluted to a concentration of ~10K 
cells per well and cocultured with 107 HKLM-OVA and 25K CFSE-labeled OT-I T cells for 3 
days before analysis for CFSE dilution. 
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During the process of cross presentation, viral or tumor-derived antigens are presented to 
CD8+ T cells by the Batf3-dependent CD8α+/XCR1+ classical dendritic cell (cDC1). We 
designed a functional CRISPR screen for novel regulators of cross presentation, and identified 
the BEACH-domain containing protein WDFY4 as essential for cross-presentation of cell-
associated antigens by cDC1. WDFY4 was not, however, required for MHC class II presentation 
or for cross-presentation by monocyte-derived DCs.  In contrast to Batf3-/- mice, Wdfy4-/- mice 
have normal lymphoid and non-lymphoid cDC1 populations that produce IL-12 and protect 
against Toxoplasma gondii infection.  However similar to Batf3-/- mice, Wdfy4-/- mice fail to 
prime virus-specific CD8+ T cells in vivo or induce tumor rejection, revealing a critical role for 
cross-presentation in anti-viral and anti-tumor immunity.  
4.2 Introduction 
Presentation of antigens as peptides bound to proteins of the major histocompatibility 
complex (MHC) is the principal mechanism by which innate cells promote antigen-specific T 
cell immunity1. Classical dendritic cells (cDC) are particularly efficient antigen presenting cells 
and comprise two major functionally distinct subsets, the cDC1 and cDC22-4. The cDC1 
lineage2,5 is the most efficient at priming cytotoxic CD8+ T cells to exogenously-derived 
antigens, a process termed cross-presentation6-10. This specialization was observed in Batf3-/- 
mice that specifically lack cDC1 development and cannot mount cytotoxic T cell responses to 
viruses and tumors10-24. However, since these studies have only analyzed these responses in the 
context of mice lacking cDC1, the role of cross-presentation versus other cDC1-specific effector 




Cross-presentation has been studied using different cell types and various forms of 
antigen, and not all findings have been confirmed in vivo26.  DCs generated from monocytes 
(moDCs) or whole bone marrow cultured in vitro with GM-CSF with or without IL-427-29 are 
heterogeneous, resembling both macrophages and DCs30, and use a cross-presentation program 
divergent from the cDC1 in vivo26,31,32.  Studies of moDCs have produced two major models of 
cross-presentation; one that involves transport of  exogenous antigen to the cytosolic proteasome 
before peptide loading in the endoplasmic reticulum (ER)1,7,33-35, and another where peptide 
loading occurs directly in phagosomes by fusion with vesicles containing the peptide-loading-
complex36,37.  The latter pathway may be regulated by the SNARE family member Sec22b, 
although two recent studies of Sec22b deficient mice arrived at different conclusions as to the 
role of Sec22b in T cell priming to cell-associated antigens in vivo38,39.  These differences 
highlight the need for systematic investigation into the mechanisms of cross-presentation in 
vivo39,40. 
Through a CRISPR-Cas9 screen we found that WDFY4 appeared to play a role in cross-
presentation of HKLM-OVA. WDFY4 is a large protein of almost 4,000 amino acids that is 
highly expressed in cDC1s and expressed to a lower extent in cDC2s and subsets of B cells41,42.  
Currently, little work has been done analyzing the function of WDFY4.  The only literature 
making mention of the gene are a subset of genome-wide association studies that found single 
nucleotide polymorphisms either within or near the Wdfy4 gene in the context of lupus and 
arthritis43-45.  Recently, a mechanistic study suggested a phenotype in WDFY4-deficient B cells 
that could lead to development of lupus46. There are four total WDFY family members, the most 
well characterized of which is WDFY3 (also known as Alfy)42.  WDFY3 was first described as 
the gene Blue Cheese (Blchs) in drosophila, where it was observed that Blchs mutants had 
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reduced life spans due to the formation of protein aggregates in their brains47. A similar 
phenotype has been observed in mice, where loss of WDFY3 leads to alterations in brain 
physiology and the development of neurologic diseases48.  Work done in mice has linked 
WDFY3 to the autophagy pathway, where it has been shown to interact with autophagy 
regulators such as p62 and LC3 in the formation of autophagosomes during selective 
autophagy49-51.   
 WDFY4 belongs to a small group of only eight human proteins that contain a Beige and 
Chediak-Higashi (BEACH) domain42. The other members of this family include LYST, NBEA, 
NBEAL1-2, LRBA, NSMAF, and WDR81; genes that have been associated with a range of 
human diseases from Chediak-Higashi syndrome to autism42.  The beach domain is thought to be 
involved in interactions with membranes, suggesting that BEACH domain containing proteins 
are involved in the regulation of vesicular traffic in some way42.  Indeed, the BEACH domain 
containing protein LRBA has been shown to regulate the recycling of CTLA4, an important 
immune cell regulatory molecule, by influencing it's movement between the cell surface in 
lysosomes through interactions with its intracellular tail52.  The functions of WDFY3 and LRBA 
suggest that WDFY4 likely acts on the transport of specific vesicles that could contain either 
antigen or members of the peptide loading complex in cDC1s. It is possible that WDFY4 is 
acting as a key regulator of antigen transport through the cross-presentation pathway, and 
therefore is essential for the development of proper responses to viruses and tumors. 
4.3 Results 
We expressed single guide RNAs (sgRNAs)53 for candidates (Table 3.2) by retrovirus 
under the U6 promoter and infected DC progenitors from Cas9 transgenic mice54 (Figure 3.4). 
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Cells were cultured in Flt3L for 7d, sorted to purify infected cDCs, and tested for cross-
presentation (Figure 3.5).   
Cross-presentation was substantially impaired by two independent sgRNAs for WD 
Repeat- and FYVE Domain-Containing Protein 4 (Wdfy4), a member of the BEACH (Beige and 
Chediak-Higashi) domain containing family of proteins42 (Figure 4.1A).  WDFY4 is highly 
expressed in mouse and human cDC1 (Figure 4.2), with 80% species similarity55. Wdfy4 is one 
of 9 BEACH-domain containing proteins42 and has three closely related family members.  
However, CRISPR targeting using sgRNAs for Wdfy1, Wdfy2, Wdfy3 did not impair cross-
presentation, in contrast to Wdfy4 (Figure 4.1B). Thus, Wdfy4 appears to be unique within this 
gene family for supporting cross-presentation by cDC1.  
To evaluate the in vivo function of Wdfy4, we obtained mice with exon 4 deleted by 
CRISPR/Cas9 genome editing, leading to translational termination due to a reading frame shift 
when exon 3 splices to exon 5 (Figure 4.3).  Wdfy4-/- mice are viable, born in normal Mendelian 
ratios and have normal development of hematopoietic lineages, including cDCs (Figure 4.1C and 
4.1D and 4.4), which express Irf8 and have normal turnover kinetics (Figure 4.4H and 4.4I), and 
T cells (Figure 4.5).  In particular, cDC1 develop in Wdfy4-/- mice, unlike Batf3-/- mice, and 
express CD24, XCR1 and CD103 normally (Figure 4.1C, 4.1D, 4.4B, and 4.4F).  However, 
cDC1 from Wdfy4-/- mice show a striking defect in cross-presentation of both cell-associated and 
bacterial-associated antigen in vitro (Figure 4.1E, 4.1F, 4.6A) and show reduced efficiency for 
soluble OVA presentation compared with WT cDC1 (Figure 4.1G).  Notably, Wdfy4-/- cDC1 
cross-present soluble OVA with the efficiency of cDC2, which are not influenced by the loss of 
Wdfy4 (Figure 4.1G).  However, Wdfy4-/- cDC1 can directly present antigen introduced into the 
cytoplasm by osmotic shock or virus, a process that is equally efficient in cDC1 and cDC2 
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(Figure 4.6B and 4.6D), suggesting that Wdfy4-/- cDC1 have the capacity to present endogenous 
antigens on MHCI. 
 MoDCs can cross-present both soluble and cell-associated antigens in vitro27,56,57, but use 
a distinct transcriptional program from cDC131.  We find that moDCs derived from WT and 
Wdfy4-/- mice cross-present antigens with the same efficiency, both for cell-associated (Figure 
4.6E) and soluble OVA (Figure 4.6F), suggesting that moDCs use a Wdfy4-independent pathway 
for cross-presentation. The defect in cross-presentation by Wdfy4-/- cDC1 is specific, since MHC 
class II antigen processing was unchanged in Wdfy4-/- mice for both cell-associated and soluble 
antigens (Figure 4.1H and 4.6G). MHC class II antigen processing by B cells is also normal in 
Wdfy4-/- mice (Figure 4.7A), which are able to generate germinal center B cells and T follicular 
helper (TFH) cells in response to immunization with sheep red blood cells (Figure 4.7B and 
4.7E).   
cDCs from Wdfy4-/- mice expressed normal levels of MHCI at steady state and after 
activation (Figure 4.8A and 4.8B), upregulated costimulatory molecules CD80/86 and expressed 
cytokines normally (Figure 4.8C-F). Loss of Wdfy4 also did not influence gene expression in 
cDC1s at steady state or after activation in tumor-bearing mice (Figure 4.8G and 4.8H). Despite 
their inability to cross-present, Wdfy4-/- cDC1 are capable of taking up and degrading soluble 
antigens normally (Figure 4.9A and 4.9B) and phagocytosing labeled HKLM-OVA, as seen both 
microscopically (Figure 4.9C) and by quantification of this phagocytosis as measured by FACS 
(Figure 4.9D). 
To explore the mechanism of action of WDFY4, we analyzed various cellular 
compartments of wild-type and Wdfy4-/- cDC1 by confocal microscopy and found minimal 
differences in distribution of MHCI stores, ER, early endosomes, lysosomes, late endosomes, or 
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the peptide-loading complex at steady state (Figure 4.10) or Rab43 (a molecule previously 
described to be involved in cross-presentation32), p62 (autophagic vesicles), Rab7 (late 
endosomes), or Lamp1 (lysosomes) after antigen phagocytosis (Figure 4.11). Electron 
microscopy of WDFY4-deficient ex vivo cDC1 showed the presence of large and numerous lipid 
bodies throughout the cytoplasm that were not present in wild-type cells (Figure 4.12, 4.13A, and 
4.13C). However, these lipid bodies were not present in Flt3L-derived cDC1 from Wdfy4-/- mice 
(Figure 4.13B and 4.13C), which still have a defect in cross-presentation of cell-associated 
antigen (Figure 4.13D), suggesting that the lipid bodies are not necessary to cause the defect in 
cross-presentation in Wdfy4-/- cDC1.  
To determine interacting partners of WDFY4, we generated four individually FLAG-
tagged sub-regions of WDFY4 spanning the entire protein (Figure 4.14A). We stably transduced 
these fragments into the murine DC line JAWSII58, and performed affinity purification-mass 
spectrometry (AP-MS) to isolate WDFY4 binding partners. We found 143 candidates enriched 
by different regions of the WDFY4 protein, with the largest number binding to the FL4 fragment 
of WDFY4 that contains the PH, BEACH, WD40, and FYVE domains (Figure 4.14A, Table 
4.1). We performed gene ontology analysis to determine the biological processes most likely 
influenced by WDFY459. The fragments FL1 and FL2 of WDFY4 associated with proteins 
involved in "protein complex assembly," and therefore may be involved in forming multimeric 
protein structures or scaffolding vesicular machinery (Figure 3.14B, Table 4.2). FL3 and FL4 
associated with proteins involved in "protein localization," "vesicle transport," and "cytoskeletal 
organization,” suggesting a role for WDFY4 in proper subcellular vesicular targeting (Figure 
4.14C, Table 4.3). Notably, FL4 associated with components critical to the formation, function, 
and trafficking of endocytic vesicles, including clathrin (Cltc, Clta)60, subunits of the AP-2 
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clathrin adaptor complex (Ap2a1, Ap2a2, Ap2b1)60, modulators of cytoskeleton dynamics 
(Iqgap1, Actn4)61,62, and several members of the vacuolar-type (H+) ATPase (Atp6v0a3, 
Atp6va1, Atp6v1f)63 (Figure 4.14D, Table 4.1 and 4.4). FL4 also selectively associated with 
Hsp90ab1, a member of the HSP90 chaperone family involved in endosome-to-cytosol 
translocation of antigen during cross-presentation64-67 (Figure 4.14D-F). While heat-shock 
proteins such as Hspa8 and Hsp1a1 can appear as artifacts in AP-MS data due to their function 
as chaperones68, Hsp90ab1 is rarely detected in this manner, and therefore its association may 
represent a functional interaction with WDFY4. 
We then sought to determine which vesicles WDFY4 may be acting on by determining its 
intracellular location.  We visualized full-length Twin-Strep-tagged69 WDFY4 in JAWSII cells 
by confocal microscopy and found that it localized to the periphery of the cytosol near the 
plasma membrane (Figure 4.14G). WDFY4 was poorly co-localized with the cell surface 
receptor DEC-205, intracellular MHCI stores and lysosomes, but demonstrated moderate co-
localization with early endosomes and the ER. cDC1 have been previously shown to have well 
defined and extensive ER structures which may extend throughout the cytosol near vesicular 
compartments70, and lead to co-localization with components of the endosomal pathway. 
WDFY4 shows highest correlation with endosomal markers clathrin and Rab11 (Figure 4.14G 
and 4.14H), suggesting that it localizes to an endosomal compartment near the plasma 
membrane. Taken together, these data suggest that WDFY4 functions in trafficking between the 
cell surface and endosomes and thus may regulate multimeric protein assembly required for 
proper formation and localization of endocytic vesicles.  
 We then examined the role of WDFY4 in cross-presentation of cell-associated antigens in 
vivo. CFSE-labeled OT-I T cells showed strong in vivo proliferation induced by immunization 
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with OVA-loaded splenocytes when transferred into Wdfy4+/- mice, but not Wdfy4-/- mice (Figure 
4.15A and 4.15B), confirming an in vivo defect in cross-presentation.  IL-12 produced by cDC1 
in response to soluble tachyzoite antigen (STAg) is required for innate immune protection 
against T. gondii, as illustrated by the susceptibility of Batf3-/- mice to lethal infection by this 
pathogen25.  In contrast, Wdfy4-/- mice are resistant to T. gondii infection, similar to Wdfy4+/- 
mice (Figure 4.15C). These results indicate that cross-presentation is not required for innate 
protection against T. gondii, and that Wdfy4-/- cDC1 are not globally impaired in function.   
We also evaluated CD8+ T cell responses of Wdfy4-/- mice to cowpox virus infection, a 
model in which effective CD8+ T cell priming is thought to be mediated primarily by Batf3-
dependent cells through cross-presentation13. Batf3-/- mice that lack cDC110-13 have a defect in 
priming antigen-specific CD8+ T cells to several viruses10-13, but these studies only indirectly 
show that this is due to a lack of cross-presentation, since a loss of alternative functions of cDC1 
could conceivably be the cause.  However, we now show that Wdfy4-/- mice, that retain cDC1 
cells which cannot cross-present, also have a severely impaired antigen-specific CD8+ T cell 
responses to cowpox virus (Figure 4.15D, 4.15E, 4.16A-D). This defect in cross-presentation is 
not restricted to cowpox virus, since Wdfy4-/- mice also show a defect in priming CD8+ T cells to 
infection by West Nile virus (Figure 4.16E). However, Wdfy4-/- mice show normal priming of 
CD4+ T cells to West Nile, indicating that WDFY4 functions for in vivo cross-presentation to 
CD8+ T cells, but not for priming of CD4+ T cells (Figure 4.16F). 
 Studies with Batf3-/- mice suggested that cDC1 were required for tumor rejection10. To 
examine the role of cross-presentation directly, we evaluated growth of the highly immunogenic 
1969 regressor fibrosarcoma15 in WT, Wdfy4+/-, Wdfy4-/- and Batf3-/- mice (Figure 4.15F).  
Tumors were readily rejected by WT mice, but not by Batf3-/- mice (Figure 4.15F) as expected15. 
98 
 
However, tumors were also rejected by heterozygous Wdfy4+/- mice, but grew uncontrolled in 
Wdfy4-/- mice similar to Batf3-/- mice (Figure 4.15F and 4.17A). These results with germline-
deficient Wdfy4-/- mice indicate an in vivo requirement for WDFY4 in tumor rejection, but do not 
pinpoint its function to cDC1.  To test whether the in vivo defect in Wdfy4-/- mice is cDC1-
intrinsic, we generated mixed bone-marrow (BM) chimeras using mixtures of either WT: Batf3-/- 
or Wdfy4-/- : Batf3-/- BM (Figure 4.15G).  WT: Batf3-/- chimeras rejected tumors normally, but 
Wdfy4-/- : Batf3-/- chimeras, in which cDC1 develop only from the Wdfy4-/- BM, failed to control 
tumor growth (Figure 4.15G).  These results indicate that the defect in tumor rejection results 
from loss of Wdfy4 expression in cDC1.  Notably, in Wdfy4-/- mice, cDC1 do infiltrate into 
tumors as they expand (Figure 4.15H and 4.17B), yet they induce less recruitment of CD8+ T 
cells to tumors, similar to the lack of CD8+ T cells in tumors in Batf3-/- mice (Figure 4.15I).  
4.4 Discussion      
WDFY4 is one of nine mammalian BEACH-domain containing proteins (BDCP) that 
typically also contain a PH-like domain and WD repeats42. BDCP function as protein scaffolds 
that regulate intracellular vesicle fission and fusion events, and several are associated with 
human diseases42. For example, mutations in Lyst cause the Chédiak-Higashi syndrome, a 
primary immunodeficiency disorder characterized by defective neutrophil phagolysosome 
formation and cytotoxic T cell degranulation71,72. Mutations in Lrba result in immune 
dysregulation in regulatory T cells due to  improper trafficking of CTLA4 from endosomes to 
lysosomes by the clathrin adaptor AP-152,73.  WDFY3, the closest WDFY4 homolog, regulates 
recruitment of polyubiquitinated protein aggregates to autophagosomes by interactions with p62, 
Atg5, Atg12, Atg16L, LC3 and TRAF649-51,74. Although cross-presentation of cell-associated 
antigens does not involve autophagy75, WDFY4 conceivably may regulate vesicular trafficking 
99 
 
pathways, a concept supported by its localization to submembrane endosomes and  its interaction 
with endocytic and cytoskeletal machinery.  These WDFY4-dependent trafficking pathways may 
be required for translocation of dead-cell antigen ligated by the cDC1-specific receptor 
CLEC9A76 to specific compartments to promote cross-presentation77. Further investigation of the 
mechanisms of WDFY4 may elucidate novel components of the cross-presentation pathway and 

















Table 4.1: Proteins enriched by mass spectrometry 












Sample Proteins Enriched (2/3)
FL1 Actbl2 Actl6a Aifm2 Arpc1b Arpc5 Atp5j Bag6 Card9 Cpsf6 Dctn4 Dgat1 Dhrs7b Eif3g Ganab Hdac6 Mapk6 Mroh1 Nomo1 Nup160 Pfkfb3 Psmd4 Ran Rps25 Sort1 Tmed9 Vps50 Wdfy4
FL2 Actbl2 Actl6a Actr3 Aifm2 Arpc2 Atg13 Atp5j Bag6 Cd44 Cers2 Clta Dctn4 Ddx23 Fip1l1 Ganab Gvin1 Hdac6 Hspa1b Hspa2 Hspa8 IgG1_bovineKif5c Lrch4 Mroh1 Mybbp1a Myo1d Nt5c2
Pabpc1 Pfkfb3 Pls3 Psmd11 Psmd8 Rps19 S100a4 Sf3b3 Smarcd1 Sort1 Spin1 Tfrc Thrap3 Trappc8 Ulk1 Vps41 Vwa8 Wdfy4
Myo1c Myo5a Myo6 Pfkfb3 Plec Ppp1ca Ppp1r18 Sept11 Siglec1 Snrpd2 Sort1 Sptbn1 Tcirg1 Tpm1 Tpm2 Tpm3 Wdfy4
FL3 Acta2 Actb Actbl2 Actn1 Actn4 Actr3 Ahnak2 Ap2b1 Arhgap9 Arpc2 Arpc4 Atp6v0a1 Atp6v0d1 Atp6v0d2 Atp6v1f Cald1 Clta Cltc Cpsf6 Iqgap1 Lima1 Lsp1 Myh11 Myh9 Myl12a Myl12b Myl6
FL4 Abcd2 Acap2 Acta2 Actb Actbl2 Actl6a Actn4 Actr3 Adm Ahnak Ahnak2 Ap2a1 Ap2a2 Ap2b1 Apobr Araf Arfgef2 Arhgap9 Arpc2 Arpc4 Atp6v0d1 Atp6v0d2 Atp6v1a Atp6v1f Bag6 Cald1 Calm2
Ccdc88a Cct3 Cct6a Cd44 Cd68 Cfl2 Chil4 Clns1a Clta Cltc Copg2 D1Pas1 Dhrs7b Dnaja1 Efhd2 Ganab Hcls1 Hsp90ab1 Hspa1b Hspa2 Hspa5 Hspa8 Hyou1 Iqgap1 Kif5c Lima1 Lsp1
Mpc2 Mpeg1 Mroh1 Msn Myh10 Myh11 Myh9 Myl12a Myl12b Myl6 Myl6b Myo1c Myo1e Myo1f Plec Plod3 Ppp1ca Psma1 Psma4 Rpl24 Rplp1 Rps27a Sdhb Sec61a1 Sfxn3 Siglec1 Sort1




Table 4.2: GO Terms for FL1/FL2 fragments 









SUID % Associated Genes Associated Genes Found GOID GOTerm Group PValue Nr. Genes Term PValue
2427 1.388888836 [Actr3, Arpc1b, Arpc2, Arpc5, Hdac6, Hspa1b, Hspa8, Pls3] GO:0097435 supramolecular fiber organization {Group2=7.689871029925464E-5} 8 5.34E-04
2428 1.134644508 [Actr3, Arpc1b, Arpc2, Arpc5, Clta, Cpsf6, Hdac6, Hspa1b, Hspa8, Psmd11, Psmd4, Psmd8, Rps19, Ulk1, Vps41] GO:0071822 protein complex subunit organization {Group2=7.689871029925464E-5} 15 1.45E-05
2429 0.994694948 [Actr3, Arpc1b, Arpc2, Arpc5, Clta, Cpsf6, Dgat1, Hdac6, Hspa1b, Psmd11, Psmd4, Psmd8, Rps19, Ulk1, Vps41] GO:0065003 macromolecular complex assembly {Group2=7.689871029925464E-5} 15 6.78E-05
2430 0.749375522
[Actl6a, Actr3, Atg13, Bag6, Clta, Dctn4, Hdac6, Hspa8, Kif5c, Mybbp1a, Myo1d, Nup160, Psmd8, Ran, Sort1, 
Tmed9, Vps41, Vps50] GO:0051641 cellular localization {Group1=6.057261404642146E-4} 18 6.06E-04
2431 0.980392158 [Actl6a, Atg13, Clta, Dctn4, Hdac6, Hspa8, Kif5c, Mybbp1a, Myo1d, Nup160, Psmd8, Ran, Sort1, Vps41, Vps50] GO:0046907 intracellular transport {Group1=6.057261404642146E-4} 15 8.00E-05
2432 0.755857885
[Actr3, Arpc1b, Arpc2, Arpc5, Atg13, Bag6, Clta, Cpsf6, Dgat1, Hdac6, Hspa1b, Hspa2, Pls3, Psmd11, Psmd4, 
Psmd8, Ran, Rps19, Ulk1, Vps41] GO:0044085 cellular component biogenesis {Group2=7.689871029925464E-5} 20 2.22E-04
2433 0.99765259
[Actr3, Arpc1b, Arpc2, Arpc5, Clta, Cpsf6, Dgat1, Hdac6, Hspa1b, Hspa8, Psmd11, Psmd4, Psmd8, Rps19, Smarcd1, 
Ulk1, Vps41] GO:0043933 macromolecular complex subunit organization {Group2=7.689871029925464E-5} 17 1.80E-05
2434 1.357466102 [Actr3, Arpc1b, Arpc2, Arpc5, Clta, Hdac6, Hspa1b, Psmd11, Psmd4, Psmd8, Rps19, Vps41] GO:0034622 cellular macromolecular complex assembly {Group2=7.689871029925464E-5} 12 2.22E-05
2435 0.579547584
[Actl6a, Actr3, Aifm2, Arpc1b, Arpc2, Arpc5, Atg13, Bag6, Cd44, Cers2, Clta, Cpsf6, Dgat1, Hdac6, Hspa1b, Hspa2, 




SUID % Associated Genes Associated Genes Found GOID GOTerm Group PValue Nr. Genes Term PValue
1253 2.917771816 [Actl6a, Ccdc88a, Cct3, Cct6a, Hcls1, Hsp90ab1, Iqgap1, Msn, Myo1c, Sptbn1, Tcp1] GO:1903829 positive regulation of cellular protein localization {Group3=1.7911444457370406E-9, Group5=5.400723098059407E-11, Group6=9.289432501882645E-13} 11 9.53E-06
1254 3.378378391 [Actr3, Arpc2, Arpc4, Cfl2, Hcls1, Hspa1b, Hspa8, Lima1, Myo1c, Sptbn1] GO:1902903 regulation of supramolecular fiber organization {Group6=9.289432501882645E-13} 10 6.99E-06
1255 3.472222328
[Actn1, Actn4, Actr3, Arpc2, Arpc4, Ccdc88a, Cfl2, Hcls1, Hsp90ab1, Hspa1b, Hspa8, Lima1, Myh10, Myh11, Myo1c, 
Plod3, Sptbn1, Tpm1, Tpm2, Tpm3] GO:0097435 supramolecular fiber organization {Group6=9.289432501882645E-13} 20 6.00E-11
1256 3.063457251 [Acta2, Actr3, Adm, Arpc2, Arpc4, Cfl2, Clns1a, Hcls1, Hsp90ab1, Lima1, Msn, Myo1c, Plod3, Sptbn1] GO:0090066 regulation of anatomical structure size {Group6=9.289432501882645E-13} 14 2.88E-07
1257 1.739788175
[Actr3, Ap2b1, Arpc2, Arpc4, Atp6v0a1, Cct3, Cfl2, Clta, Cltc, Cpsf6, Hcls1, Hsp90ab1, Hspa1b, Hspa8, Lima1, Msn, 
Myh11, Myo1c, Plod3, Psma4, Sept11, Sptbn1, Tcp1] GO:0071822 protein complex subunit organization {Group2=4.007090667982035E-10, Group6=9.289432501882645E-13} 23 9.31E-07
1258 1.167434692
[Acta2, Actb, Actr3, Adm, Arpc2, Arpc4, Atp6v0a1, Atp6v0d1, Atp6v0d2, Atp6v1a, Bag6, Calm2, Cct3, Cct6a, Cd44, 
Cfl2, Clns1a, Hcls1, Hsp90ab1, Hspa5, Hspa8, Lima1, Mpc2, Msn, Myh10, Myh9, Myl12b, Myo1c, Myo5a, Myo6, Plod3, 
Rps27a, Sfxn3, Sptbn1, Tcp1, Thy1, Tpm1, Txn1] GO:0065008 regulation of biological quality {Group0=3.0590363954994164E-6} 38 3.06E-06
1259 2.017937183
[Actl6a, Calm2, Ccdc88a, Cct3, Cct6a, Cltc, Dnaja1, Hcls1, Hsp90ab1, Iqgap1, Mpc2, Msn, Myo1c, Myo5a, Sptbn1, 
Tcp1, Thy1, Txn1] GO:0060341 regulation of cellular localization {Group3=1.7911444457370406E-9, Group5=5.400723098059407E-11} 18 2.33E-06
1260 1.794453502
[Actl6a, Actn4, Actr3, Ap2a1, Ap2a2, Ap2b1, Atp6v0d1, Atp6v0d2, Calm2, Ccdc88a, Clta, Cltc, Copg2, Hcls1, 
Hsp90ab1, Hspa8, Hyou1, Kif5c, Mpc2, Msn, Myh10, Myh9, Myo1c, Myo5a, Myo6, Rps27a, Sec61a1, Sort1, Sptbn1, 
Thy1, Tmed9, Txn1, Vps53] GO:0051649 establishment of localization in cell {Group5=5.400723098059407E-11} 33 6.48E-10
1261 1.706910849
[Acap2, Actl6a, Actn4, Actr3, Ap2a1, Ap2a2, Ap2b1, Atp6v0d1, Atp6v0d2, Bag6, Calm2, Ccdc88a, Cct3, Cct6a, Clta, 
Cltc, Copg2, Dnaja1, Hcls1, Hsp90ab1, Hspa5, Hspa8, Hyou1, Iqgap1, Kif5c, Mpc2, Msn, Myh10, Myh9, Myo1c, Myo5a, 
Myo6, Rps27a, Sec61a1, Sort1, Sptbn1, Tcp1, Thy1, Tmed9, Txn1, Vps53] GO:0051641 cellular localization {Group5=5.400723098059407E-11} 41 7.85E-12
1262 2.678571463 [Actr3, Arpc2, Arpc4, Ccdc88a, Cfl2, Cltc, Hcls1, Hspa1b, Lima1, Myo1c, Myo1f, Sptbn1] GO:0051493 regulation of cytoskeleton organization {Group6=9.289432501882645E-13} 12 8.66E-06
1263 1.281746984
[Abcd2, Actl6a, Actn4, Actr3, Adm, Ap2a1, Ap2a2, Ap2b1, Apobr, Araf, Arfgef2, Atp6v0a1, Atp6v0d1, Atp6v0d2, 
Atp6v1a, Atp6v1f, Bag6, Calm2, Ccdc88a, Cct3, Cct6a, Clns1a, Clta, Cltc, Copg2, Dnaja1, Hcls1, Hsp90ab1, Hspa2, 
Hspa5, Hspa8, Hyou1, Kif5c, Mpc2, Msn, Myh10, Myh9, Myo1c, Myo1e, Myo1f, Myo5a, Myo6, Psma1, Rps27a, 
Sec61a1, Sfxn3, Siglec1, Sort1, Sptbn1, Tcp1, Thy1, Tmed9, Txn1, Vps53] GO:0051234 establishment of localization {Group5=5.400723098059407E-11} 54 6.22E-11
1264 1.642178059
[Actl6a, Actn4, Actr3, Arpc2, Arpc4, Ccdc88a, Cct3, Cct6a, Cfl2, Hspa1b, Hspa5, Iqgap1, Msn, Myo1c, Psma1, Tcp1, 
Thy1, Tmed9, Vps13c] GO:0051130 positive regulation of cellular component organization {Group4=4.007090667982035E-10, Group6=9.289432501882645E-13} 19 2.27E-05
1265 1.375332713
[Actl6a, Actn4, Actr3, Arpc2, Arpc4, Ccdc88a, Cct3, Cct6a, Cd44, Cfl2, Cltc, Hcls1, Hspa1b, Hspa2, Hspa5, Hspa8, 
Iqgap1, Lima1, Msn, Myh10, Myh9, Myl12b, Myo1c, Myo1f, Psma1, Sptbn1, Tcp1, Thy1, Tmed9, Tpm1, Vps13c] GO:0051128 regulation of cellular component organization {Group4=4.007090667982035E-10, Group6=9.289432501882645E-13} 31 1.24E-06
1266 1.83006537
[Actl6a, Actn4, Ap2a1, Ap2a2, Ap2b1, Atp6v0d1, Atp6v0d2, Ccdc88a, Clta, Cltc, Copg2, Hcls1, Hsp90ab1, Hspa8, 
Hyou1, Kif5c, Mpc2, Msn, Myh10, Myo1c, Myo5a, Myo6, Rps27a, Sec61a1, Sort1, Sptbn1, Txn1, Vps53] GO:0046907 intracellular transport {Group5=5.400723098059407E-11} 28 1.35E-08
1267 1.446855903
[Actl6a, Actn4, Ap2a1, Ap2a2, Ap2b1, Arfgef2, Bag6, Cct6a, Clta, Cltc, Copg2, Dnaja1, Hcls1, Hsp90ab1, Hspa8, Mpc2, 
Myh9, Myo1c, Myo5a, Myo6, Sec61a1, Sptbn1, Tcp1, Tmed9, Txn1, Vps53] GO:0045184 establishment of protein localization {Group5=5.400723098059407E-11} 26 4.94E-06
1268 1.525821567
[Actr3, Ap2b1, Arpc2, Arpc4, Atp6v0a1, Cct3, Cfl2, Clns1a, Clta, Cltc, Cpsf6, Hcls1, Hsp90ab1, Hspa1b, Hspa8, Lima1, 
Msn, Myh11, Myo1c, Plod3, Psma4, Rpl24, Sept11, Snrpd2, Sptbn1, Tcp1] GO:0043933 macromolecular complex subunit organization {Group2=4.007090667982035E-10, Group6=9.289432501882645E-13} 26 1.84E-06
1269 2.402957439 [Actr3, Ap2b1, Arpc2, Arpc4, Atp6v0a1, Clta, Cltc, Hcls1, Hsp90ab1, Hspa1b, Myh11, Myo1c, Sptbn1] GO:0043623 cellular protein complex assembly {Group6=9.289432501882645E-13} 13 1.14E-05
1270 1.738570452
[Acap2, Actl6a, Ap2a1, Ap2a2, Ap2b1, Bag6, Ccdc88a, Cct3, Cct6a, Clta, Cltc, Copg2, Dnaja1, Hcls1, Hsp90ab1, Hspa5, 
Hspa8, Iqgap1, Msn, Myo1c, Myo5a, Myo6, Sec61a1, Sptbn1, Tcp1, Thy1, Txn1] GO:0034613 cellular protein localization {Group3=1.7911444457370406E-9, Group5=5.400723098059407E-11} 27 7.82E-08
1271 2
[Acap2, Actl6a, Bag6, Ccdc88a, Cct3, Cct6a, Dnaja1, Hcls1, Hsp90ab1, Hspa5, Hspa8, Msn, Sec61a1, Sptbn1, Tcp1, 
Txn1] GO:0033365 protein localization to organelle {Group3=1.7911444457370406E-9, Group5=5.400723098059407E-11} 16 1.03E-05
1272 1.653611779
[Actl6a, Actr3, Arpc2, Arpc4, Ccdc88a, Cct3, Cct6a, Cfl2, Cltc, Hcls1, Hspa1b, Lima1, Msn, Myo1c, Myo1f, Sptbn1, Tcp1, 
Tmed9, Vps13c] GO:0033043 regulation of organelle organization {Group3=1.7911444457370406E-9, Group4=4.007090667982035E-10, Group6=9.289432501882645E-13} 19 2.06E-05
1273 1.348819733
[Acap2, Actl6a, Actn4, Ap2a1, Ap2a2, Ap2b1, Apobr, Arfgef2, Bag6, Ccdc88a, Cct3, Cct6a, Clta, Cltc, Copg2, Dnaja1, 
Hcls1, Hsp90ab1, Hspa5, Hspa8, Iqgap1, Kif5c, Mpc2, Msn, Myh9, Myo1c, Myo5a, Myo6, Plod3, Sec61a1, Sptbn1, 
Tcp1, Thy1, Tmed9, Txn1, Vps53] GO:0033036 macromolecule localization {Group5=5.400723098059407E-11} 36 2.30E-07
1274 3.416149139 [Actr3, Arpc2, Arpc4, Ccdc88a, Cfl2, Hcls1, Lima1, Myh9, Myo1c, Myo1f, Sptbn1] GO:0032970 regulation of actin filament-based process {Group6=9.289432501882645E-13} 11 2.12E-06
1275 3.426791191 [Actr3, Arpc2, Arpc4, Cfl2, Clns1a, Hcls1, Hsp90ab1, Lima1, Msn, Myo1c, Sptbn1] GO:0032535 regulation of cellular component size {Group6=9.289432501882645E-13} 11 2.05E-06
1276 3.25900507
[Actb, Actn1, Actn4, Actr3, Arpc2, Arpc4, Ccdc88a, Cfl2, Hcls1, Lima1, Myh10, Myh11, Myh9, Myo1c, Myo1f, Sptbn1, 
Tpm1, Tpm2, Tpm3] GO:0030036 actin cytoskeleton organization {Group4=4.007090667982035E-10, Group6=9.289432501882645E-13} 19 5.66E-10
1277 3.495440722
[Acap2, Actb, Actn1, Actn4, Actr3, Arpc2, Arpc4, Ccdc88a, Cfl2, Hcls1, Lima1, Myh10, Myh11, Myh9, Myl6, Myl6b, 
Myo1c, Myo1f, Myo5a, Sptbn1, Tpm1, Tpm2, Tpm3] GO:0030029 actin filament-based process {Group6=9.289432501882645E-13} 23 1.44E-12
1278 1.515151501
[Actn1, Actn4, Actr3, Ap2b1, Arpc2, Arpc4, Atp6v0a1, Atp6v0d1, Bag6, Ccdc88a, Cct3, Cfl2, Clns1a, Clta, Cltc, Cpsf6, 
Hcls1, Hsp90ab1, Hspa1b, Hspa2, Iqgap1, Lima1, Msn, Myh10, Myh11, Myo1c, Myo6, Plec, Plod3, Psma4, Rpl24, 
Sept11, Snrpd2, Sptbn1, Tcp1, Thy1, Tpm1] GO:0022607 cellular component assembly {Group2=4.007090667982035E-10, Group6=9.289432501882645E-13} 37 4.41E-09
1279 2.093802452
[Actn4, Adm, Ap2a1, Ap2a2, Ap2b1, Apobr, Arfgef2, Clta, Cltc, Copg2, Hspa8, Hyou1, Msn, Myh10, Myh9, Myo1e, 
Myo1f, Myo5a, Myo6, Psma1, Siglec1, Sort1, Sptbn1, Tmed9, Vps53] GO:0016192 vesicle-mediated transport {Group1=7.193960081190489E-9} 25 7.19E-09
1280 1.121704936
[Actb, Actl6a, Actn1, Actn4, Actr3, Adm, Ap2b1, Arfgef2, Arpc2, Arpc4, Atp6v0a1, Atp6v0d1, Bag6, Ccdc88a, Cct3, 
Cct6a, Cd44, Cfl2, Clns1a, Clta, Cltc, Cpsf6, Hcls1, Hsp90ab1, Hspa1b, Hspa2, Hspa5, Hspa8, Iqgap1, Kif5c, Lima1, Lsp1, 
Msn, Myh10, Myh11, Myh9, Myl12b, Myo1c, Myo1e, Myo1f, Myo5a, Myo6, Plec, Plod3, Psma1, Psma4, Rpl24, 
Rps27a, Sec61a1, Sept11, Snrpd2, Sort1, Sptbn1, Tcp1, Thy1, Tmed9, Tpm1, Tpm2, Tpm3, Vps13c] GO:0016043 cellular component organization {Group2=4.007090667982035E-10, Group4=4.007090667982035E-10} 60 4.01E-10
1281 1.401050806
[Actl6a, Actn4, Ap2a1, Ap2a2, Ap2b1, Arfgef2, Clta, Cltc, Copg2, Dnaja1, Hcls1, Hsp90ab1, Hspa8, Mpc2, Myh9, 
Myo1c, Myo5a, Myo6, Sec61a1, Sptbn1, Tcp1, Tmed9, Txn1, Vps53] GO:0015031 protein transport {Group5=5.400723098059407E-11} 24 2.20E-05
1282 2.321724653 [Actl6a, Actr3, Arpc2, Arpc4, Ccdc88a, Cct3, Cct6a, Cfl2, Hspa1b, Msn, Myo1c, Tcp1, Tmed9, Vps13c] GO:0010638 positive regulation of organelle organization {Group3=1.7911444457370406E-9, Group4=4.007090667982035E-10, Group6=9.289432501882645E-13} 14 7.49E-06
1283 5.29801321 [Actr3, Arpc2, Arpc4, Cfl2, Hcls1, Lima1, Myo1c, Sptbn1] GO:0008064 regulation of actin polymerization or depolymerization {Group6=9.289432501882645E-13} 8 2.31E-06
1284 3.89221549 [Actn1, Actn4, Actr3, Arpc2, Arpc4, Cfl2, Hcls1, Lima1, Myo1c, Sptbn1, Tpm1, Tpm2, Tpm3] GO:0007015 actin filament organization {Group6=9.289432501882645E-13} 13 5.11E-08
1285 1.979345918
[Actb, Actn1, Actn4, Actr3, Arpc2, Arpc4, Ccdc88a, Cfl2, Cltc, Hcls1, Hspa1b, Lima1, Lsp1, Myh10, Myh11, Myh9, 
Myo1c, Myo1f, Sptbn1, Thy1, Tpm1, Tpm2, Tpm3] GO:0007010 cytoskeleton organization {Group4=4.007090667982035E-10, Group6=9.289432501882645E-13} 23 9.39E-08
1286 1.169415236
[Actb, Actl6a, Actn1, Actn4, Actr3, Arfgef2, Arpc2, Arpc4, Atp6v0d1, Bag6, Ccdc88a, Cct3, Cct6a, Cfl2, Cltc, Hcls1, 
Hsp90ab1, Hspa1b, Hspa2, Lima1, Lsp1, Msn, Myh10, Myh11, Myh9, Myo1c, Myo1f, Rpl24, Rps27a, Sec61a1, Sort1, 
Sptbn1, Tcp1, Thy1, Tmed9, Tpm1, Tpm2, Tpm3, Vps13c] GO:0006996 organelle organization {Group2=4.007090667982035E-10, Group4=4.007090667982035E-10, Group6=9.289432501882645E-13} 39 1.95E-06
1287 2.4866786 [Actn4, Adm, Ap2a1, Ap2a2, Ap2b1, Apobr, Clta, Cltc, Myh9, Myo1e, Myo6, Psma1, Siglec1, Sort1] GO:0006897 endocytosis {Group1=7.193960081190489E-9} 14 3.41E-06
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Table 4.3: GO Terms for FL3/FL4 fragments 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Synj1 NF NF 




























































Arpc5 NF NF 



























































































































































    
 
Table 4.4. Sum intensities of mass-spectrometry targets for empty and FL4  
Representative analysis of proteins pulled down after flag purification of JAWSII cells expressing either empty vector or Flag-tagged 

















Figure 4.1.  Wdfy4 is selectively required for cross-presentation of cell-associated antigens 
by cDC1.  (A) Cross-presentation was measured for Cas9-transgenic cDC1 expressing two 
sgRNA (1 and 2; middle and bottom) for Wdfy4 or a scramble control (top) that were generated 
as described in (Fig. 1I). T cell proliferation shown by percentages of CFSE- OT-I cells.  (B) 
Cross-presentation by cDC1 expressing sgRNAs for Wdfy1, Wdfy2, Wdfy3 and Wdfy4 was 
measured as described in (Fig. 1I). Scr=Scramble. Activated T cells gated as CFSE-CD44+.  Data 
indicate mean ± SEM of 3 independent experiments (C) cDC1 and cDC2 development was 
assessed by flow cytometry in WT, Wdfy4-/- and Batf3-/- mice, plots were pre-gated as B220-
CD11c+MHCII+ and then gated as cDC1 (XCR1+Sirpα-) or cDC2 (XCR1-Sirpα+).(D) absolute 
cell numbers of cDC1 and cDC2 in WT and Wdfy4-/- mice. Each dot indicates one mouse, bar 
indicates mean.  (E) FACS sorted cDC1 and cDC2 from spleens of WT and Wdfy4-/- mice were 
assayed for presentation to OT-I (CFSE-CD44+)  in response to the indicated concentrations of 
HKLM-OVA. (F) FACS sorted cDC1 and cDC2 from spleens of bone marrow chimeric mice 
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with WT or Wdfy4-/- bone marrow were assayed for presentation to OT-I (CFSE-CD44+) in 
response to indicated concentrations of OVA-loaded irradiated splenocytes from MHCI TKO 
mice. A negative control of splenocytes osmotically pulsed in the absence of OVA, OVA-, was 
included (G) FACS sorted  cDC1 and cDC2 from spleens of WT and Wdfy4-/- mice were assayed 
for presentation to OT-I (CFSE-CD44+) in response to indicated concentrations of soluble OVA. 
(H) FACS sorted cDC1 and cDC2 from spleens of WT and Wdfy4-/- mice were assayed for 
presentation to OT-II (CFSE-CD44+) in response to indicated concentrations of OVA-loaded 
irradiated splenocytes from MHCII KO mice. A negative control of splenocytes osmotically 
pulsed in the absence of OVA, OVA-, was included. For all figures, data indicate mean ±SEM 
for three independent experiments, *P<0.05; **P<0.01; ****P<0.0001 using 2-way ANOVA 


























Figure 4.2. Expression profile of Wdfy4. (A) Mouse gene expression profile of Wdfy4 in 



































Figure 4.3. Characterization of Wdfy4-/- mice. (A) Wdfy4-/- mice were generated by the 
Knockout Mouse Phenotyping Program (KOMP) at The Jackson Laboratory.  The schematic 
shows the WT and targeted Wdfy4 locus for exons 3 to 5, showing the locations of the four 
sgRNAs (red triangles) used for CRISPR/Cas9 to delete exon 4.  (B) Shown is the genomic 
sequence surrounding exon 4 (black), exon 4 coding region (red), the flanking splice AG 
acceptor and GT splice donor nucleotides (bold), and the sequences of the four sgRNAs used for 
CRISPR/Cas9 targeting (blue). (C) Genotyping strategy for identifying Wdfy4+ and Wdfy4-  
alleles uses the oligonucleotide primers (a-c), whose locations relative to exon 4 are indicated. 
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The WT allele is identified as a 170 bp PCR product generated with primers a and b.  The 
targeted allele is identified from the 226 bp PCR product with a and c.  (D)  Shown are the 
protein sequence of Wdfy4 encoded by exons 3 through 5 of the WT locus (left) and the mutant 
Wdfy4 protein resulting from the splicing of exon 3 to exon 5 (right) in the targeted locus.  
Because the coding region of exon 4 contain 107 nucleotides, splicing from exon 3 to 5 results in 














































Figure 4.4. Normal DC development in Wdfy4-/- mice.  (A) Percentages of cDC1 (B220-
CD11c+MHCII+CD24+ Sirpα-) and cDC2 (B220-CD11c+MHCII+CD24lo Sirpα+)  from spleen of 
Wdfy4+/+ and Wdfy4-/- mice. Dot indicates one mouse, bar indicates mean. (B) Representative 
flow cytometry plots from spleen of Wdfy4+/+ and Wdfy4-/- mice. Pregated as B220-. (C) 
Percentages of cDC1 (CD45+CD64-B220-CD11c+MHCII+CD24+ Sirpα-)  and cDC2 
(CD45+CD64-B220-CD11c+MHCII+CD24lo Sirpα+)  from lung of Wdfy4+/+ and Wdfy4-/- mice. 
Dot indicates one mouse, bar indicates mean. (D-E)  Migratory (CD11clo MHC-IIhi) and resident 
(CD11chi MHC-IIlo) cDC1 (resident: CD24+Sirpα-, migratory: CD103+CD11b-) and cDC2 
(resident: CD24-Sirpα+, migratory: CD11b+CD103-) from mLN (D) or sLN (E) were 
distinguished and shown as a percentage of total cDCs (left) or total cell numbers (right). Dot 
indicates one mouse, bar indicates mean (F) Representative flow cytometry plots of migratory 
sLN DCs from Wdfy4+/+ and Wdfy4-/- mice. Pregated B220-CD11cloMHCIIhi. (G) Thymic 
migratory (CD11clo MHC-IIhi) and resident (CD11chi MHC-IIlo) cDCs were distinguished within 
cDC1 (resident: CD24+Sirpα-, migratory: CD103+Sirpα-) and cDC2 (resident: CD24-Sirpα+, 
migratory: CD103-Sirpα+) and shown as a percentage of total cDCs (left) or total cell numbers 
(right). Dot indicates one mouse, bar indicates mean.   No statistically significant differences in 
cDC subsets were identified between WT and Wdfy4-/- mice for any tissues tested. (H) 
Intracellular staining for IRF8 in splenic cDCs from Wdfy4+/+, Wdfy4-/-, and Batf3-/- mice 
compared to Irf8-/- control (gray histogram). (I) BrdU incorporation in indicated cell types over 
time after daily injections of Wdfy4+/- and Wdfy4-/- mice. Data shown as mean ± SEM of three 






























Figure 4.5. Normal T cell development in Wdfy4-/- mice. (A-C) TCRβ+ T cells from spleens of 
Wdfy4+/+ and Wdfy4-/- mice are shown for CD4 and CD8 expression (A), and for activation 
markers CD44 and CD62L (B) for CD4 (left) and CD8 (right) T cells respectively. No 
significant differences in percentages or total numbers of CD4 or CD8 T cells were found 































Figure 4.6. WDFY4 acts specifically in cDC1-mediated cross-presentation. 
(A) Sort-purified cDC1 and cDC2 from spleens of WT and Wdfy4-/- mice were assayed for 
presentation of UVC-irradiated OVA-expressing cells (bm1) to OT-1 T cells. Activated T cells 
gated as CFSE-CD44+. (B) Sorted cDC1 and cDC2 from WT or Wdfy4-/- Flt3L cultures were 
osmotically loaded with 10mg/ml soluble OVA and then diluted to indicated cell concentrations 
and cultured with 25K CFSE-labeled OT-I T cells for three days and analyzed for CFSE dilution 
(CFSE-CD44+). Control DCs were osmotically shocked but given no OVA (C) Representative 
flow cytometry plots showing infection of OVA-GFP virus (left) and expression of Kb-
SIINFEKL complexes (right) in WT or Wdfy4-/- cDC1 (B220-CD11c+MHCII+CD24+Sirpα-) 
compared to empty vector control. (D) OT-I proliferation (CFSE-CD44+) of WT or Wdfy4-/- 
cDCs after infection with empty vector or OVA-GFP vector. (E-F) MoDCs generated from 
sorted BM monocytes from WT or Wdfy4-/- mice were put in culture for four days with 20ng/ml 
GM-CSF and IL-4. 25K moDCs were cultured for three days with 25K CFSE-labeled OT-I cells 
and the indicated concentrations of OVA- or PBS- loaded splenocytes (E) or soluble OVA (F). 
OT-I activation measured as CFSE-CD44+. (G) Sort purified cDC1 and cDC2 from spleens of 
WT or Wdfy4-/- mice were cultured for three days with CFSE-labeled OT-II T cells and the 
indicated concentrations of soluble OVA. Data is shown as percentage of CFSE-CD44+ OT-II 
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cells. For all figures data shown as mean ±SEM from three independent experiments, 

















































Figure 4.7. Wdfy4-/- mice are capable of inducing normal B cell responses. 
(A) 50K sorted B220+ B cells were co-cultured for three days with 25K CFSE-labeled OT-II T 
cells and 100µg/ml soluble OVA with or without 1µg/ml LPS and assayed for CFSE dilution 
(CFSE-CD44+). Data shown as mean ± SEM of three independent experiments. (B-C) Wdfy4+/- 
and Wdfy4-/-  mice were injected i.p. with sheep red blood cells and spleens were analyzed seven 
days later for induction of germinal center B cells, summarized in (C). Cells were pre-gated on 
B220+IgD-CD19+. Each dot indicates one mouse, bar indicates mean. (D-E) Wdfy4+/- and Wdfy4-
/-  mice were injected i.p. with sheep red blood cells and spleens were analyzed seven days later 
for induction of TFH cells, summarized in (E). Cells were pre-gated on B220
-TCRβ+CD4+CD62L-






Figure 4.8. Wdfy4-deficient cDCs are capable of producing signals for T cell priming 
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(A) Flow cytometry of splenic cDC1 and cDC2 from WT or Wdfy4-/- mice for MHC-I compared 
to MHC-I TKO control mice (gray histogram). Pre-gated on cDC1(B220-
CD11c+MHCII+CD24+Sirpα-)  or cDC2 (B220-CD11c+MHCII+CD24-Sirpα+)  (B) Flow 
cytometry of day eight Flt3L cultured cDC1 from WT or Wdfy4-/- mice for MHC-I with either no 
treatment (black line) or four hours of culture with 1µg/ml LPS (blue bar). Numbers indicate 
MFI. Pre-gated on cDC1 (B220-CD11c+MHCII+CD24+Sirpα-). (C) Representative flow 
cytometry of expression of CD80 and CD86 in cDC1 cells generated from Flt3L cultured bone 
marrow of indicated genotypes after eight days. Cells were stimulated for four hours with 
1µg/mL LPS to induce activation. Pre-gated on cDC1 (B220-CD11c+MHCII+CD24+Sirpα-) . (D-
F) Production of IL-12p40 (D), TNFα(E), or IL-12p40 and TNFα (F) by cDC1 (left, B220-
CD11c+MHCII+CD24+Sirpα-) or cDC2 (right, B220-CD11c+MHCII+CD24-Sirpα+) generated in 
Flt3L cultures for nine days to indicated stimuli. Data shown as mean ± SEM for three 
independent experiments. (G-H) Gene expression data from Wdfy4+/- or Wdfy4-/- cDC1 from the 
draining (G) or non-draining (H) inguinal sLN from tumor bearing mice 6 days after injection of 




































Figure 4.9. Wdfy4-deficient cDCs can take up and degrade antigen. 
(A) Representative flow cytometry plots of DQ-OVA (10µg/ml) degradation by cDC1 (left, 
B220-CD11c+MHCII+CD24+Sirpα-) or cDC2 (right, B220-CD11c+MHCII+CD24-Sirpα+) 
generated in Flt3L cultures for nine days, read out by FITC+ fluorescence. (B)  Percentage of 
Wdfy4+/+ (black) or Wdfy4-/- (red) FITC+ cDCs after culture with unlabeled OVA (10µg/ml), DQ-
OVA (10µg/ml), or DQ-OVA (10µg/ml) + MG132 (5µg/ml) for indicated times. data shown as 
mean ±SEM from three independent experiments. (C) Representative microscopy images of 
Flt3L generated DCs from indicated genotypes allowed to uptake HKLM-647 for 4 hours and 
stained for Rab43 (green) to distinguish cDC1. (D) Quantification of percentage of HKLM-647+ 
cDC1 (left, B220-CD11c+MHCII+CD24+Sirpα-) or cDC2 (right, B220-CD11c+MHCII+CD24-
Sirpα+) after four hours of culture of 1 million Flt3L generated DCs from BM of indicated 




















Figure 4.10. Wdfy4-deficient cDCs have normal cellular structures 
(A-F) Confocal microscopy of day 10 Flt3L-cultured DCs attached to alcian blue coated 
coverslips for four hours. Cells were fixed, permeabilized, and stained with antibodies against 
β2m (A), Calnexin (B), EEA1 (C), Lamp1 (D), Rab7 (E), or Tap1 (F) which were secondary 
stained with antibodies conjugated to AF488 (green) or AF647 (red) before mounting on slides 
using Prolong Gold antifade + DAPI (blue). Scale bars indicate 5µm. Staining quantified for 
each stain on left, each dot indicates one cell, bar indicates mean. n.s. not significant (P>.05); * 









































Figure 4.11. Wdfy4-deficient cDCs have normal cellular structures after antigen uptake. 
(A-D) Confocal microscopy of day 10 Flt3L-cultured DCs attached to alcian blue coated 
coverslips for four hours in the presence of AF647-labeled HKLM-OVA (red). Cells were fixed, 
permeabilized, and stained with antibodies against RAB43 (A), p62 (B), Rab7 (C), or Lamp1 (D) 
which were secondary stained with antibodies conjugated to AF488 (green) before mounting on 
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slides using Prolong Gold antifade + DAPI (blue). Area of staining quantified for each stain on 

















































Figure 4.12. Wdfy4-deficient cDC1 have increased presence of intracellular lipid bodies. 
(A-B) Representative EM images of Wdfy4+/+ (A) or Wdfy4-/- (B) cells analyzed by electron 






Figure 4.13. Presence of lipid bodies in Wdfy4-deficient cDC1 does not explain cross-
presentation defect 
(A) Representative EM images of Wdfy4+/+ or Wdfy4-/- cDC1 taken ex vivo from spleen, scale 
bars indicate 500nm (B) Representative EM images of Wdfy4+/+ or Wdfy4-/- cDC1 from Flt3L 
cultures, scale bars indicate 2µm (C) Quantification of the number of lipid bodies per cell for 
indicated samples. Each dot indicates one cell, bar indicates mean. (D) Cross-presentation of 107 
HLKM-OVA to OT-1 T cells by cDC1 from Wdfy4+/+ or Wdfy4-/- Flt3L cultures. T cell 
activation assayed as CFSE-CD44+. Bars indicate mean ±SEM, ns, not significant (P>0.05); ** 





















Fig. 4.14. WDFY4 acts near the plasma membrane and associates with proteins involved in 
localization and vesicular transport. 
(A) Diagram of truncated fragments of WDFY4 protein, showing predicted domains within FL4 
fragment. Numbers indicate amino-acid locations of fragments. (B) ClueGO visualization of 
gene ontology terms enriched after immunoprecipitation of fragments from (A) in the mouse DC 
line JAWSII, expressing either FL1 or FL2 fragments. Small circles P<.001, large circles 
P<.0001. Colors indicate Gene Ontology (GO) term groups. (C) ClueGO visualization of gene 
ontology terms enriched after immunoprecipitation of fragments from (A) in the mouse DC line 
JAWSII expressing either FL3 or FL4 fragments. Small circles P<3x10-5, large circles P<3x10-6. 
Colors indicate GO term groups. (D) Scatterplot of representative data for sum intensity of 
proteins found after mass spectrometry between FL4 expressing and empty-vector expressing 
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JAWSII cells. (E) Western blot of Flag immunoprecipitates from HEK293 cells transfected with 
empty-vector or Flag-tagged WDFY4 fragments 1 to 4 (top), and input control for β-actin 
(bottom) (F) Western blot for endogenous Hsp90 in Flag immunoprecipitates from HEK293 
transfected with empty-vector or Flag-tagged WDFY4 fragments 1 to 4 (top) and input control 
for endogenous Hsp90 (bottom) (G) Confocal microscopy of JAWSII cells overexpressing full 
length Twin-Strep-tagged WDFY4, stained for anti-Strep (green), various cellular markers (red), 
and DAPI (blue). Scale bars indicate 5µm. (H) Quantification of co-localization between 
WDFY4 and intracellular markers from images in (G), each dot represents one cell, bar indicates 










































Fig. 4.15. Wdfy4-/- mice are unable to cross-present in vivo 
(A-B) Representative flow cytometry analysis of in vivo cross-presentation to 500K irradiated 
splenocytes loaded with OVA injected i.v. into mice of the indicated genotypes one day after 
injection of 500K CFSE-labeled OT-I cells. Mice were harvested three days after antigen 
injection, quantified in (B). Data pre-gated on OT-I cells and shown as percentage of CFSE- cells 
(A) or CFSE-CD44+ cells (B).  Data are pooled from three independent experiments; each point 
represents one mouse. (C) Survival of mice of the indicated genotypes to injection of 200 Pru.luc 
T. gondii tachyzoites over 30 days. WDFY4+/- n=9, WDFY4-/- n=8, Batf3-/- n=3. (D-E) 
Representative flow cytometry plots of CD8 T cells (pre-gate CD4-CD3+CD8+) in lungs of naïve 
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or cowpox infected mice, quantified in (E). Each dot represents one mouse, bar indicates mean. 
(F) Mice of the indicated genotypes were injected with 1x106 fibrosarcoma cells s.c. and tumors 
were measured daily starting at day three after injection. (G) Mixed bone marrow chimeras with 
bone marrow of indicated genotypes were injected into lethally irradiated CD45.1+ WT B6 mice. 
Eight weeks later, mice were injected with 1x106 fibrosarcoma cells s.c. and tumors were 
measured daily starting at day three after injection. Data show mean ± SEM of 9 mice per group.  
(H) Quantification of cDC1 in tumors at either day 6 or day 21 after injection taken from mice of 
indicated genotypes. Gated as B220-CD11c+MHCII+CD103+CD11b-.  Each dot indicates one 
mouse, bar indicates mean.  (I) Quantification of CD8 T cells in tumors at either day 6 or day 21 
after injection taken from mice of indicated genotypes. Gated as CD45+TCRβ+CD8α+CD4-.  
Each dot indicates one mouse, bar indicates mean. For all figures, ** P<.01;  **** P<0.0001 








































Figure 4.16. Wdfy4-deficient mice cannot prime CD8 T cells to cowpox virus infection. 
(A-C) Quantification of number (A,C) or percentage (B) of tetramer+CD8 T cells from lung (A) 
or spleen (B,C) of infected or uninfected (naïve) Wdfy4+/- or Wdfy4-/- mice. Each dot represents 
one mouse, bars indicate mean. (D) Representative flow cytometry of CD8 T cells (pregate CD4-
CD3+CD8+) from the spleen of naïve or infected Wdfy4+/- or Wdfy4-/- mice. (E) Percentage of 
Tetramer+CD44+ cells within CD8 T cell population in spleen of mice eight days after West Nile 
Virus infection. (F) Percentage of Tetramer+ cells within CD4 T cell population in spleen of 
mice eight days after West Nile Virus infection. Each dot indicates one mouse, bar indicates 
mean, ns, not significant, *P<0.05; **P<0.01, ****P<.0001 using 2-way ANOVA with Tukey's 











Figure 4.17. Analysis of tumors from Wdfy4-/- or Batf3-/- mice. 
(A) Representative images of tumors from WT and Wdfy4-/- mice. (B) Representative flow 
cytometry plots indicating Batf3-dependent populations in mLN (pre-gate B220-
CD11c+MHCII+) compared to WT (left) and representative flow cytometry plots showing the 
presence of Batf3-dependent DC subsets in tumors (pre-gate B220-CD3-NK1.1-CD11c+MHCII+) 


































4.5 Materials and Methods 
Mice 
All mice were bred and maintained in specific pathogen-free facilities according to 
institutional guideline protocols approved by the Animal Studies Committee of Washington 
University in St. Louis. WT C57BL/6 (WT), C57BL/6-Tg(TcraTcrb)1100Mb/J (OT-I), 
C57BL/6-Tg(TcraTcrb)425Cbn/J (OT-II) were purchased from The Jackson Laboratory. 
C57BL/6NF-Wdfy4em1(IMPC)J/J (Stock no. 029334) were generated through the KOMP2 project at 
The Jackson Laboratory. MHCI TKO mice (Kb−/−Db−/−β2m−/−) were originally provided by H.W. 
Virgin and T. Hansen (Washington University, St. Louis, MO78). 4-14 week old mice that were 
age and sex matched were used for all experiments. For bone marrow chimeras B6.SJL (B6.SJL-
PtprcaPepcb/BoyJ) were purchased from Charles River Laboratories. Chimeras were generated 
by lethally irradiating mice and injecting them with 4-6 million bone marrow cells i.v.  
Genotyping primers for Wdfy4em1(IMPC)J/J are a: TTCTGCAGCAGGACAGACAC, b: 
TTTAGGAGCAGGTTGCCATC, c: ATGCCCTCTTCCCAACTTCT.  
For bone marrow chimeras B6-Ly5.1/Cr (Charles River) mice were γ-irradiated with 1050rad 
and allowed to recover one day before i.v. injection of 50/50 mixes of Wdfy4+/+/Batf3-/- or 
Wdfy4-/-/Batf3-/- bone marrow. Mice rested for eight weeks post bone marrow injection before 
use in tumor experiments. 
Antibodies and Flow Cytometry 
  Flow cytometry and cell sorting were completed on a FACS CantoII or FACS Aria 
Fusion instrument (BD) and analyzed using FlowJo analysis software (Tree Star). Staining was 
performed at 4ºC in the presence of Fc block (2.4G2; BD) in magnetic-activated cell-sorting 
(MACS) buffer (PBS + .5% BSA + 2mM EDTA). The Following antibodies were used. From 
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BD Biosciences: CD117 (2B8), CD135 (A2F10.1), Ly6C (AL-21), MHCI (AF6-88.5), CD4 
(RM4-5), CD8α (53-6.7), CD11b (M1/70), B220 (RA3-6B2), CD64 (X54-5/7.1), CD19 (1D3), 
CD95 (Jo2), CD3 (145-2C11), CD45 (30-F11); from Tonbo Biosciences: MHCII (M5/114.15.2), 
CD44 (IM7), CD45.1 (A20), CD45.2 (104), CD11c (N418); from Biolegend: CD103 (2E7), 
XCR1 (ZET), CD115 (AFS98), Ter119 (Ter-119), Ly6G (1A8), TCRβ (H57-597), GL-7 (GL7), 
CXCR5 (L138D7), PD-1 (29F.1A12), CD3 (145-2C11), CD8 (53-6.7), CD4 (RMA4-5), CD44 
(IM7), CD16/32 (93) ; from eBiosciences: TCRVα2 (B20.1), CD90.1 (HIS51), CD90.2 (53-2.1), 
IL-12p40 (C17.8), F4/80 (BM8), SIINFEKL/H-2Kb (25-D1.16), CD317 (eBio927); from 
Invitrogen: CD172α (P84), TNFα (MP6-XT22), CD45 (30F11), IgD (11-26c). 
For immunofluorescence, the following antibody was purchased from Invitrogen: Alexa Fluor 
488 goat anti-mouse IgG (H+L). Anti-Rab43 (2E6) was produced in house as described 
previously32. From abcam: anti-SQSTM1 (ab56416), anti-Rab7 (ab50533), anti-
Lamp1(ab24170), anti-β2m (ab75853), anti-calnexin (ab22595), anti-EEA1 (ab2900). From 
Santa Cruz: anti-Tap1 (B-8). From IBA Lifesciences: StrepMAB-Classic. 
  H-2Kb-TSYKFESV tetramers were produced in the Immunomonitoring Laboratory 
within the Center for Human Immunology and Immunotherapy Programs (Washington 
University). West Nile tetramers: Db-WNV NS4B, I-Ab-WNV E 641-655, I-Ab-WNV NS3 372-
386, I-Ab-WNV NS3 111-125 were generated by the NIH Tetramer Core Facility. 
Cell sorting 
  Splenic and Flt3L DCs were sorted as B220–MHCII+CD11c+CD24+CD172α– (cDC1) and 
B220–MHCII+CD11c+CD24–CD172α+ (cDC2). Monocytes were sorted from the bone marrow as 
Ly6G–CD19–Ter119–CD11c–CD115+CD117–Ly6C+CD11b+. OT-1 cells were sorted from the 
spleen as B220–CD11c–CD4–CD8+CD45.1+Vα2+. OT-II cells were sorted from the spleen as 
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B220–CD11c–CD8–CD4+CD45.1+Vα2+. Infected DCs for CRISPR screen were sorted as 
CD90.1+. Splenic B cells were sorted as B220+Thy1.2–CD11c–. 
DC Preparation 
  To harvest DCs from lymphoid tissues, organs were digested in 250µg/ml collagenase B 
(Roche) and 30 U/ml DNase I (Sigma-Aldrich) for 30-60min at 37ºC with stirring in complete 
IMDM + 10% FCS (I10F). Erythrocytes (RBCs) were lysed using ACK lysis buffer (150mM 
ammonium chloride, 10mM potassium bicarbonate, and .1mM EDTA). Before sorting DCs were 
enriched using CD11c microbeads (Miltenyi Biotech).  For peripheral tissue DCs, organs were 
digested with collagenase D (Roche) and DNaseI (Sigma-Aldrich) for 1hr at 37ºC with stirring in 
5ml cIMDM. 
BM culture with Flt3L 
  Tibias, femurs, and hips from mice were crushed into MACS buffer and RBCs were 
removed with ACK lysis buffer. BM cells were cultured at 2x10^6 cells/ml in cIMDM 
containing 5% FLT3L for 8-10 days. Loosely adherent cells were harvested for analysis. 
moDC preparation 
  Tibias, femurs , and hips were crushed into macs buffer and depleted of B220+ and 
Ly6G+ cells using MagniSort streptavidin beads (Thermo Fisher). Sorted monocytes were 
cultured in 2ml I10F with 20ng/ml GM-CSF and 20ng/ml IL-4 (Peprotech) for 4 days. Loosely 
adherent cells were harvested for analysis 
sgRNA vector design 
The ires-GFP fragment from the MSCV-ires-GFP retrovirus vector was replaced with 
Thy1.1 cDNA from MSCV-ires-Thy1.1 retrovirus vector79 using Xho1 and EcoR1 digests to 
produce Thy1.1- RV. Two PCR DNA fragments containing the hU6 promoter and gRNA 
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scaffold from pSpCas9(BB)-2A-GFP (PX458) (a gift from Feng Zhang (Addgene plasmid 
#48138)80) and a Bbs1 stuffer fragment from pLentiCrisprV1, provided by Feng Zhang 
(Addgene plasmid #49535) were sequentially cloned into the T easy vector (Promega). An 
EcoR1 fragment from the resulting plasmid was cloned into the EcoR1 site of Thy1.1-RV to 
produce Thy1.1-hU6-gRNA-Bbs1 stuffer-RV. To produce retroviral guide plasmids, annealed 
oligonucleotides with Bbs1 compatible overhangs and containing guide target sequences as 
described81 were ligated into Bbs1 digested Thy1.1-hU6-gRNA-Bbs1 stuffer-RV. 
Antigen presentation assays 
In vivo cross-presentation assays were performed as described previously8. MHCI TKO 
splenocytes were osmotically loaded with 10mg/ml soluble ovalbumin (Worthington 
Biochemical Corporation), irradiated at 1350rad, and 500,000 cells were injected i.v. into mice 
that had been injected with 500,000 CFSE-labeled OT-I T cells one day prior. After 3 days, 
spleens were harvested, mashed, and analyzed for CFSE dilution of OT-I cells. In vitro cross-
presentation assays were performed using 10,000 sorted cDCs and 25,000 CFSE-labeled OT-I 
cells co-cultured for 3 days before analysis of CFSE dilution.  
HKLM-OVA (a gift from H. Shen, University of Pennsylvania, Philadelphia, PA) and 
soluble OVA were prepared as described previously32, OVA-loaded splenocytes were prepared 
as described above. Bm1 T OVA cells76 (a gift from C. Reis e Sousa, Francis Crick Institute, 
London, UK) were UVC irradiated with 240mJ/cm2 one day prior to plating with sorted cDCs 
and OT-1. 
For direct-presentation assays, cDC1 and cDC2 were sorted from day 10 Flt3L cultures 
as described above. Cells were then osmotically loaded with 10mg/ml soluble ovalbumin 
(Worthington Biochemical Corporation) and co-cultured for 3 days with CFSE-labeled OT-I 
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cells. For alternative direct presentation bone marrow was infected with viruses containing an 
empty vector or an OVA expression plasmid before culturing in Flt3L to generate DCs. 7 days 
after infection cDC1 and cDC2 were either stained for Kb-SIINFEKL complexes (25-D1.16) or 
cultured with CFSE-labeled OT-1 T cells for 3 days and assayed for T cell proliferation. 
For B cell antigen presentation assays, B cells were sorted from spleens as described 
above. 50K B cells were then co-cultured for 3 days with CFSE-labeled OT-II cells and 
100µg/ml soluble ovalbumin (Worthington Biochemical Corporation) with or without 1µg/ml 
LPS from Escherichia coli (O55:B5; Sigma-Aldrich). 
For FACS of Kb-SIINFEKL, Day 8 Flt3L cultured DCs were cultured for 48 additional 
hours with either 0.1mg/ml soluble OVA or 1x106 OVA-loaded irradiated splenocytes prepared 
as described above.  
Cross-presentation screen 
Retroviral vectors were transfected into Platinum-E cells as described82 and supernatant 
containing virus was collected after 2 days. Sorted Lin-cKIThi cells from the bone marrow of 
Cas9-expressing mice (a gift from Feng Zhang54) were infected with viral supernatants with 
2µg/ml polybrene at 2,250r.p.m. for at least 1hr. Cells were then grown in Flt3L culture for 7 
days before sorting for Thy1.1+ cells. Sorted cells were then diluted to a concentration of ~10K 
cells per well and cocultured with 107 HKLM-OVA and 25K CFSE-labeled OT-I T cells for 3 
days before analysis for CFSE dilution. 
DC turnover assay 
Mice were injected daily with 1mg BrdU and spleens were harvested on days 2, 4, and 6 
for flow cytometry. Spleens were digested as described above and then fixed and stained 
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according to the BrdU Flow Kit procedure (BD). pDCs were identified as CD11clowB220+Bst2+ 
and B cells were identified as CD11c-B220+. 
In vitro TLR Stimulation 
200K Flt3L cultured DCs were plated and stimulated with either: 1µg/ml LPS from 
Escherichia coli (O55:B5; Sigma-Aldrich), 50µg/ml PolyI:C (Sigma-Aldrich), 63nM ODN1826, 
class B CpG oligonucleotide (CpG; InvivoGen), 2.5µg/ml STAg (prepared as previously 
described83) or 107 HKLM-OVA (prepared as previously described32). Cells were stimulated for 
1hr, treated with 1µg/ml brefeldin A (Sigma-Aldrich), and then incubated 4hrs. Cells were 
washed, prepared for surface staining, fixed in 4% paraformaldehyde (Electron Microscopy 
Sciences), and then permeabilized with .5% saponin for intracellular staining. 
For analysis of CD80/86 expression cells were prepared as described above and 
incubated with 1µg/ml LPS from Escherichia coli (O55:B5; Sigma-Aldrich) before surface 
staining. 
DQ-Ovalbumin degradation assay 
200K cells from day 9 Flt3L cultures were incubated with either 10µg/ml soluble OVA 
(Worthington Biochemical Corporation), 10µg/ml DQ-Ovalbumin (Thermo Fisher), or 10µg/ml 
DQ-OVA + 5µg/ml MG132 (Sigma-Aldrich) for either 5, 15, 30, or 60min. Cells were washed at 
the indicated timepoints with PBS and surface stained for DC markers before analysis for FITC+ 
cells. 
HKLM phagocytosis assay 
1 million cells from day 10 Flt3L cultures were harvested and plated with either 2x108 
AlexaFluor647 (generated as described previously32) labeled HKLM-OVA or no antigen at 
either 4ºC or 37ºC for 4hrs. After incubation DCs were enriched to remove HKLM using 
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CD45.2-biotin [104] (eBiosciences) and MojoSort separation (BioLegend) and stained for DC 
markers for flow cytometry. 
WDFY4 overexpression constructs 
The cDNA fragments for 4 individual domains of murine WDFY4 were synthesized as 
gene blocks (Thermo Fisher). A Twin-Strep® tag was placed at the 5’ end of Fragment 1. Silent 
mutations were introduced in all fragments to remove endogenous BamHI sites. Gene blocks 
were synthesized with the following 5’/3’ restriction enzyme sites: BamHI/AatII (Fragment 1), 
AatII/BstEII (Fragment 2), BstEII/AgeI (Fragment 3), AgeI/SpeI (Fragment 4). Each gene block 
was cloned individually then in sequence into pBluescript (Addgene) and then cloned into 
MSCV-IRES-Thy1.179 using 5’ BglII site and 3’ blunt end to produce MSCV-TwinStrep-
WDFY4-IRES-Thy1.1 vector. 
For proteomics and co-immunoprecipitation experiments, 2XFLAG tagged fragments of 
domains 1-4 were created using PCR and the above constructs as template. Each fragment was 
cloned into MSCV-IRES-Thy1.1 using a 5’ BglII site and either a 3’ SalI site or 3’ blunt end. 
Immunoprecipitation and mass spectrometry 
JAWSII cells (ATCC) stably expressing constructs for empty vector or Flag-tagged GFP, 
FL1, FL2, FL3, or FL4 were grown up to 50-100 million cells and harvested. Cells were lysed 
using lysis buffer (1% NP-40, 20mM Tris, 127mM NaCl, 10% Glycerol, 2mM EDTA, 1mM 
EGTA, 50mM NaF) with protease inhibitors for 30min and spun to clear. Cleared lysates were 
incubated for 3.5hrs with magnetic beads conjugated to an anti-Flag antibody [M2] (Sigma) in 
Tap wash buffer (50mM Tris, 100mM KCl, 5mM MgCl2, .2mM EDTA, 10% Glycerol, .1% NP-
40, .2mM PMSF, 1mM DTT) before washing. Proteins were eluted from beads using a 3xFlag 
peptide (Sigma) for 1hr and precipitated using tricholoroacetic acid before submitting for mass 
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spectrometry. LC-MS/MS was performed at the Taplin Mass Spectometry Facility (Harvard 
Medical School) using an LTQ Orbitrap Velos Pro ion-trap mass spectrometer (Thermo Fisher) 
and Sequest software. GO terms were generated using the ClueGO plugin for Cytoscape. 
For immunoprecipitation in HEK293 cells, cells were transiently transfected with TransIT-LT1 
(Mirus) and lysates were prepared 24-48hrs after transfection as described above. Cleared lysates 
were incubated for 2hrs with magnetic beads conjugated to an anti-Flag antibody [M2] (Sigma) 
in Tap wash buffer before washing with Tap wash buffer and elution by boiling in sample buffer 
containing beta-mercaptoethanol.  
Western Blot 
For Western analysis, the following antibodies were purchased from Abcam: anti-hsp90 
beta (ab32568); from Millipore Sigma: anti-FLAG (M2); from Santa Cruz Biotechnology, Inc: 
anti–β-actin (C4). 
Whole-cell extracts or immunoprecipitates were denatured in Laemmli sample buffer at 
95°C for 5 min. Samples were run on a 4-20% Mini-Protean TGX precast gels (Bio-Rad) and 
transferred onto a nitrocellulose membrane (Bio-rad). Immunoblots were blocked in TBS 
containing 3% BSA or 5% nonfat milk and 0.1% Tween 20 at room temperature for 1 h and then 
incubated with primary antibody overnight at 4°C. After washing, membranes were incubated 
with goat anti–rabbit IgG (H + L) or goat anti–mouse IgG (H + L) conjugated to horseradish 
peroxidase (Jackson ImmunoResearch Laboratories, Inc.) for 1 h at room temperature in 5% 
nonfat milk and 0.1% Tween 20 TBS. Then, membranes were washed and developed with 






  The MCA-induced fibrosarcoma 1969 used in this study was generated in a female 
C57BL/6 Rag2−/− mouse, was tested for mycoplasma, and was banked at low-passage as 
previously described15,84. Tumor cells derived from frozen stocks and propagated in vitro in 
RPMI media supplemented with 10% FCS (Hyclone) were washed three times with PBS, 
resuspended at a density of 6.67 x 106 cells/ml in endotoxin-free PBS and then 150 μl was 
injected subcutaneously into the flanks of recipient mice. Tumor growth was measured with a 
caliper and expressed as the area based on two perpendicular diameters.  
  For FACS of tumor infiltrating cells tumors were harvested either at day 6 or after 20-25 
days of growth, chopped using a razor blade, and digested in Collagenase B (Roche), 
Collagenase D (Roche), and DNaseI (Sigma-Aldrich) for 45min at 37ºC with constant agitation. 
Microarrays 
  Tumors were injected into mice as described above and allowed to grow for 6 days. On 
day 6 mice were harvested and inguinal lymph nodes from either the flank with the tumor 
(draining) or the opposite flank (non-draining) were harvested, digested, and sorted for cDC1 
(MHCII+CD11c+XCR1+). RNA was extracted and purified using the Nucleospin xs RNA 
isolation kit (Macherey-Nagel), amplified with the Ovation Pico WTA System (NuGEN), and 
hybridized to Mouse Gene 1.0 ST arrays (Affymetrix). Expression values were analyzed after 
robust multiarray average (RMA) and quantile normalization using ArrayStar 4 software 
(DNASTAR). 
Infection and Immunization  
  For Toxoplasma gondii,10-14 week old mice were injected with the type II Prugniaud 
strain of T. gondii expressing a firefly luciferase and GFP transgene (provided by J. Boothroyd, 
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Stanford University, Palo Alto, CA) at a dose of 200 tachyzoites intraperitoneally per mouse as 
described previously25. Mice were monitored over 30 days for survival and weight loss. 
  For cowpox, age- and sex- matched mice were used at 8-10 weeks of age. Mice were 
anesthetized with ketamine/xylazine and were inoculated intranasally (i.n.) with 5000 pfu of 
BAC-derived cowpox Brighton Red85 in 30 μL of minimum essential medium (MEM) 
(Mediatech). At 7 days post-infection, lungs were harvested, minced, and digested with 22.4 
μg/mL DNase I (type II; Sigma) and 0.7 mg/mL collagenase (Sigma) at 37°C for 30 minutes. 
Digested lungs were then passed through 70-μm cell strainers and red blood cells were lysed 
(0.15 M NH4Cl, 10 mM KHCO3, and 0.1 mM EDTA). Spleens were passed through 70-μm 
strainers without digestion and red blood cells were lysed. Cells were stained with Fixable 
Viability Dye eFlour 506 (eBioscience) prior to cell surface staining.  
  For SRBC immunization 2x108 sheep red blood cells (Colorado Serum Company) were 
injected i.p. into 8-10 week old mice. Spleens were harvested seven days later and analyzed for 
germinal center B cell and Tfh development. 
  For West Nile Virus, age- and sex-matched mice were used at 10-12 weeks of age. Mice 
were infected with 102 PFU of West Nile Virus via foot pad injection. After eight days spleens 
were harvested and analyzed for CD8 and CD4 T cell responses. Cells were stained with Fixable 
Viability Dye eFluor 506 (eBioscience) prior to cell surface staining. 
Confocal microscopy 
  JAWSII cells or DCs from day 10 Flt3L cultures were allowed to adhere to Alcian blue 
(Electron Microscopy Sciences) coated coverslips at 500K cells/coverslip. Cells were fixed with 
4% paraformaldehyde, quenched with .4M glycine, and blocked using BlockAid (Invitrogen) 
with .2% saponin. Cells were stained overnight in PBS + .2% saponin + 2% FBS at 4ºC, washed 
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with PBS + .2% saponin three times and stained with secondary antibodies for at least 2hrs at 
4ºC in PBS + .2% saponin + 2% FBS. Coverslips were mounted in ProLong Gold Antifade with 
DAPI (Invitrogen). Labeled HKLM-OVA was prepared as described 32. 
  Images were acquired on a Nikon A1Rsi confocal microscope using a 60x oil immersion 
objective and analyzed using ImageJ. 
Statistics 
  Statistical analysis was performed using GraphPad Prism (GraphPad Software). Two-way 
ANOVA with Tukey's multiple comparison test or Mann-Whitney U test was performed to 
determine statistical significance. 
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In this dissertation we developed assays to study the in vivo cross-presentation pathway 
and used these assays to discover two novel genes, Rab43 and Wdfy4, that function in a cDC1-
specific cross-presentation pathway. While the cross-presentation pathway has been the subject 
of much research over the past decade, little work has been done to translate in vitro results to in 
vivo relevance. Underscoring this point is the widespread use of bone-marrow derived dendritic 
cells in this field, which have recently been shown to perform cross-presentation through a 
mechanism distinct from cDC1, calling into question the in vivo relevance of these studies. Here, 
we show the discovery of the first genetic mouse model for the lack of cross-presentation (the 
Wdfy4-/- mouse) and use this mouse to illustrate the essential role of cross-presentation in anti-
tumor and anti-viral immune responses. In addition, we have developed a novel screening 
approach to analyze the relevance of genes of interest to the in vivo cross-presentation pathway. 
Further use of this protocol may help find additional novel regulators of cross-presentation and 
expand on the mechanisms presented here for Rab43 and WDFY4. 
5.2 Rab43 is required for optimal cross-presentation in vivo 
Rab proteins are small GTPases that regulate vesicular identity, movement, and fusion 
events1-3. Multiple Rab proteins have previously been shown to be involved in the cross-
presentation pathway, including Rab27a, Rab34, and Rab3c4-6. However, these molecules were 
only studied in GM-CSF-derived dendritic cells which recent data has shown are not an accurate 
model for in vivo cross-presentation7. We found that Rab43, a cDC1-specific Rab protein, was 
necessary for efficient cross-presentation in vivo8. While we did not determine how Rab43 
functioned mechanistically in the cross-presentation pathway, we were able to localize it to the 
golgi-apparatus, suggesting a potential role for Rab43 in movement of peptide-loading 
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machinery either to the cell surface or to an antigen-containing vesicle. Further work analyzing 
the cross-presentation pathway may help to elucidate at what point Rab43 acts, and what types of 
vesicles it acts on. 
Besides Rab43, Rab7b is the other DC1 specific Rab protein8.  Rab7b has been shown in 
macrophages to regulate movement of TLRs, altering signaling dynamics9,10.  Rab7b is also used 
as a marker for late endosomes3,11,12.  Since Rab proteins often function in cascades, it is possible 
that both Rab43 and Rab7b are involved in a similar process to regulate antigen or peptide-
loading complex movement during cross-presentation13,14.  Like Rab43, the role of Rab7b has 
never been described in cDC1s. Generation of Rab7b knockout mice, along with Rab43 and 
Rab7b double knockout animals may provide useful insight into if Rab7b acts in cross-
presentation and may provide a link between antigen degradation in the lysosome and peptide-
loading complex movement from the golgi. 
5.3 Development of a CRISPR-based screen for cross-presentation 
  We generated a CRISPR-Cas9 screen to find genes involved in the cross-presentation 
pathway that relied on a T cell based readout of presentation of heat killed Listeria 
monocytogenes that expressed ovalbumin. Using this screen we were able to identify WDFY4 
(discussed in chapter 4) as a novel regulator of in vivo cross-presentation7. In total we tested 35 
genes out of 80 genes of interest that were defined based on their cDC1 specificity, changes in 
expression levels upon DC activation, and dependence on Batf3. Further studies on the 
remainder of these genes may provide additional insights into the cross-presentation pathway and 
help expand on the mechanisms described for Rab43 and WDFY4. 
  The screen procedure is also useful for expanding on our mechanistic studies of WDFY4. 
After performing proteomics to find WDFY4 interacting partners we have generated guide RNA 
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for some of those genes to determine if they are involved in the cross-presentation pathway. We 
think the screen is a valuable tool for studying cross-presentation and may aid in our discovery of 
novel members of the pathway through studies of either our candidate list or partners of 
WDFY4. 
5.4 WDFY4 is essential for virus and tumor clearance through cross-presentation 
WDFY4 is one of eight human proteins that contains a Beige and Chediak-Higashi 
(BEACH) domain15. Previously, WDFY4 had only been studied in Genome Wide Association 
Studies (GWAS), where it was shown to possibly be a risk factor for lupus16-18. It was recently 
reported that this may be due to a function of WDFY4 in noncanonical autophagy in B cells19. 
This is consistent with the previously studied role of WDFY3, which shares significant 
homology with WDFY4, in autophagy in the brain20-23. We became interested in the role of 
Wdfy4 in cross-presentation based on the results of a Crispr-Cas9 screen, and obtained a 
knockout mouse from Jackson Labs in order to study the function of WDFY4 in vivo24. 
WDFY4-deficient DC1s are unable to cross-present cell-associated antigens, but remain 
capable of presenting on MHCII. This is the first example of a model for selective cross-
presentation deficiency.  We used the WDFY4 knockout mice to study the role of cross-
presentation in vivo under different immune challenges. First we tested the response to 
Toxoplasma gondii, a parasite that requires IL-12 produced by DC1s for clearance, but likely not 
cross presentation25. We found that WDFY4-deficient mice were still able to clear Toxoplasma 
infection, unlike Batf3 knockout mice that lack DC1s. Work with DC1-deficient mice has 
suggested that cross-presentation is essential for the clearance of viruses and tumors26. To test 
the role of WDFY4 during viral infection we used two distinct viral models. First, we infected 
WDFY4 mice with cowpox virus, a virus that is capable of blocking traditional MHCI 
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presentation, and analyzed priming of cowpox-specific CD8 T cells27. We found that WDFY4 
KO mice were unable to prime CD8 T cells to cowpox infection, suggesting an essential role for 
cross-presentation in protection against this virus. We also performed a West Nile Virus 
infection, which allowed us to analyze the priming of both CD8 and CD4 T cells by West Nile-
specific tetramers. Like with cowpox infection, WDFY4-deficient mice were unable to prime 
CD8 T cells against West Nile Virus; however, they were able to prime normal numbers of CD4 
T cells, again suggesting a specific role for WDFY4 in cross-presentation. 
Studies with Batf3-deficient mice also showed that DC1s are essential for the clearance 
of immunogenic tumors26. To test if this is due to their ability to cross-present we injected a 
MCA-induced sarcoma subcutaneously into wild-type and WDFY4 knockout mice28. In this 
tumor model the wild-type mice completely cleared the tumor around 10-14 days after injection.  
However, the WDFY4-deficient animals were unable to control the tumor, similar to the Batf3 
knockouts, underscoring the essential role of cross-presentation in tumor rejection. 
We also sought to determine the molecular mechanism of WDFY4 within the cross-
presentation pathway. Using immuno-precipitation and mass-spectrometry of WDFY4 fragments 
we found that interacting partners include the endocytosis regulator clathrin, actin regulator 
IQGAP1, and heat shock protein HSP90ab1. This was consistent with its intracellular 
localization near the plasma membrane, suggesting that WDFY4 functions in a vesicular 
transport pathway, likely either for the movement of antigen or MHC to the correct locations for 
cross-presentation to occur. 
5.5 Conclusions and future studies 
 Here we have described two genes that have been confirmed to play a role in the cross-
presentation pathway in vivo. Further analysis of the mechanism of action of either of these 
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genes will provide important insight into how cross-presentation occurs and may help refute or 
validate the contributions of the molecules and pathways previously described to function in this 
process that were only studied in bone-marrow derived DCs7. For Rab43, studies on Rab7b or 
other potential Rab effector molecules may help to describe which vesicles Rab43 may be 
decorating, and provide an explanation for how the golgi apparatus is involved in the cross-
presentation pathway. For WDFY4 additional structural studies or deeper analysis of the protein 
may help to inform further mass-spectrometry experiments and aid in the identification of 
interacting partners. It appears the C-terminus of the WDFY4 protein interacts with endocytic 
machinery, but the function and domain structure of the N-terminus remains largely unknown. 
Determining WDFY4 interacting partners and validating their role in cross-presentation through 
our novel CRISPR-Cas9 screen will help further describe this pathway and may provide insights 
into how to best target antigens to DCs while developing vaccination strategies for viruses or 
tumors. 
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 The BATF3-dependent cDC1 lineage of conventional dendritic cells (cDCs) is required 
for rejection of immunogenic sarcomas and for rejection of progressive sarcomas during 
checkpoint blockade therapy.  One unique function of cDC1 is the efficient cross-presentation of 
tumor-derived neo-antigens to CD8+ T cells, but it is not clear that this is the only unique 
function of cDC1 required for tumor rejection.  We recently showed that BATF3 functions 
during cDC1 lineage commitment to maintain IRF8 expression in the specified cDC1 progenitor. 
However, since cDC1 progenitors do not develop into mature cDC1 in Batf3-/- mice, it is still 
unclear whether BATF3 has additional functions in mature cDC1 cells. A transgenic Irf8-Venus 
reporter allele increases IRF8 protein levels sufficiently to allow autonomous cDC1 development 
in spleens of Batf3-/- mice. These restored Batf3-/- cDC1s are transcriptionally similar to control 
wild type cDC1s, but have reduced expression of a restricted set of cDC1-specific genes.  
Notably, restored Batf3-/- cDC1 are able to cross-present cell-associated antigens both in vitro 
and in vivo. However, Batf3-/- cDC1 exhibit altered characteristics in vivo and importantly are 
unable to mediate tumor rejection.  These results show that BATF3, in addition to regulating Irf8 
expression to stabilize cDC1 lineage commitment, also controls expression of a small set of 
genes required for cDC1-mediated tumor rejection. These BATF3-regulated genes may be useful 
targets in immunotherapies aimed at promoting tumor rejection.    
A1.2 Introduction 
Conventional dendritic cells (cDCs) develop as two major lineages that are dependent on 
distinct transcriptional programs for their development1. The cDC1 lineage is dependent on the 
transcription factors IRF8 and BATF3 for development, and expresses certain unique markers 
such as CD8, CD103 and XCR1 in various tissues1. BATF3-dependent cDC1s are specialized 
for antigen cross-presentation and are required for anti-viral and anti-tumor CD8 T cell 
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responses2-4. In particular, BATF3-dependent cDC1s are required for rejection of immunogenic 
syngeneic fibrosarcomas2, and type I interferon signaling supports this capacity5,6. BATF3-
depdendent cDC1s are also required for T cell priming in response to DNA vaccines7 and their 
abundance in humans tumors correlated with improved tumor regression8,9. Recently, the ability 
of checkpoint blockade to mediate anti-tumor responses against progressively growing sarcomas 
was shown to also require BATF3-dependent cDC1s10-12. However, despite the clearly important 
role of cDC1 cells in anti-tumor immunity, much remains unclear about how they survey tissues 
and initiate immune responses.   
IRF8 and BATF3 play distinct roles in cDC1 development, which proceeds through 
distinct specification and commitment stages13. IRF8 is required for development of a cDC1-
specified bone marrow (BM) progenitor, which is missing in Irf8–/– mice. In contrast, this 
specified progenitor develops in Batf3–/– mice, but fails to commit to mature cDC1s and instead 
diverts to the DC2 lineage due to the inability to sustain the normal high levels of Irf8 
expression13. In this cDC1-specified progenitor, BATF3 and IRF8 cooperate in binding to an 
enhancer containing several AP-1/IRF consensus elements (AICEs)14 that functions to sustain 
Irf8 autoactivation initiated earlier in development13. Thus, at least one function of BATF3 is 
exerted in the commitment stage of cDC1 development.  
Since there is currently no system for conditional deletion of Batf3, it has been difficult to 
determine whether BATF3 also functions in cDC1 cells during immune responses. The normal 
requirement for Batf3 for cDC1 development can be bypassed under some conditions, although 
the mechanism is not completely understood. Splenic CD8+ cDC1 were restored in Batf3–/– 
mice during infection by Mycobacteria tuberculosis15, or by administration of IL-12, and this 
restoration was blocked by in vivo neutralization by IFN-15. Molecularly, Batf can compensate 
for Batf3 in cDC1 development15, and cDC1 development induced by IL-12 in Batf3–/– mice was 
reduced in Batf–/– Batf3–/– mice, suggesting some role for Batf in the mechanism of restoration15. 
cDC1 development is transiently restored after transfer of Batf3-/- bone marrow into irradiated 
recipients16, although the basis for this effect is unclear.  In addition, Batf3–/– mice on the 
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C57BL/6 genetic background frequently retain a population of cells resembling cDC1 in skin 
draining lymph nodes, but not in the spleen or other tissues15.  The basis for this strain- and 
tissue-specific phenomenon has not been established, but may be specific to microbiota, as it is 
not observed in all colonies of C57BL/6 Batf3–/– mice.  
 A more recent system for BATF3 compensation is based on the particular molecular 
mechanism of cDC1 development13. Crossing a transgenic Irf8VENUS reporter strain17 with Batf3–
/– mice also restores cDC1 development13. In this case, cDC1 development appears to result from 
the increased IRF8 expression arising due to the three intact copies of IRF8 present in the BAC 
reporter transgenes, leading to autonomous Irf8 autoactivation13.  In the present study, we used 
this Irf8VENUS reporter system to allow an examination of cDC1 cells that develop and maintain 
IRF8 expression in the absence of BATF3 for their capacity to function in cross-presentation and 
tumor rejection, and to identify transcriptional gene targets requiring BATF3. 
A1.3 Results 
Transgenic IRF8 overexpression eliminates dependence of cDC1 on Batf3 for development 
Transgenic Irf8VENUS reporter mice possess three co-integrated copies of a phage artificial 
chromosome containing a 130-kb Irf8 genomic region with an internal ribosome entry site and 
sequence encoding the yellow fluorescent protein VENUS into the Irf8 3′ untranslated region17. 
Thus, mice with one transgenic reporter allele have a total of five functional Irf8 loci, resulting in 
increased IRF8 expression that was approximately 2 fold higher in Irf8VENUS+ cDC1 cells 
compared with Irf8VENUS– cDC1 cells13. Despite this slight IRF8 overexpression, expression of 
the Venus reporter is similar to endogenous Irf8 expression is several ways, such as being 
expressed at high levels in cDC1 and pDC lineages, and importantly being reduced in DC2 cells 
to the low level typical of Irf8VENUS– DC213. 
We have previously shown that Batf3–/– Irf8VENUS+ mice had normal cDC1 development 
in contrast to Batf3–/– Irf8VENUS– mice, which have impaired cDC1 development13. Conceivably, 
this effect of compensation could be dependent on endogenous levels of Batf expressed in DCs, 
in the manner of IL-12-dependent compensation observed previously15. To address this, we 
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asked whether restoration of cDC1 in Batf3–/– Irf8VENUS+ mice was due to compensation by 
endogenous Batf (Figure A1.1). Mice that were lacking both Batf and Batf3, Batf–/– Batf3–/– 
Irf8VENUS–, had no CD24
+ CD172a– cDC1s in spleen (Figure A1.1A). This cDC1 population was 
restored by introduction of the Irf8VENUS reporter in Batf–/– Batf3–/– Irf8VENUS+ mice at a slightly 
reduced percentage compared to wild type (WT) mice (Figure A1.1A and A1.1B). Similarly, 
using XCR1 instead of CD24 to identify the cDC1population18, cDC1 were restored in spleens of 
both Batf3–/– Irf8VENUS+ mice and doubly deficient Batf–/– Batf3–/– Irf8VENUS+, and percentages of 
these were also reduced compared to WT (Figure A1.1C and A1.1D).  These results indicate that 
cDC1 restoration in Batf3–/– Irf8VENUS+ mice bypasses dependence on either Batf3 or Batf, unlike 
restoration induced by IL-12 observed previously15. Further, these results suggest that in spleen 
cDC1s the expression of XCR1 is not completely dependent on BATF3 or BATF, unlike IRF8.  
Batf3-/- cDC1 can cross-present cell-associated antigen   
We analyzed the ability of Batf3–/– cDC1 restored by the Irf8VENUS transgene to cross-
present cell-associated antigen in vitro (Figure A1.2). cDC1 purified from WT spleens, that were 
either Irf8VENUS– or Irf8VENUS+, were able to cross-present to OT-1 T cells (Figure A1.2A and 
A1.2B), as expected. cDC1 purified from spleens of Batf3–/– Irf8VENUS+ (Figure A1.2A and 
A1.2B) and Batf–/– Batf3–/– Irf8VENUS+ mice (Figure A1.2C and A1.2D) cross-presented cell-
associated ovalbumin as efficiently as WT cDC1 in vitro. As a control, DC2 cells purified from 
either WT or Batf–/– Batf3–/– Irf8VENUS+ mice were unable to cross-present cell-associated antigen 
(Figure A1.2C and A1.2D), as expected.  Next we compared the efficacy of cross-presentation 
using a dose titration of HKLM-OVA (Figure A1.3).  cDC1 purified from spleens of Batf3–/– 
Irf8VENUS+cDC1 were able to cross-present HKLM-ova to OT-1 T cells as well as those purified 
from WT spleens, that were either Irf8VENUS– or Irf8VENUS+ (Figure A1.3A). As a control, cDC2 
did not cross-present HKLM-OVA, as expected (Figure A1.3B). Thus, cDC1 cells that express 
IRF8 but lack BATF3 and BATF proteins are capable of in vitro cross-presentation.  
We have previously shown that cDC1 restored by IL-12 treatment of Batf3–/– mice were 
capable of cross-presentation in vivo15. We next tested whether Batf3–/– Irf8VENUS+ mice could 
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cross-present cell-associated antigen in vivo. Transferred OT-1 CD8 T cells proliferated in 
spleens and inguinal lymph nodes of WT mice, either with or without Irf8VENUS (Figure A1.2E 
and A1.2F). No OT-1 proliferation was observed in spleens or lymph nodes of Batf3–/– mice 
without Irf8VENUS, as expected. However, OT-1 proliferation was observed in spleens and lymph 
nodes of Batf3–/– Irf8VENUS+ and was equivalent to that in WT mice. These results show that 
cDC1s do not require BATF3 for in vivo cross-presentation function.  We recently reported that 
cross-presentation of cell-associated antigens by monocyte-derived DCs (mo-DCs) is also 
independent of BATF3 and BATF19.  Similarly, cross-presentation in cDC1s is not dependent on 
BATF3 itself, although the development of the cDC1 lineage is.  
Batf3-/- cDC1 do not mediate fibrosarcoma rejection in vivo 
Previously, we showed that transplanted immunogenic fibrosarcomas cannot be rejected 
by Batf3–/– mice, but that IL-12 treated Batf3–/– mice reacquire a population of cDC1 cells and 
can also mount anti-tumor responses2,15. However, using IL-12-induced cDC1 restoration, it is 
possible that IL-12 might independently augment tumor rejection by actions on targets cells 
other than cDC1 in Batf3–/– mice.  Thus, there was a need to evaluate the intrinsic capacity of the 
Batf3-/- cDC1 to mediate tumor rejection in another system.  Therefore, we next asked whether 
Batf3–/– Irf8VENUS+ mice could also reject tumors, using a C57BL/6 regressor fibrosarcoma, 1969,  
that is rejected by WT mice5,20 (Figure A1.4). 
WT mice were able to reject the 1969 fibrosarcoma independently of being Irf8VENUS- or 
Irf8VENUS+ (Figure A1.4A). By contrast, tumors grew progressively in Batf3–/– Irf8VENUS– mice, as 
expected (Figure A1.4A). However, tumors also grew progressively in Batf3–/– Irf8VENUS+ mice 
(Figure A1.4A), despite the presence of cDC1 cells capable of cross-presentation (Figure A1.1). 
Tumors were of similar sizes in WT and Batf3–/– mice 7-8 days after implantation, for both 
Irf8VENUS- and Irf8VENUS+ mice. However, on day 18, tumors in WT mice were rejected 
completely, while large tumors persisted in all Batf3–/– mice, both Batf3–/– Irf8VENUS- and Batf3–/– 
Irf8VENUS+ genotypes (Figure A1.4B).  
[172] 
 
We also examined the infiltration of 1969 tumors by DCs and T cells in these mice. 
There was an infiltration of MHCII+ CD11c+ cells into tumors of all mice, and tumors in WT 
Irf8VENUS+ mice contained XCR1+ cDC1 and CD8+ T cells (Figure A1.4C-E) as expected. By 
contrast, progressively growing tumors in both Batf3–/– Irf8VENUS- and Batf3–/– Irf8VENUS+ mice 
lacked XCR1+ cDCs and CD8+ T cells. The lack of CD8+ T cells in these tumors is consistent 
with the lack of tumor rejection in these mice. Thus, despite restoration of cDC1 development 
and cross-presentation in Batf3–/– Irf8VENUS+ mice, these Batf3–/– Irf8VENUS+ cDC1 are insufficient 
for tumor rejection.  
DCs in skin of Batf3–/– Irf8VENUS+ mice lack XCR1 expression. 
 Conceivably, cDC1 might mediate tumor rejection by priming T cells though cross-
presentation of tumor antigens delivered to lymph nodes through lymphatics.  Alternately, 
rejection might require cDC1 to acquire antigens directly from tumors and traffic to lymph nodes 
to prime T cells. We therefore analyzed the cDC populations in dermis of non-tumor bearing 
mice (Figure A1.5).  First, dermis of both Irf8VENUS– Batf3+/+ (WT) and Irf8VENUS+ Batf3+/+ mice 
contained the two major DC populations, the CD11b+ cDC2, and XCR1+ CD24+ CD11b– cDC1 
(Figure A1.5B).  In addition, dermal DCs from Batf3–/– Irf8VENUS– mice included CD11b+ DC2, 
but not XCR1+ CD24+ CD11b– cDC1. However, dermal DCs from Batf3–/– Irf8VENUS+ mice 
included the CD11b+ cDC2 and CD24+ CD11b– cDC1, but unexpectedly these CD24+ CD11b– 
DCs did not express XCR1 (Figure A1.5C).  
Next, we analyzed resident and migratory cDC1 populations in skin draining lymph 
nodes (SDLN) (Figure A1.6). The resident gate, identified as CD11chi MHCIIint, contained 
CD24+ CD172a– cDC1 in WT mice, both Irf8VENUS–and Irf8VENUS+. These cDC1s also expressed 
high levels of XCR1 (Figure A1.6A and A1.6B).  The migratory DC gate, identified as CD11cint 
MHCIIhi, also contained CD24+ CD172a– cDC1s in WT mice, both Irf8VENUS–and Irf8VENUS+. 
However, XCR1 expression on these migratory cDC1s was lower than XCR1 expression on 
resident cDC1 cells, consistent with increased maturation in migratory compared to resident 
DCs21 (Figure A1.6A and A1.6C). 
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We have previously observed that SDLN from Batf3–/– mice on the C57BL/6 background 
can retain a CD24+ CD172a– population resembling cDC1s22. Their development has been 
attributed to compensation by BATF15.  As expected, Batf3–/– Irf8VENUS– mice retain this residual 
cDC1 population in the resident DC gate of the SDLN, and have lower XCR1 expression and 
increased CD172a expression compared with WT CD24+ CD172a– resident cDCs (Figure 
A1.6B). In contrast, in Batf3–/– Irf8VENUS+ mice, the CD24+ CD172a– cDC1 population expresses 
similar levels of CD24 and CD172a compared with WT mice (Figure A1.6B), but lower levels of 
XCR1, being expressed on 50% of the CD24+ CD172a– cDC1s. 
The residual CD24+ CD172a– cDC1s are much less abundant in the migratory gate of 
SDLNs from Batf3–/– Irf8VENUS– mice and here they do not express XCR1 at all (Figure A1.6C). 
Migratory CD24+ CD172a– cDC1s were restored in Batf3–/– Irf8VENUS+ mice, but these also did 
not express XCR1. Thus, in contrast to spleen, the Irf8-Venus transgene does not fully restore 
XCR1 expression by cDC1 in the dermis and SDLN in the absence of BATF3. These results may 
suggest that there may be parallel pathways for inducing XCR1 expression, one of which is 
Batf3-dependent, and another that is dependent on a signal present in the spleen and LN, but 
lacking in the dermis. This conditional regulation of XCR1 could be similar to our previous 
demonstration of the expression of CD103 whose expression can be both Batf3-dependent and 
induced by GM-CSF in the absence of BATF322. 
We wanted to test whether cDC1s from skin and from the migratory gate of SDLN of 
Batf3–/– Irf8VENUS+ mice are able to cross-present cell-associated antigen. As expected, migratory 
DCs from naive mice were already matured and had lost the capacity to cross-present newly 
acquired antigen to OT-1 T cells (Figure A1.7A)21,23. Not surprisingly, our isolation procedure 
for skin dendritic cells resulted in their maturation, so we could not directly assay their cross-
presentation capacity24. Therefore, to answer this question, we implanted a fibrosarcoma 
expressing membrane anchored ovalbumin, 1956-ova, and asked whether migratory cDCs 
purified from SDLN could stimulate proliferation of OT-1 T cells in vitro (Figure A1.7B). Since 
we have shown previously, that cDC1 and not cDC2 are uniquely capable of cross-presentation 
[174] 
 
(Figure A1.3)25, we did not separate cDC1 from cDC2 in this experiment. Migratory, but not 
resident, cDCs from 1956-ova tumor-bearing WT Irf8VENUS– and WT Irf8VENUS+ mice stimulated 
robust OT-1 proliferation. Migratory cDCs from Batf3–/– Irf8VENUS+ mice also stimulated OT-1 
proliferation at approximately 40% of WT, but significantly more than their counterparts from 
the resident gate (Figure A1.7B).  We conclude that migratory cDC1s from SDLN in Batf3–/– 
Irf8VENUS+ can cross-present antigen. However, we cannot be sure that these migratory cDC1s 
acquired antigen while they resided in the skin and it remains a possibility that migration of skin 
cDC1s or their antigen processing may be altered.  
  Identification of Batf3-dependent target genes in cDC1 cells.   
To determine Batf3-dependent genes that may be important for tumor rejection, we used 
microarray analysis to compare cDC1s purified from spleens of WT Irf8VENUS–, WT Irf8VENUS+, 
and Batf3–/– Irf8VENUS+ mice (Figure A1.8). First, the increased level of IRF8 provided by the 
Irf8VENUS transgene in WT cDC1s did not cause an overall increase in gene expression for cDC1-
associated genes (Figure A1.8A). A slight increase in Irf8 expression between Irf8VENUS+ and 
Irf8VENUS– cDC1s was observed, presumably a result of the Irf8 transgenes, but other cDC1-
associated genes, such as Btla, Itgae, CD8a, Clec9a and Xcr1, were not affected by Irf8VENUS. 
Importantly, Batf was not induced by Irf8VENUS, which indicates that compensation by Batf is 
unlikely to be the mechanism by which Irf8VENUS restores cDC1 in Batf3–/– mice.  
To determine which cDC1-associated genes were dependent on Batf3 for their 
expression, we compared cDC1s from WT Irf8VENUS+ mice and Batf3–/– Irf8VENUS+ mice (Figure 
A1.8 and A1.9). Approximately 10 genes had decreased expression in Batf3–/– Irf8VENUS+ cDC1 
from spleen compared with WT Irf8VENUS+ cDC1 (Figure A1.8C).  Itga8 had the highest fold 
change (10.4x) between WT Irf8VENUS+ and Batf3–/– Irf8VENUS+ cDC1s. Other Batf3-dependent 
genes with 3 fold or greater changes between Batf3+/+ Irf8VENUS+ and Batf3–/– Irf8VENUS+ cells 
included the signaling adaptor molecule Clnk, the phosphatase Ppef2 and Gcsam, among others. 
We found no genes that were increased by the Irf8VENUS transgene in WT cells, with the 
exception of Irf8 itself.  Among a list of genes important for development or function in DCs, 
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including Id2, Ciita, Nfil3, Zeb2 and Irf4, none were Batf3-dependent (Figure A1.9A).  
Interestingly, compared to WT Irf8VENUS+ cDC1s, Batf3–/– Irf8VENUS+ cDC1 had higher 
expression of CCR7 and CCR5, which are known to be involved in DC migration to lymph 
nodes26,27, but no difference in expression of other chemokine receptors, including Xcr1 (Figure 
A1.9B). Itga8 was the only integrin whose expression was Batf3-dependent (Figure A1.9C).   
However, we had observed that XCR1 expression was reduced in Batf3–/– Irf8VENUS+ 
migratory cDC1 from SDLN compared to WT mice (Figure A1.6C), so we wondered if other 
genes were also reduced in the lymph node cDC1s. We analyzed cDC1s from SDLNs of WT 
Irf8VENUS+ mice and Batf3–/– Irf8VENUS+ mice by microarray (Figure A1.8C and A1.9D).  All but 
one of the spleen Batf3-dependent genes, Ctla2b, were also Batf3-dependent in resident cDC1s 
from SDLN (Figure A1.8C). These genes were also reduced in migratory, i.e. mature, cDC1s 
compared to resident cDC1s from WT Irf8VENUS+ mice, and were not further reduced in Batf3–/– 
Irf8VENUS+ migratory cDC1s. A total of 34 genes, including 8 listed for spleen, were reduced in 
Batf3–/– Irf8VENUS+ resident cDC1s compared to WT Irf8VENUS+ resident cDC1s (Figure A1.9D). 
28 of these genes are among the approximately 900 genes that are 3 fold or greater reduced in 
migratory cDC1s compared to resident cDC1s from WT Irf8VENUS+ mice. 15 genes whose 
expression was not already completely reduced upon maturation were reduced in Batf3–/– 
Irf8VENUS+ compared to WT Irf8VENUS+migratory cDC1s.  Xcr1 is 9.1 fold reduced in migratory 
compared to resident cDC1s from WT Irf8VENUS+mice, and stands out as being the only gene that 
is Batf3-dependent in both resident and migratory cDC1s.  In summary, the most strongly Batf3-
dependent genes are also genes that are reduced upon the maturation of cDC1, and so are more 
strongly expressed in resident cDC1 compared to migratory cDC1.    
We analyzed IRF8 and BATF3 ChIP-seq binding in genomic loci of Batf3-dependent 
genes (Figure A1.10). Shown are some examples, Clnk, Gcsam, Itga8 and Xcr1, whose 
expression is specific to cDC1 compared to cDC2, is unaffected by the presence of the Irf8VENUS 
transgene in wild type mice, and is Batf3-dependent (Figure 1.10A).  For each of these genes we 
could find strong BATF3 and IRF8 binding located in open chromatin as assessed by peaks of 
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H3K27Ac, either in the gene body (Gcsam) or nearby (Clnk, Itga8 and Xcr1) (Figure 1.10B), 
suggesting these genes may be direct targets of Batf3 and Irf8.  To begin to address which of the 
Batf3-dependent genes might be required for tumor rejection, we implanted 1969 fibrosarcoma 
cells into mice with conditional deletion of Itga8 (Figure A1.11). As controls, wild type mice 
could reject 1969 tumor cells (Figure A1.11A) but Batf3-/- mice could not (Figure A1.11B). 
However, the conditional loss of Itga8 in CD11c+ cells was not sufficient to abrogate tumor 
rejection (Figure A1.11C).  Additional analysis will be required to determine which components 
of the Batf3-dependent pathway are required for tumor rejection. 
A1.4 Discussion 
 Our aim was to determine which cDC1-specific genes rely on Batf3 for their expression 
and whether any of these are required for tumor rejection mediated by cDC1. The requirement 
for Batf3 in maintaining Irf8 expression during cDC1 development has prevented a direct 
determination of Batf3 target genes in cDC1, because cDC1 normally fail to develop in Batf3–/– 
mice. In this study, we developed a system to allow cDC1 development in the absence of 
BATF3, and identified a relatively small number of cDC1 genes rely on Batf3 for their 
expression.  Importantly, this set of BATF3-target genes includes genes required for cDC1 to 
mediate tumor rejection.   
One important BATF3 transcriptional target gene is Irf8.  The high level of IRF8 
expression that is required for cDC1 development is achieved by Irf8 autoactivation that depends 
on the cooperative interaction between IRF8 and BATF3.  This interaction is likely mediated 
through an Irf8 +32kb enhancer that contains multiple AICEs where BATF3 and IRF8 
cooperatively bind13. We took advantage of the phenomenon that the Irf8-Venus reporter can 
maintain cDC1 development in the absence of BATF3 and BATF to discover whether the 
function of cDC1 is entirely a property of high IRF8 expression or whether other genes in mature 
cDC1 that may require BATF3 for their expression might contribute to cDC1 function. 
First, we found that the cDC1 that develop in Batf3-/- Irf8VENUS+ mice were capable of 
cross-presentation of cell-associated antigen, a process that is specific to the cDC1 lineage25.  
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Thus, the transcriptional program for cross-presentation of cell-associated antigens may rely 
solely on high Irf8 expression, and not directly on Batf3-dependent gene expression.  However, 
we found that Batf3-/- Irf8VENUS+ mice, like Batf3-/- mice, cannot reject immunogenic 
fibrosarcomas that are normally rejected by wild type mice, despite functional cross-presentation 
in vivo.  This result is in contrast to the case where cDC1 development was restored in Batf3-
deficient mice by IL-12 treatment, where cDC1 restoration led to restored resistance to 
Toxoplasma gondii,  restoration of cross-presenting cDC1 and to capacity for tumor rejection15. 
Thus, IL-12 treatment may provide additional or different signals that may not be present in the 
Batf3–/– Irf8VENUS+ mice that compensates for the absence of BATF3 in cDC1 for these functions.   
All of the identified candidate genes whose expression requires Batf3 are expressed more 
highly in cDC1 compared to DC2 cells. Such genes but may be required for tumor rejection but 
would not be predicted to be required for cDC1 development or cross-presentation.  For 
example, Itga8 as a heterodimer with Itgb1, 81, has several reported ligands including 
osteopontin, fibronectin, vitronectin, nephoronectin, tenascin C and MFGE828-31. Although Itga8 
expression is not limited to the immune system, its expression on cDC1s could facilitate 
interactions with the tumor microenvironment18,32.  However, a single gene defect in Itga8 
expression did not block tumor rejection. but this may be due to redundancy with other partners 
of Itgb1, which will require future studies.  
Besides in cDC1s, Gcsam and its human counterpart HGAL are also highly expressed in 
germinal center B cells. Gcsam is a cytoplasmic protein that contains a putative immune tyrosine 
activation motif. Gcsam's biologic role is unknown, but it has been shown that Gcsam is 
dispensable for the germinal center reaction33. Another Batf3-dependent candidate is Clnk, a 
member of the Blnk/SLP-76 adapter family. In addition to cDC1s, Clnk is expressed in activated 
T cells, IL-2 activated NK cells, and mast cells34. No immune defects were observed in Clnk-
deficient mice but this was attributed to potential compensation by SLP-76. cDC1 specific 
functions for these and other BATF3-target genes have not been evaluated in the context of 
tumor rejection.  
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XCR1 has been recognized as a robust marker of cDC35.  In our study, Xcr1 was not 
initially seen to be strongly dependent on Batf3 in splenic cDC1, but is more strongly Batf3 
dependent in cDC1 from SDLNs. Xcr1 expression is also diminished upon cDC1 maturation in 
SDLNs, being reduced by 9 fold in migratory cDC1 relative to resident cDC1. These 
observations could imply that Xcr1 gene is regulated differentially in different tissues. XCL1 
produced by CD8 T cells can act as a chemoattractant for XCR1+ cDC1s36. It is possible that lack 
of XCR1 on migratory cDC1s could help explain lack of tumor rejection in the Batf3-/- Irf8VENUS+ 
mice.  In a vaccinia infection model, Xcr1 was required for the clustering of CD8 T cells with 
cDC37.  Another study showed that NK cell release of XCL1 in tumors may recruit cDC1 into 
tumors, but stated that loss of Xcr1 was not sufficient to block intra-tumor cDC1 accumulation38. 
However, as far as we are aware, neither these studies nor others39,40, reported whether loss of 
















Figure A1.1. Irf8VENUS bypasses the need for both Batf3 and Batf in cDC1 development in 
spleen. (A) FACS analysis of splenocytes of the indicated genotypes gated on live singlets that 
were B220- CD11c+ MHCII+. Numbers indicate the percentage of cells in the CD24+ CD172a– 
gate. (B) Accumulated FACS analyses for samples analyzed as in (A). Each symbol represents a 
single mouse. One way ANOVA, Sidak's multiple comparisons test; Adjusted P value: * 0.0341; 
**** <0.0001. (C) FACS analysis of splenocytes gated on live singlets that were B220- CD11c+ 
MHCII+. Numbers indicate the percentage of cells in the XCR1+ CD172a– gate. (D) 
Accumulated FACS analyses for samples analyzed as in (C). Each symbol represents a single 
mouse. One way ANOVA, Holm-Sidak's multiple comparisons test, alpha 0.05; adjusted P 











Figure A1.2. Cross-presentation by IRF8VENUS restored cDC1 does not require Batf3 or 
Batf.  (A, B) CFSE dilution within OT-1 T cells on day 3 after in vitro exposure to sorted splenic 
cDC1 from mice of the indicated genotype and no antigen (0), or with 50000 (50) or 100000 
(100)  irradiated ovalbumin-loaded MHCI–/– splenocytes . Numbers indicate the percentage of 
CD44+ OT-1 cells with diluted CFSE.  OT-1 cells were identified as live singlet CD45.1+Va2+ 
CD3+ CD8+.  (A) Representative FACS analysis.  (B) Each circle represents an individual 
mouse.  (C, D) CFSE dilution within OT-1 T cells on day 3 after in vitro exposure to sorted 
splenic cDC1 or cDC2 from mice of the indicated genotype and no antigen (0) or 100000 (100)  
irradiated ovalbumin-loaded MHCI–/– splenocytes. Numbers indicate the percentage of CD44+ 
OT-1 cells with diluted CFSE.  (C) Representative FACS analysis. (D) Proliferation is expressed 
as a percentage of OT-1 T cell proliferation after exposure to wild type cDC1 and 100000 
irradiated ovalbumin-loaded MHCI–/– splenocytes. Each circle within matching genotypes for 
cDC1 and cDC2 represents an individual mouse. (E, F) FACS analysis of CFSE-labelled OT-1 T 
cells from spleens (E) or inguinal lymph nodes (SDLN, F) after transfer into mice of the 
indicated genotype. CFSE dilution was analyzed on day 3 after injection of CFSE-labeled OT-1 
T cells on day -1 followed by irradiated ovalbumin-loaded splenocytes on day 0. Numbers 
indicate the percentage of CD44+ OT-1 cells with diluted CFSE.  OT-1 cells were identified as 
live singlet CD45.1+ V2+ CD3+ CD8+.  Batf3+/+IRF8VENUS–, n=2; Batf3+/+IRF8VENUS+, n=1; 


















Figure A1.3. Similar efficacy of antigen cross-presentation between WT and Irf8-VENUS 
restored Batf3-/- cDC1.  (A) cDC1 were purified from spleen from mice of the indicated 
genotypes.  10,000 cDC1 per well were assessed for cross-presentation to 25,000 OT-1 cells and 
the indicated number of HKLM-OVA.  Each symbol represents a duplicate. The experiment was 


























Figure A1.4.  Batf3 is required for tumor rejection even in Irf8VENUS+ mice.   (A, B) Mice of 
the indicated genotype were injected with 1 x 106 1969 fibrosarcoma cells subcutaneously. Data 
are combined from three experiments. (A) Each line represents mean tumor diameter for an 
individual mouse. (B) Mean tumor diameter compared between the indicated genotypes on day 
7-8 and day 18. Each symbol represents an individual tumor. (C, D, E) FACS analysis of 
fibrosarcomas from mice of the indicated genotype on day 9-10.  (C) Representative FACS 
analysis. CD45+ 7AAD– cells, pre-gated as B220-, were analyzed for the percentage of CD11c+ 
MHCII+ cells and the percentage of CD11c- MHCII- cells (first column). CD11c+ MHCII+ cells 
the percentage of XCR1+ CD172a– cDC1s (second column). MHCII– CD11c– cells were 
analyzed for CD8+ XCR1– T cells (third column).  (D,E) Cumulative FACS analysis from 
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fibrosarcomas grown in mice of the indicated genotype. Each symbol represents an individual 
tumor. (D) XCR1+ cDCs. One way ANOVA, Sidak's multiple comparisons test, alpha 0.05; 
adjusted P value: *, 0.0241; ns, 0.8645. (E) CD8+ T cells. One way ANOVA, Sidak's multiple 

























Figure A1.5.  Batf3–/– IRF8VENUS+ mice lack XCR1+ dermal cDC1s. (A-C) FACS analysis of 
ear skin of non-tumor bearing mice of the indicated genotype. (A) Percentage of MHCII+ 
CD11c+ cells.  Cells were pre-gated as 7AAD– CD45+ B220– CD326INT/LOW.  (B) CD24+ CD11b– 
cells within MHCII+ CD11c+ cells from (A). (C) CD24+ XCR1+ cDC1s within MHCII+ CD11c+ 



















Figure A1.6. Batf3–/– IRF8VENUS+ mice lack XCR1+ migratory cDC1s in SDLN. (A-C) FACS 
analysis of SDLN (pooled inguinal, axial, brachial) of non-tumor bearing mice of the indicated 
genotype. (A) Gating for resident cDCs (MHCIIint CD11chi), and migratory cDCs (MHCIIhi 
CD11cint), is shown. Cells were pre-gated as B220–, CD326int/low.  (B) Resident cDCs (MHCIIint 
CD11chi) as gated from (A) were analyzed for the percentage of CD24+ CD172a– or XCR1+ 
CD172a– cDC1s.  (C) Migratory cDCs (MHCIIhi CD11cint) as gated from (A) were analyzed for 
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the percentage of CD24+ CD172a– or XCR1+ CD172a– cDC1s. Data are representative of 6 


























Figure A1.7. Restored cDC1 from SDLN of Irf8-VENUS Batf3-/- mice can cross-present cell-
associated antigen. (A) Total cDCs from resident or migratory gates as indicated of pooled 
SDLNs of WT mice were assayed for cross-presentation of HKLM-OVA.  cDCs were used in a 
ratio of 2.5 OT-1 T cells per cDC.  Each symbol is a replicate well.  (B)  1 x 106 tumor cells 
(1956-OVA) were implanted subcutaneously at four sites. cDCs from migratory and resident 
gates of SDLNs were purified 4 or 7 days later, and assayed for cross-presentation to OT-1 T 
cells in vitro. cDCs were used in a ratio of 2.5 OT-1 T cells per cDC.  Each symbol is a replicate 








Figure A1.8. A limited number of cDC1 specific genes are Batf3-dependent.  (A-C)  
Microarray analysis of cDCs from mice of the indicated genotype. (A) Fold change in expression 
of annotated probe sets between cDC1 and cDC2 (x-axis) is plotted against the fold change in 
expression between WT Irf8VENUS+ and WT Irf8VENUS– cells (y-axis).  (B) Fold change in 
expression of annotated probe sets between cDC1 and cDC2 (x-axis) is plotted against fold 
change between WT Irf8VENUS+ and Batf3–/– Irf8VENUS+ cells (y-axis).  (C) Expression of cDC1-
specific genes that were ≥2.6 fold more highly expressed in WT Irf8VENUS+ compared to Batf3–/– 
Irf8VENUS+ cDC1 from spleen, shown for spleen cDC1, and for resident and migratory cDC1 
from SDLN (pooled inguinal, brachial and cervical).  FC indicates the fold change in gene 
expression between WT Irf8VENUS+ and Batf3–/– Irf8VENUS+ cells.  Each column represents an 








Figure A1.9.  Gene expression cDC1 from SDLNs.  (A) Gene expression in splenic cDC1 of 
the indicated genotype.  Shown are genes related to cDC development or function.  (B) 
Expression of chemokine receptors in splenic cDC1.  (C) Expression of integrin genes in splenic 
cDC1. For A-C, FC indicates the fold change in gene expression between WT Irf8VENUS+ and 
Batf3–/– Irf8VENUS+ splenic cDC1. (D)  Gene expression in resident or migratory cDC1 from the 
indicated genotypes of mice for genes that were at least 3 fold different in expression between 
WT Irf8VENUS+ and Batf3–/– Irf8VENUS+  in either resident or migratory cDC1. Genes with bolded 
names are also 3 fold different in splenic cDC1 between WT Irf8VENUS+ and Batf3–/– Irf8VENUS+ 
mice as shown in Figure 6C.  FC: fold change indicates the fold change in gene expression 
between WT Irf8VENUS+ and Batf3–/– Irf8VENUS+ cDC1 from resident or migratory gates. FC is 
also shown for expression between WT resident versus WT migratory cDC1.  Each column 





















Figure A1.10. Batf3-dependent genes harbor nearby enhancers binding BATF3/IRF8.  (A) 
Expression of selected Batf3-dependent genes in the indicated cell type and genotype.  Each 
symbol represents an independent expression array.  Two-tailed unpaired t tests; alpha= 0.05.  
(B) ChIP-seq analysis for H3K27Ac, BATF3 and IRF8 in WT cDC1 for the indicated loci, Clnk, 
Gcsam, Itga8, and Xcr1 as indicated.  Previously reported H3K27Ac, BATF3 and IRF8 ChIP-








Figure A1.11.  Itga8 is not required for tumor rejection of 1969 regressor fibrosarcoma. 
Mice of the indicated genotypes were injected subcutaneously with 1 x 106 tumor cells.  Shown 
is mean tumor diameter after the indicated days in WT (Itga8F/F cre-) (A), Batf3-/- (B) or Itga8F/F 




A1.5 Materials and Methods 
Mice. 
Wild type and Batf3–/– on C57Bl/6 background were crossed to IRF8VENUS 17 as 
previously described13. Experiments using Batf3–/– Batf–/– mice used a mixed 
129S6/SvEV/C57Bl/6 background41. C57BL/6-Tg(TcrTcr)1100Mjb/J (OT-1) mice were 
purchased from Jackson Laboratories. MHCI KO mice (Kb–/–Db–/–2m–/–; TKO) were a gift from 
Herbert W. Virgin and Ted Hansen, Washington University, St. Louis42. Mice harboring a 
conditional allele of Itga8 (Itga8F/F) were obtained from Jackson Laboratories as B6.129S6-
Itga8tm1.1Rdav/J and crossed to CD11c-Cre43.  All mice were maintained in a specific 
pathogen–free animal facility following institutional guidelines and with protocols approved by 
the Animal Studies Committee at Washington University in St. Louis, an Institutional Animal 
Care and Use Committee (IACUC). Experiments were performed with sex matched mice 6-20 
weeks of age without randomization or blinding.  
Antibodies and flow cytometry. 
Cells were stained at 4°C in the presence of Fc Block (2.4G2; BioXcell) in flow 
cytometry buffer (0.5% BSA/ PBS). The following anti-mouse antibodies were used: from 
Becton Dickinson (BD): anti-MHCII- IA/IE (M5/114 15.2, anti-CD4 (RM4-5) and anti-CD11b 
(M1/70); from Biolegend: anti-XCR1 (ZET), anti-CD24 (M1/65), anti CD326 (G8.8), anti-TCR-
V2 (B20.1) and anti-B220 (RA3-6B2); from Tonbo Biosciences: anti-CD11c (N418) and anti-
CD45.1 (A20); from Ebioscience; anti-CD172a, anti-CD45 (30F-11) and anti-CD44 (IM7). Cells 
were analyzed on a FACSCanto II or FACS Aria Fusion flow cytometer (BD) and data were 




Tissue Preparation.  
Minced spleens, skin draining lymph nodes (pooled inguinal, cervical and brachial), and 
tumors, harvested 9-10 days after transplantation, were digested in collagenase B (0.25mg /ml) 
and DNAse1 (30u /ml) in complete IMDM (Iscove's modified Dulbecco's medium with10%FCS, 
2ME, Pen/Strep, NEAA, and Glutamine) for 40 min at 37oC with stirring and subjected to ACK 
lysis. Prior to sorting, spleen cells were enriched for CD11c+ cells (Miltenyi).  Ears were split 
into dorsal and ventral halves prior to mincing and digestion in Liberase (0.26u /ml) and 
DNAse1 (30u/ml) in complete IMDM for 40 min at 37oC with stirring. After addition of 5mM 
EDTA, suspensions were filtered through 70um nylon mesh, pelleted, subjected to ACK lysis, 
washed, and used for FACS analysis. 
Expression microarray analysis. 
cDC1, (XCR1+ CD24+ CD172a– MHCII+ CD11c+ B220–) or (CD24+ CD172a– MHCII+ 
CD11c+ B220–), were sorted from spleens, and migratory (MHCIIhi CD11clow) and resident 
(MHCII+ CD11c+) cDC1s (CD326lowCD24+ CD172a– B220-) were sorted from skin draining 
lymph nodes. Total RNA from spleen DCs was extracted using RNAqueous-Micro Kit 
(Ambion), amplified with the Ovation Pico WTA System (NuGEN) and hybridized to GeneChip 
Mouse Gene 2.0 ST microarrays (Affymetrix). Total RNA from lymph node DCs was extracted 
using Nucleo-spin RNA XS kit (Macherey-Nagel), amplified with GeneChip WT Pico Kit 
(Applied Biosystems) and hybridized to GeneChip Mouse Gene 1.0 ST microarrays 
(Affymetrix). Data were normalized by robust multiarray average summarization and quartile 






Gene expression microarray data have been deposited in the Gene Expression Omnibus 
(accession no. GSE111034).   
Tumor cell lines 
The MCA-induced fibrosarcoma 1969 was a gift from Robert Schreiber, Washington 
University School of Medicine, in 2014. It was generated in a female C57BL/6 Rag2−/− mouse, 
was tested for mycoplasma, and was banked at low-passage as previously described5,20. Tumor 
cells derived from frozen stocks and propagated in vitro in RPMI media supplemented with 10% 
FCS (Hyclone) were washed three times with PBS, resuspended at a density of 6.67 x 106 cells 
ml−1 in endotoxin-free PBS and then 150 μl was injected subcutaneously into the flanks of 
recipient mice. Tumor growth was measured with a caliper and expressed as the average of two 
perpendicular diameters.  An immunogenic fibrosarcoma expressing membrane ovalbumin was 
generated from the MCA-induced progressor fibrosarcoma 1956, also a gift from Robert 
Schreiber, in 2014. An mOVA fragment pCI-neo-mOVA (Addgene #25099) was ligated into 
MSCV-IRES-Thy1.1 vector44 to generate MSCV-mOVA-IRES-Thy1.1.  1956 tumor cells 
retrovirally transduced with this vector were sorted for expression of Thy1.1 and surface OVA 
expression was validated using flow cytometry (Millipore AB1225).   
Cross-presentation assays. 
Cross presentation assays were as described25,45. Briefly, MHCI-deficient splenocytes 
were ACK-lysed, loaded with ovalbumin (Worthington) in hypertonic medium (0.5M sucrose, 
10% w/v polyethylene glycol 1000, 10mm Hepes, RPMI 1640 pH 7.2) and irradiated (13.5Gy).  
OT-1 T cells (CD4- B220- CD11c- CD8a+ V2+) were sorted from ACK-lysed, B220-macs 
depleted OT-1 splenocytes and labeled with CFSE.  For in vivo cross-presentation, mice were 
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injected intravenously (i.v.) with 500000 CFSE-labeled OT-1 T cells and on the next day with 
PBS or varying numbers of ovalbumin-loaded MHCI-deficient splenocytes. Three days later, 
spleens and inguinal lymph nodes were harvested for analysis of CFSE dilution by FACS.  For in 
vitro cross-presentation, cDC1 (CD24+ CD172a- CD11c+ MHCII+ B220-) were sorted from 
splenocytes that had been positively enriched for CD11c+ cells (Miltenyi).  Sorted cDC1 were 
placed in 96 well round bottom plates with ovalbumin-loaded MHCI-deficient splenocytes or 
heat killed Listeria monocytogenes expressing ovalbumin HKLM-ova)25 and CFSE labeled OT-1 
T cells in Iscove’s MEM  at 37oC in a CO2 incubator. Alternatively, migratory and resident DCs 
were sorted from mice 4 or 7 days after subcutaneous implantation of 1956-ova tumor cells and 
were placed in 96 well round bottom plates with CFSE labeled OT-1 T cells. CFSE dilution was 
analyzed on day 3.  
Statistical analysis. 
All statistical analyses were performed using Prism (GraphPad Software).  
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